<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003550.pub2" GROUP_ID="FERTILREG" ID="441501073009360425" MERGED_FROM="" MODIFIED="2015-03-23 11:06:45 +0000" MODIFIED_BY="Anja Helmerhorst" NOTES="&lt;p&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.8&lt;/p&gt;" NOTES_MODIFIED="2015-03-16 09:00:47 -0400" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0034" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2015-03-16 08:45:45 -0400" MODIFIED_BY="[Empty name]">
<TITLE>Nonlatex versus latex male condoms for contraception</TITLE>
<CONTACT>
<PERSON ID="3B53A95682E26AA20114382D371E0DCB" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Laureen</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Lopez</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>llopez@fhi360.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Clinical and Epidemiological Sciences</DEPARTMENT>
<ORGANISATION>FHI 360</ORGANISATION>
<ADDRESS_1>359 Blackwell St, Suite 200</ADDRESS_1>
<ADDRESS_2/>
<CITY>Durham</CITY>
<ZIP>27701</ZIP>
<REGION>North Carolina</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 919 5447040 ext: 11443</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-03-16 08:40:45 -0400" MODIFIED_BY="Laureen Lopez">
<PERSON ID="13632" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Maria</FIRST_NAME>
<MIDDLE_INITIALS>F</MIDDLE_INITIALS>
<LAST_NAME>Gallo</LAST_NAME>
<SUFFIX>PhD</SUFFIX>
<POSITION>Assistant Professor</POSITION>
<EMAIL_1>mgallo@cph.osu.edu</EMAIL_1>
<EMAIL_2>fjr4@cdc.gov</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Epidemiology</DEPARTMENT>
<ORGANISATION>The Ohio State University</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Columbus</CITY>
<ZIP/>
<REGION>Ohio</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 919 3080144</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="4664" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>David</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Grimes</LAST_NAME>
<SUFFIX/>
<POSITION>Clinical Professor</POSITION>
<EMAIL_1>david_grimes@med.unc.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>919-656-7227</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Dept. of Obstetrics and Gynecology</DEPARTMENT>
<ORGANISATION>University of North Carolina</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Chapel Hill</CITY>
<ZIP/>
<REGION>North Carolina</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>919-656-7227</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="3B53A95682E26AA20114382D371E0DCB" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Laureen</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Lopez</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>llopez@fhi360.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Clinical and Epidemiological Sciences</DEPARTMENT>
<ORGANISATION>FHI 360</ORGANISATION>
<ADDRESS_1>359 Blackwell St, Suite 200</ADDRESS_1>
<ADDRESS_2/>
<CITY>Durham</CITY>
<ZIP>27701</ZIP>
<REGION>North Carolina</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 919 5447040 ext: 11443</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="735D5A7582E26AA2008F53C86BBDE520" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Kenneth</FIRST_NAME>
<MIDDLE_INITIALS>F</MIDDLE_INITIALS>
<LAST_NAME>Schulz</LAST_NAME>
<SUFFIX>PhD, MBA</SUFFIX>
<POSITION>Distinguished Scientist</POSITION>
<EMAIL_1>kschulz@fhi360.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Quantitative Sciences</DEPARTMENT>
<ORGANISATION>FHI 360 and UNC School of Medicine</ORGANISATION>
<ADDRESS_1>359 Blackwell Street, Suite 200</ADDRESS_1>
<ADDRESS_2>Suite 200</ADDRESS_2>
<CITY>Durham</CITY>
<ZIP>27701</ZIP>
<REGION>North Carolina</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 919 5447040 ext. 11542</PHONE_1>
<PHONE_2/>
<FAX_1>+1 919 5447261</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2013-01-15 09:00:50 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 8/19/05&lt;/p&gt;&lt;p&gt;New studies sought but none found: 9/20/02&lt;/p&gt;&lt;p&gt;New studies found but not yet included or excluded: 6/30/05&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 7/6/05&lt;/p&gt;&lt;p&gt;Conclusions changed: 8/18/05&lt;/p&gt;&lt;p&gt;Reformatted: 7/6/05&lt;/p&gt;&lt;p&gt;New studies sought but none found: 23/05/2008&lt;/p&gt;" NOTES_MODIFIED="2013-01-15 09:00:50 -0500" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="18" MONTH="12" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="17" MONTH="12" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="20" MONTH="12" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2015-03-16 08:45:45 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;This review was updated in July 2005. One new trial was found and incorporated (Potter 2003).&lt;/p&gt;&lt;p&gt;This review was updated in May 2008. No new trials were found.&lt;/p&gt;" NOTES_MODIFIED="2015-03-16 08:45:45 -0400" NOTES_MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-03-16 08:45:45 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="3" YEAR="2015"/>
<DESCRIPTION>
<P>Added further detail in <LINK TAG="CONFLICT_OF_INTEREST" TYPE="SECTION">Declarations of interest</LINK>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2014-01-15 08:36:54 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="1" YEAR="2014"/>
<DESCRIPTION>
<P>No longer being updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-01-15 08:36:25 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-01-15 08:36:25 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="12" YEAR="2012"/>
<DESCRIPTION>
<P>Updated searches; no new studies found.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-12-17 15:16:12 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="11" YEAR="2010"/>
<DESCRIPTION>
<P>Searches were updated for MEDLINE, CENTRAL, POPLINE, LILACS, ClinicalTrials.gov, and ICTRP. No new studies were found.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-11-03 09:31:47 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Searches were updated; no new trials were found.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="21" MONTH="9" YEAR="2005"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>National Institute of Child Health and Human Development</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>U.S. Agency for International Development</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-03-16 09:00:47 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-12-17 15:33:14 -0500" MODIFIED_BY="[Empty name]">
<TITLE>Nonlatex compared to latex male condoms for birth control</TITLE>
<SUMMARY_BODY MODIFIED="2012-12-17 15:33:14 -0500" MODIFIED_BY="[Empty name]">
<P>The male condom can prevent pregnancy by keeping sperm out of the birth canal. Nonlatex condoms can be used by people who are allergic or sensitive to latex. Some people may not have used latex condoms because they did not like them. This review compared nonlatex condoms with latex condoms. The main issues were effect on birth control, whether the condom broke or slipped, and which condom people liked.</P>
<P>In December 2012, we used a computer to find randomized trials of nonlatex condoms. For the initial review, we also wrote to researchers and makers of nonlatex condoms to find other trials. We included all studies that compared a male nonlatex condom with a latex condom.</P>
<P>The eZ·on condom did not prevent pregnancy as well as latex condoms. The Avanti and the Standard Tactylon condoms were similar to latex condoms for birth control. The nonlatex condoms broke more often than the latex condoms. However, many people liked the nonlatex condoms better. They may be useful for people who are allergic or sensitive to latex.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-12-17 15:42:48 -0500" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>The male condom, which consists of a thin sheath placed over the glans and shaft of the penis, is designed to prevent pregnancy by providing a physical barrier against the deposition of semen into the vagina during intercourse. Beginning in the 1990s, nonlatex male condoms made of polyurethane film or synthetic elastomers were developed as alternative male barrier methods for individuals with allergies, sensitivities or preferences that prevented the consistent use of condoms made of latex.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The review sought to evaluate nonlatex male condoms in comparison with latex condoms in terms of contraceptive efficacy, breakage and slippage, safety, and user preferences.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-12-17 15:42:48 -0500" MODIFIED_BY="[Empty name]">
<P>In December 2012, we searched computerized databases for randomized controlled trials (RCTS) of nonlatex condoms (MEDLINE, CENTRAL, POPLINE, LILACS, ClinicalTrials.gov, ICTRP). Previous searches also included EMBASE. For the initial review, we wrote to the manufacturers of nonlatex condoms and known investigators to locate other trials not identified in our search.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-11-03 09:42:23 -0400" MODIFIED_BY="[Empty name]">
<P>The review included RCTs that evaluated a male nonlatex condom made of polyurethane film or synthetic elastomers in comparison with a latex condom.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>We evaluated all titles and abstracts located in the literature searches for inclusion. Two authors independently extracted data from the identified studies. We analyzed data with RevMan. The Peto odds ratio (Peto OR) with 95% confidence interval (CI) was calculated for each outcome of contraceptive efficacy, condom breakage and slippage, discontinuation of use, safety, and user preference. Contraceptive efficacy, early discontinuation, and safety outcomes were also measured with survival analysis techniques.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-05-08 10:13:14 -0400" MODIFIED_BY="Laureen M Lopez">
<P>While the eZ·on condom did not protect against pregnancy as well as its latex comparison condom, no differences were found in the typical-use efficacy between the Avanti and the Standard Tactylon and their latex counterparts. The nonlatex condoms had higher rates of clinical breakage than their latex comparison condoms: the Peto OR for clinical breakage ranged from 2.64 (95% CI 1.63 to 4.28) to 4.95 (95% CI 3.63 to 6.75). Few adverse events were reported. Substantial proportions of participants preferred the nonlatex condom or reported that they would recommend its use to others.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Although the nonlatex condoms were associated with higher rates of clinical breakage than their latex comparison condoms, the new condoms still provide an acceptable alternative for those with allergies, sensitivities, or preferences that might prevent the consistent use of latex condoms. The contraceptive efficacy of the nonlatex condoms requires more research.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-12-18 09:41:03 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-05-30 09:31:51 -0400" MODIFIED_BY="Laureen M Lopez">
<P>The male condom, the only reversible male contraceptive method, consists of a thin sheath placed over the glans and shaft of the penis to provide a physical barrier against the deposition of semen into the vagina during intercourse. Most commercially-produced condoms are made of latex. A small proportion (about 5% in the U.S.) is made of the intestinal cecum of lamb (<LINK REF="REF-Murphy-1990" TYPE="REFERENCE">Murphy 1990</LINK>). These 'natural membrane' or 'lambskin' condoms are considered inferior to latex condoms in that they do not provide adequate protection against sexually transmitted infections (<LINK REF="REF-Lytle-1990" TYPE="REFERENCE">Lytle 1990</LINK>; <LINK REF="REF-Minuk-1989" TYPE="REFERENCE">Minuk 1989</LINK>). Latex male condoms have been mass-produced since the mid-1800s (<LINK REF="REF-Murphy-1990" TYPE="REFERENCE">Murphy 1990</LINK>) and, currently, are widely used in many nations for contraception. In the United States, for example, an estimated 13% of women of reproductive age reported using male condoms for contraception in 1995 (<LINK REF="REF-Abma-1997" TYPE="REFERENCE">Abma 1997</LINK>). The latex condom offers a safe, effective, user-controlled contraceptive method that is easy to use and relatively inexpensive.</P>
<P>A basic measure of contraceptive effectiveness is the first-year failure rate, that is, the probability of pregnancy in the initial year of use. Although male condoms have an estimated method-specific failure rate of 2% for the first year of use, the typical-use failure rate is estimated to be 15% (<LINK REF="REF-Trussell-2007" TYPE="REFERENCE">Trussell 2007</LINK>). The difference between the method-specific failure rate and the user failure rate can be attributed to improper and inconsistent condom use. For example, fewer than half of condom users in the U.S. reported using condoms consistently at every act of intercourse (<LINK REF="REF-Mosher-1993" TYPE="REFERENCE">Mosher 1993</LINK>). Due to the difficulties in conducting efficacy studies, comparative studies of condoms have often evaluated surrogate endpoints, such as condom breakage and slippage. Prospective studies of condoms used during vaginal intercourse have shown 2% breakage and complete slippage 2% of the time (<LINK REF="REF-Warner-2007" TYPE="REFERENCE">Warner 2007</LINK>).</P>
<P>Several factors could deter couples from using condoms or could contribute to their inconsistent use. Condom users have reported decreased sensitivity and sexual enjoyment. In a U.S. national survey, for example, almost 75% of men stated that condoms decreased sensation (<LINK REF="REF-Grady-1993" TYPE="REFERENCE">Grady 1993</LINK>). Difficulties in donning and removing condoms could also reduce their efficacy and acceptability; latex condoms are tight for retention during coitus and must be unrolled in only one direction onto the penis. Furthermore, latex allergies could preclude the use of condoms. An estimated 1% to 6% of the general U.S. population is allergic to latex, and the proportion may be much higher among populations with greater exposure to latex, such as health care workers (<LINK REF="REF-Warner-2007" TYPE="REFERENCE">Warner 2007</LINK>). Poor heat conductivity and relatively low strength at maximum stretch are demonstrated disadvantages of condoms made of latex. Latex condoms can also deteriorate during storage due to the susceptibility of latex to oxidation (<LINK REF="REF-Free-1996" TYPE="REFERENCE">Free 1996</LINK>). In addition, the use of oil-based lubricants, including hand oils and body lotions, can deteriorate latex.</P>
<P>Beginning in the 1990s, male condoms composed of polyurethane film or synthetic elastomers were developed to address these limitations. These nonlatex condoms provide an option for those with allergies or sensitivities to latex. Nonlatex condoms can also be safely used with oil-based lubricants and have the potential for an increased shelf life due to their ability to withstand a broader range of storage conditions. In addition, nonlatex condoms were suggested to have a less noticeable odor, less constricting fit, and an improved ability to conduct body heat. Nonlatex condoms that are more effective and acceptable to the user than traditional latex condoms could be an important factor in increasing the consistent use of condoms as a method of contraception.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To compare the contraceptive efficacy, breakage, slippage, safety, and user preference of nonlatex male condoms versus latex male condoms.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-12-18 09:41:03 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-11-03 09:47:00 -0400" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>All randomized controlled trials in any language comparing a nonlatex male condom not made of natural membrane with a latex condom were eligible for inclusion. Although protection against sexually transmitted infections was not an outcome of the review, trials of natural membrane condoms were excluded since their use is not generally recommended due to their recognized inadequacy in protecting against the transmission of viruses (<LINK REF="REF-Lytle-1990" TYPE="REFERENCE">Lytle 1990</LINK>; <LINK REF="REF-Minuk-1989" TYPE="REFERENCE">Minuk 1989</LINK>).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Eligible participants were sexually active couples engaging in heterosexual, vaginal intercourse and without contraindications to latex or nonlatex condoms.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Any nonlatex condom not made out of natural membrane was eligible to be included. Currently, five types of nonlatex condoms are manufactured: eZ·on, Avanti, Tactylon, the Protex Original, and the Trojan Supra. Randomized controlled trials evaluating the first four types of condoms were found. </P>
<P>The nonlatex eZ·on condom (Family Health International, Research Triangle Park, NC and Mayer Laboratories, Inc., Oakland, CA) is a baggy polyurethane condom that can be donned in either direction. The eZ·on condom is 28 mm in diameter in the opening, 171 mm in length and 70 mm in width. The condom is packaged with a silicone-based lubricant. </P>
<P>The nonlatex Avanti condom (SSL International plc, Knutsford, UK) is a nipple-tipped polyurethane condom that is 33 mm in diameter in the opening, 180 mm in length, 0.035 to 0.040 mm in thickness and 64 mm in width. The condom is packaged with a silicone-based lubricant. The Avanti Super Thin condom (SSL International plc, Knutsford, UK) has the same dimensions but slightly more lubricant. Both styles of Avanti condoms were treated as the same product by the U.S. regulatory agency, the Food and Drug Administration (FDA). </P>
<P>The nonlatex Tactylon condoms (Sensicon Corporation, Vista, CA) are made of styrene ethylene butylene styrene (SEBS), a synthetic polymer used in Tactylon surgical and examination gloves (SmartPractice). The condoms come in three styles: Standard Tactylon, Baggy Tactylon, and Low-Modulus Tactylon. The Standard Tactylon has a standard cylindrical shape with a reservoir tip. The Baggy Tactylon has a diameter at the opening that is similar to traditional condoms, but the diameter is larger immediately below the open end. The Low-Modulus Tactylon has a standard cylindrical shape with a low modulus (i.e., low resistance to stretch) with a high elongation. The three condoms are packaged with a silicone-based lubricant and have similar dimensions (180 mm in length, 0.07 mm in thickness, and 52 mm in width) except that the width of the Baggy Tactylon ranges from 49 mm to 81 mm. </P>
<P>The nonlatex condom Sagami Protex Original (Sagami Rubber Industries Co, Ltd., Tokyo, Japan) is made of polyurethane. The Protex Original is 193 mm in length, 0.03 mm in thickness, and 58 mm in width. The condom is packaged with a silicone-based lubricant.</P>
<P>Any latex male condom could be the comparison method.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-11-03 09:47:00 -0400" MODIFIED_BY="[Empty name]">
<P>Outcome measures included contraceptive efficacy, condom breakage and slippage, discontinuation of use, safety, and user preference. We used the condom breakage and slippage measures proposed by Steiner and colleagues (<LINK REF="REF-Steiner-1994" TYPE="REFERENCE">Steiner 1994</LINK>):<BR/>(1) Nonclinical breakage<BR/>The number of condoms that break before intercourse while package is being opened or while condom is being put on divided by the number of condoms attempted to be used.<BR/>(2) Clinical breakage<BR/>The number of condoms that break during intercourse or withdrawal divided by the number of condoms used during intercourse.<BR/>(3) Total breakage<BR/>Both clinical and nonclinical breakage divided by the number of condoms attempted to be used.<BR/>(4) Complete slippage<BR/>The number of condoms that completely slip off the penis during intercourse or withdrawal divided by the number of condoms used during intercourse.<BR/>(5) Partial slippage<BR/>The number of condoms that partially slip off the penis during intercourse or withdrawal divided by the number of condoms used during intercourse.<BR/>(6) Total clinical failure<BR/>The number of condoms that break or slip completely off during intercourse or withdrawal divided by the number of condoms used during intercourse.<BR/>(7) Total failure<BR/>The number of condoms that break (both nonclinical and clinical breakage) or completely slip off divided by the number of condoms attempted to be used.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-12-18 09:41:03 -0500" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2012-12-18 09:41:03 -0500" MODIFIED_BY="[Empty name]">
<P>In December 2012, we searched the computerized databases of MEDLINE using PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL), POPLINE, and LILACS for studies of nonlatex condoms. We also searched for recent trials via ClinicalTrials.gov and the search portal of the International Clinical Trials Registry Platform (ICTRP). The 2012 strategies can be found in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. The 2010 strategies can be found in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>. We also searched EMBASE for the initial review and the 2006 and 2008 updates (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-12-17 15:44:10 -0500" MODIFIED_BY="Laureen M Lopez">
<P>The references of identified publications were assessed for inclusion. For the initial review, we also wrote to the manufacturers of nonlatex condoms and known investigators to request information about any other published or unpublished trials not discovered in our search.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-05-27 10:10:26 -0400" MODIFIED_BY="Laureen M Lopez">
<P>One author evaluated all titles and abstracts located in the literature searches to determine whether they met the inclusion criteria. Two authors independently extracted data from the studies identified for inclusion. Data were entered and analyzed with RevMan. The Peto odds ratio (Peto OR) with 95% confidence interval (CI) was calculated for each outcome with the number of condoms, men, women, or couples used as the denominator. Contraceptive efficacy and early discontinuation were also measured using survival analysis techniques and entered into 'Additional tables.'</P>
<P>We could not use paired analyses for the crossover trials since the data were not presented in this manner. <LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK> suggests using only the data from the first treatment period when paired data are not available; however, data by treatment period were not provided. Therefore, we treated the data from the crossover trials as if they had come from parallel trials. That is, even though the same participants were in each condom group, we analyzed the data defined by the latex and nonlatex condom groups. This approach does not take advantage of the within-participant correlations present in crossover trials. Also, the assumption of independence required by most statistical methods is violated since the same participants were included in both groups.</P>
<P>Although couples in each of the eligible trials were assigned to use multiple condoms during both the latex and nonlatex periods, the present review ignores the cluster design of the trials. Four trials (<LINK REF="STD-Bounds-2002" TYPE="STUDY">Bounds 2002</LINK>; <LINK REF="STD-Callahan-2000" TYPE="STUDY">Callahan 2000</LINK>; <LINK REF="STD-Cook-2001" TYPE="STUDY">Cook 2001</LINK>; <LINK REF="STD-Steiner-2003" TYPE="STUDY">Steiner 2003</LINK>) accounted for potential cluster effects in at least some outcomes by modeling using generalized estimating equation methods. Since data from cluster analyses were not available for most outcomes and since RevMan does not support cluster data, we treated the data as if they came from independent observations. This method, though, is less than ideal given that the probability of condom function outcomes could vary substantially between couples.</P>
<P>Due to the differences in the dimensions and materials of condom types, study results were combined for meta-analysis only when identical comparisons of nonlatex and latex condom types were made. The homogeneity of the meta-analyses was assessed by examining the results from both a fixed-effects model and a random-effects model. Since the chi-squared test for heterogeneity used in RevMan is a low-power test, the alpha level was set at 0.10. Sensitivity analyses were conducted to test the robustness of the results that appeared to be based on heterogeneous combinations. The effect of deleting each study in turn was assessed. All trials were critically appraised by examining factors that can potentially contribute to biases: the study design, blinding, randomization method, group allocation concealment, and loss to follow up and early discontinuation.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-12-17 15:35:34 -0500" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-05-27 10:11:32 -0400" MODIFIED_BY="Laureen M Lopez">
<P>Eight randomized crossover trials (<LINK REF="STD-Bounds-2002" TYPE="STUDY">Bounds 2002</LINK>; <LINK REF="STD-Callahan-2000" TYPE="STUDY">Callahan 2000</LINK>; <LINK REF="STD-Cook-2001" TYPE="STUDY">Cook 2001</LINK>; <LINK REF="STD-Frezieres-1998" TYPE="STUDY">Frezieres 1998</LINK>; <LINK REF="STD-Frezieres-2000" TYPE="STUDY">Frezieres 2000</LINK>; <LINK REF="STD-Potter-2003" TYPE="STUDY">Potter 2003</LINK>; <LINK REF="STD-Steiner-1993" TYPE="STUDY">Steiner 1993</LINK>; <LINK REF="STD-Trussell-1992" TYPE="STUDY">Trussell 1992</LINK>) and three randomized parallel trials (<LINK REF="STD-Frezieres-1999" TYPE="STUDY">Frezieres 1999</LINK>; <LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK>; <LINK REF="STD-Steiner-2003" TYPE="STUDY">Steiner 2003</LINK>) satisfied the criteria for inclusion. The 11 eligible trials recruited sexually active, adult couples in a monogamous, heterosexual relationship and who were not at risk for sexually transmitted diseases. Nine trials were conducted in the U.S., one trial (<LINK REF="STD-Bounds-2002" TYPE="STUDY">Bounds 2002</LINK>) was located in the U.K., and one was done in France (<LINK REF="STD-Potter-2003" TYPE="STUDY">Potter 2003</LINK>). Two trials differed from the others by restricting participation to couples using condoms for contraception prior to study entry (<LINK REF="STD-Frezieres-2000" TYPE="STUDY">Frezieres 2000</LINK>; <LINK REF="STD-Potter-2003" TYPE="STUDY">Potter 2003</LINK>). Couples in the crossover trials were to use two to six condoms of each type. The study periods were 5 to 12 weeks, except for two trials (<LINK REF="STD-Bounds-2002" TYPE="STUDY">Bounds 2002</LINK>; <LINK REF="STD-Potter-2003" TYPE="STUDY">Potter 2003</LINK>) that did not report the duration for each condom period. The three randomized parallel trials (<LINK REF="STD-Frezieres-1999" TYPE="STUDY">Frezieres 1999</LINK>; <LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK>; <LINK REF="STD-Steiner-2003" TYPE="STUDY">Steiner 2003</LINK>) were the only studies that were designed to measure contraceptive efficacy. Although the two earlier trials (<LINK REF="STD-Frezieres-1999" TYPE="STUDY">Frezieres 1999</LINK>; <LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK>) had a longer (six-month) duration than the crossover studies, the condom breakage, slippage and acceptability data were based on a nested study of the condoms used for the first five acts of intercourse, and therefore are comparable with data from the crossover trials in terms of the number of condoms used and the duration of the study period. In contrast, the breakage and slippage data from the most recent efficacy study (<LINK REF="STD-Steiner-2003" TYPE="STUDY">Steiner 2003</LINK>) were collected from the entire seven-month study.</P>
<P>Four types of nonlatex condoms and eight latex condoms were evaluated in 14 nonlatex and latex condom combinations. The baggy polyurethane eZ·on condom was compared to the latex Kimono Select condom in two studies (<LINK REF="STD-Cook-2001" TYPE="STUDY">Cook 2001</LINK>; <LINK REF="STD-Steiner-2003" TYPE="STUDY">Steiner 2003</LINK>) and to the latex Durex Gossamer condom in a third study (<LINK REF="STD-Bounds-2002" TYPE="STUDY">Bounds 2002</LINK>). Both the Kimono Select (180 mm in length, 54 mm in diameter and 0.06 mm in thickness) and Durex Gossamer (178 mm in length, 52 mm in diameter and 0.065 mm in thickness) condoms are standard-shaped devices that are packaged in a silicone-based lubricant.</P>
<P>The second nonlatex condom, the polyurethane Avanti condom, was evaluated in four trials (<LINK REF="STD-Bounds-2002" TYPE="STUDY">Bounds 2002</LINK>; <LINK REF="STD-Frezieres-1998" TYPE="STUDY">Frezieres 1998</LINK>; <LINK REF="STD-Frezieres-1999" TYPE="STUDY">Frezieres 1999</LINK>; <LINK REF="STD-Frezieres-2000" TYPE="STUDY">Frezieres 2000</LINK>). The <LINK REF="STD-Bounds-2002" TYPE="STUDY">Bounds 2002</LINK> study compared the Avanti condom to the latex Durex Gossamer condom. <LINK REF="STD-Frezieres-1998" TYPE="STUDY">Frezieres 1998</LINK> and <LINK REF="STD-Frezieres-1999" TYPE="STUDY">Frezieres 1999</LINK> compared the Avanti with the latex Ramses Sensitol condom. The Ramses Sensitol condom is identical to the Avanti condom in length and open-end circumference. Also, both are reservoir-tipped and packaged in a silicone-based lubricant. However, the Avanti condom is thinner (0.035 to 0.040 mm versus 0.070 to 0.080 mm) and wider when laid flat (64 mm versus 52 mm) than the Ramses Sensitol condom. <LINK REF="STD-Frezieres-2000" TYPE="STUDY">Frezieres 2000</LINK> compared the Avanti with the latex Trojan-Enz condom. Both condoms are cylindrical with a reservoir tip and are similar in length (180 mm), but the Trojan-Enz condom is thicker (0.075 mm versus 0.04 to 0.05 mm) and is narrower when laid flat (52 mm versus 57 mm). Also, the Trojan-Enz is packaged in an aqueous-based lubricant while the Avanti condom comes in a silicone-based lubricant. Both condoms were distributed to the study participants with the lubricant Astroglide (Biofilm, Inc.).</P>
<P>The third nonlatex condom comes in three styles: Standard Tactylon, Baggy Tactylon, and Low-Modulus Tactylon. One study (<LINK REF="STD-Steiner-1993" TYPE="STUDY">Steiner 1993</LINK>) compared the three lubricated Tactylon styles to the standard, lubricated latex condom distributed by the U.S. Agency for International Development (USAID). A second study (<LINK REF="STD-Callahan-2000" TYPE="STUDY">Callahan 2000</LINK>) compared the three Tactylon condoms to the latex Aladan condom. The lubricated Aladan condom has a standard cylindrical, reservoir-tipped shape 183 mm in length, 52 mm in width and 0.07 mm in thickness. Three trials (<LINK REF="STD-Frezieres-2000" TYPE="STUDY">Frezieres 2000</LINK>; <LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK>; <LINK REF="STD-Trussell-1992" TYPE="STUDY">Trussell 1992</LINK>) evaluated the Standard Tactylon condom versus the latex Trojan-Enz condom. While the Standard Tactylon and the Trojan-Enz condoms were lubricated in two trials (<LINK REF="STD-Frezieres-2000" TYPE="STUDY">Frezieres 2000</LINK>; <LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK>), the condoms were distributed without lubrication in the third (<LINK REF="STD-Trussell-1992" TYPE="STUDY">Trussell 1992</LINK>). <LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK> also compared the Standard Tactylon to the LifeStyles condom (52 mm in width, 180 mm in length and 0.06 mm thick) with the lubricant Astroglide distributed to the study participants.</P>
<P>The fourth nonlatex condom was made of polyurethane and known as Protex Original in Europe and Sagami Original in Japan. <LINK REF="STD-Potter-2003" TYPE="STUDY">Potter 2003</LINK> compared the Protex Original with a control latex condom supplied by the same manufacturer, Sagami Rubber Industries Co., Ltd. The polyurethane condom was thinner than the latex condom (0.03 mm versus 0.06 mm). The Protex Original was also slightly wider (58 mm versus 52 mm) and slightly longer (193 mm versus 189 mm). Both types of condoms were packaged with the same quantity of a silicone-based lubricant.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-05-08 10:18:33 -0400" MODIFIED_BY="Laureen M Lopez">
<P>The 'Characteristics of included studies' table includes details related to the methodological quality of each of the studies. Despite the provision of condoms in similar packages (<LINK REF="STD-Callahan-2000" TYPE="STUDY">Callahan 2000</LINK>; <LINK REF="STD-Frezieres-1999" TYPE="STUDY">Frezieres 1999</LINK>), the participants could not be blinded to the group assignment in any of the trials due to differences in condom attributes. Study investigators and staff were blinded in three studies (<LINK REF="STD-Frezieres-1998" TYPE="STUDY">Frezieres 1998</LINK>; <LINK REF="STD-Frezieres-1999" TYPE="STUDY">Frezieres 1999</LINK>; <LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK>) and outcome assessors were blinded in five studies (<LINK REF="STD-Cook-2001" TYPE="STUDY">Cook 2001</LINK>; <LINK REF="STD-Frezieres-1998" TYPE="STUDY">Frezieres 1998</LINK>; <LINK REF="STD-Frezieres-1999" TYPE="STUDY">Frezieres 1999</LINK>; <LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK>; <LINK REF="STD-Steiner-2003" TYPE="STUDY">Steiner 2003</LINK>). Randomization was conducted using random sampling numbers (<LINK REF="STD-Bounds-2002" TYPE="STUDY">Bounds 2002</LINK>); computer-generated numbers (<LINK REF="STD-Frezieres-1998" TYPE="STUDY">Frezieres 1998</LINK>; <LINK REF="STD-Frezieres-1999" TYPE="STUDY">Frezieres 1999</LINK>; <LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK>); a computer-generated, permuted block scheme stratified by site only (<LINK REF="STD-Cook-2001" TYPE="STUDY">Cook 2001</LINK>) or site and prior condom experience (<LINK REF="STD-Steiner-2003" TYPE="STUDY">Steiner 2003</LINK>); or an undescribed method (<LINK REF="STD-Callahan-2000" TYPE="STUDY">Callahan 2000</LINK>; <LINK REF="STD-Frezieres-2000" TYPE="STUDY">Frezieres 2000</LINK>; <LINK REF="STD-Potter-2003" TYPE="STUDY">Potter 2003</LINK>; <LINK REF="STD-Steiner-1993" TYPE="STUDY">Steiner 1993</LINK>; <LINK REF="STD-Trussell-1992" TYPE="STUDY">Trussell 1992</LINK>). Group allocation was concealed using sealed, sequentially-numbered containers (<LINK REF="STD-Frezieres-1998" TYPE="STUDY">Frezieres 1998</LINK>); sealed, sequentially-numbered opaque containers (<LINK REF="STD-Cook-2001" TYPE="STUDY">Cook 2001</LINK>; <LINK REF="STD-Frezieres-1999" TYPE="STUDY">Frezieres 1999</LINK>; <LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK>); or a centralized telephone allocation process (<LINK REF="STD-Steiner-2003" TYPE="STUDY">Steiner 2003</LINK>). The remaining six trials did not report the method of allocation concealment.</P>
<P>The proportion of eligible couples who were recruited but subsequently declined participation ranged from 11% to 64% for the six trials that reported this information (<LINK REF="STD-Frezieres-1998" TYPE="STUDY">Frezieres 1998</LINK>; <LINK REF="STD-Frezieres-1999" TYPE="STUDY">Frezieres 1999</LINK>; <LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK>; <LINK REF="STD-Potter-2003" TYPE="STUDY">Potter 2003</LINK>; <LINK REF="STD-Steiner-1993" TYPE="STUDY">Steiner 1993</LINK>; <LINK REF="STD-Trussell-1992" TYPE="STUDY">Trussell 1992</LINK>). The combined loss to follow up and early discontinuation rates ranged from 2% to 47% in the 11 trials. About 8% of couples in the <LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK> trial were disqualified after randomization and excluded from the analyses. Pregnancy at enrollment was the most common reason given for disqualification (13 women in the Tactylon, 3 in the LifeStyles, and 9 in the Trojan-Enz group). Two couples were excluded from the analyses in <LINK REF="STD-Potter-2003" TYPE="STUDY">Potter 2003</LINK>, due to ambiguous responses. The exclusion of randomized participants from the analysis is inappropriate since it can bias the results (<LINK REF="REF-Schulz-2002b" TYPE="REFERENCE">Schulz 2002b</LINK>).</P>
<P>
<LINK REF="STD-Callahan-2000" TYPE="STUDY">Callahan 2000</LINK> deviated from the proposed condom breakage and slippage standard definitions (<LINK REF="REF-Steiner-1994" TYPE="REFERENCE">Steiner 1994</LINK>) by classifying breaks that occurred after withdrawal as nonclinical breakage. The remaining trials either followed the standard breakage and slippage definitions or presented the data in a manner that allowed their extraction. The randomized study design ideally prevents bias due to a learning effect. Almost a quarter (23.9%) of the couples in the crossover trial by <LINK REF="STD-Steiner-1993" TYPE="STUDY">Steiner 1993</LINK> did not follow perfectly the randomized order for the use of the four study condoms and 8.8% did not use the two assigned condoms of the same type consecutively. <LINK REF="STD-Steiner-1993" TYPE="STUDY">Steiner 1993</LINK> argued that the lack of compliance with the designated order was unlikely to have more than a minimal effect on the measures of condom functionality since most couples were experienced condom users and would have gained an inconsequential amount of condom experience during the study. While departure from the randomized condom order potentially is an issue in a second crossover trial (<LINK REF="STD-Trussell-1992" TYPE="STUDY">Trussell 1992</LINK>), the authors did not describe any violations in condom use order. The remaining five crossover studies used a study design that was unlikely to lead to changes in the assigned order of condom use.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-12-17 15:35:34 -0500" MODIFIED_BY="Laureen M Lopez">
<P>The nonlatex condoms did not fare as well as the latex condoms in terms of total failure and total clinical failure. For five comparisons, the Peto OR of total failure for the nonlatex condoms versus their latex comparisons varied between 1.92 (95% CI 1.08 to 3.40) and 3.47 (95% CI 2.82 to 4.27). Six comparisons did not have statistically significantly different Peto ORs and three comparisons did not report data for total failure. For eight comparisons, the Peto OR of total clinical failure for the nonlatex versus latex condoms ranged from 1.94 (95% CI 1.28 to 2.95) to 4.41 (95% CI 3.51 to 5.54), but it was not statistically significantly different for six comparisons. Clinical breakage, rather than nonclinical breakage or slippage, was responsible for the higher rates of condom failures with the nonlatex condoms. The Peto OR of clinical breakage for the nonlatex condoms versus their latex comparison condoms ranged from 2.64 (95% CI 1.63 to 4.28) to 4.95 (95% CI 3.63 to 6.75), except for five comparisons that did not show statistically significant differences. Most comparisons for nonclinical breakage, complete slippage, or partial slippage did not find differences between the nonlatex and latex condoms. The Avanti versus the Ramses Sensitol condom (Peto OR 0.23; 95% CI 0.06 to 0.90) and the Baggy Tactylon versus the USAID condom (Peto OR 3.73; 95% CI 1.43 to 9.72) were the only comparisons with statistically significant findings for nonclinical breakage. The only comparisons with statistically significant Peto ORs of complete slippage were for the eZ·on versus the latex Kimono Select (Peto OR 2.26; 95% CI 1.35 to 3.77) and for the Avanti versus the latex Ramses Sensitol condom (Peto OR 3.57; 95% CI 2.58 to 4.95).</P>
<P>Only one trial found an important difference in contraceptive efficacy. Since the a priori null hypothesis of the inferiority of the nonlatex condom for typical-use efficacy was not rejected, <LINK REF="STD-Steiner-2003" TYPE="STUDY">Steiner 2003</LINK> concluded that the eZ·on condom did not protect against pregnancy as well as the nonlatex Kimono Select condom (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). However, no statistically significant differences in typical-use efficacy were found for the Avanti versus the latex Ramses Sensitol or the Standard Tactylon versus the combined LifeStyles and Trojan-Enz latex condoms (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). The Peto OR of pregnancy, calculated with the number of condoms (<LINK REF="STD-Frezieres-1999" TYPE="STUDY">Frezieres 1999</LINK>) or the number of women (<LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK>) as the denominator, also did not show any statistically significant advantages of either condom group in preventing pregnancies.</P>
<P>Discontinuation rates varied widely. Two parallel trials (<LINK REF="STD-Frezieres-1999" TYPE="STUDY">Frezieres 1999</LINK>; <LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK>) reported six-month cumulative life-table rates of early discontinuation per 100 women. Women in the Avanti group were significantly more likely to discontinue the trial early (P value 0.002 from article; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>) than those in the latex Ramses Sensitol group. The Avanti condom users also were significantly more likely to discontinue for condom-related reasons than the latex condom users (P value 0.01 from article). The life-table overall discontinuation rates for the Standard Tactylon users compared to the combined group of latex Lifestyles and Trojan-Enz users were not significantly different (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). In the third parallel trial (<LINK REF="STD-Steiner-2003" TYPE="STUDY">Steiner 2003</LINK>), the Peto OR showed that the eZ·on and the latex Kimono Select groups were similar for overall discontinuation.</P>
<P>Several important differences were found in the frequency of adverse events. Two trials reported data on "medical events," which the authors defined as any genital problem that remained for less than 24 hours (<LINK REF="STD-Callahan-2000" TYPE="STUDY">Callahan 2000</LINK>; <LINK REF="STD-Cook-2001" TYPE="STUDY">Cook 2001</LINK>). These transient symptoms included genital burning, irritation, itching, rash, and bruising. No differences in medical events were detected in <LINK REF="STD-Cook-2001" TYPE="STUDY">Cook 2001</LINK>. In <LINK REF="STD-Callahan-2000" TYPE="STUDY">Callahan 2000</LINK>, the Standard Tactylon was associated with fewer medical events when compared with the latex Aladan condom; the Peto OR of medical events was 0.35 (95% CI 0.19 to 0.63) for males and 0.39 (95% CI 0.27 to 0.57) for females. The Baggy Tactylon (Peto OR 0.49; 95% CI 0.35 to 0.70) and the Low-Modulus Tactylon (Peto OR 0.61; 95% CI 0.43 to 0.85) resulted in fewer medical events for females when compared with the Aladan condom (<LINK REF="STD-Callahan-2000" TYPE="STUDY">Callahan 2000</LINK>). Irritation, burning, itching and genital pain were the most commonly reported medical events in the trial comparing the three Tactylon styles to the Aladan condom (<LINK REF="STD-Callahan-2000" TYPE="STUDY">Callahan 2000</LINK>). The <LINK REF="STD-Frezieres-1999" TYPE="STUDY">Frezieres 1999</LINK> efficacy study reported on transitory discomfort to males, including painful constriction, irritation, itching and burning. The Avanti users were less likely than users of the Ramses Sensitol condom to report these events (Peto OR 0.63; 95% CI 0.58 to 0.68). The <LINK REF="STD-Steiner-2003" TYPE="STUDY">Steiner 2003</LINK> efficacy trial reported on "genital adverse experiences," which they defined as possibly or probably product-related adverse events. Males did not report differences in genital adverse experiences by condom type (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). However, female eZ·on condom users were less likely to report genital problems than their latex Kimono Select counterparts, with a hazard ratio of 0.6 (95% CI 0.5 to 0.8) stratified by center and prior condom experience (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>). In <LINK REF="STD-Potter-2003" TYPE="STUDY">Potter 2003</LINK>, males reported more itching, burning, and prickling when using the Protex Original than when using the latex condom (Peto OR 1.65; 95% CI 1.21 to 2.24).</P>
<P>Most studies either did not report adverse events or did not have enough power to adequately detect differences between groups. In <LINK REF="STD-Cook-2001" TYPE="STUDY">Cook 2001</LINK>, adverse events included two men who reported genital irritation or mild genital rash and four women who reported mild or moderate genital irritation, genital rash, severe genital edema, or labial edema. The participants with adverse events were evenly divided between the eZ·on and the latex Kimono Select condom groups. <LINK REF="STD-Callahan-2000" TYPE="STUDY">Callahan 2000</LINK> reported one adverse event, which was a case of vaginitis by a woman using the Baggy Tactylon condom. In the <LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK> trial, none of the male participants reported adverse events that they believed to be probably or possibly related to the study condoms. Women reported 15 adverse events, including yeast infection, urinary tract infection, allergy to latex condom, and undiagnosed events.</P>
<P>Few of the trials found statistically significant differences in the acceptability of the condom types. Males in the <LINK REF="STD-Bounds-2002" TYPE="STUDY">Bounds 2002</LINK> trial reported less often that the eZ·on was easy to don than the latex Durex Gossamer (Peto OR 0.49; 95% CI 0.29 to 0.82). In the <LINK REF="STD-Frezieres-1999" TYPE="STUDY">Frezieres 1999</LINK> efficacy study, the male users of the Avanti condom reported less often that they would recommend their assigned condom than the latex Ramses Sensitol condom users (Peto OR 0.34; 95% CI 0.25 to 0.47). In a second efficacy trial (<LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK>), male Standard Tactylon users reported less often than male Lifestyles users that they would recommend their study condom (Peto OR 0.58; 95% CI 0.37 to 0.90). Female Standard Tactylon users reported less often than female Trojan-Enz users that they would recommend their study condom (Peto OR 0.55; 95% CI 0.34 to 0.88) (<LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK>). Finally, the Low-Modulus Tactylon condom was chosen as the overall preferred condom more often than the latex comparison condom among the participants in the two crossover trials who used the three types of Tactylon condoms and either the latex Aladan condom (<LINK REF="STD-Callahan-2000" TYPE="STUDY">Callahan 2000</LINK>) or the standard USAID latex condom (<LINK REF="STD-Steiner-1993" TYPE="STUDY">Steiner 1993</LINK>). The Peto OR of preferred condom for the Low-Modulus Tactylon versus the Aladan condom was 1.63 (95% CI 1.20 to 2.23) for males and 1.48 (95% CI 1.08 to 2.01) for females. The Peto OR for the Low-Modulus Tactylon versus the standard USAID latex condom was 1.83 (95% CI 1.24 to 2.69) for males and 1.52 (95% CI 1.04 to 2.23) for females. In comparing the Protex Original with a standard latex condom, <LINK REF="STD-Potter-2003" TYPE="STUDY">Potter 2003</LINK> used eight condom properties rather than an overall preference item. The Protex Original was preferred for thinness and odor, while the latex condom was preferred for its sound, touch and feel, and ease of unrolling.</P>
<P>Only three comparisons included identical latex and nonlatex condom types and, thus, were eligible to be combined in meta-analyses: 1) the eZ·on versus the Kimono Select (<LINK REF="STD-Cook-2001" TYPE="STUDY">Cook 2001</LINK>; <LINK REF="STD-Steiner-2003" TYPE="STUDY">Steiner 2003</LINK>); 2) the Avanti versus the latex Ramses Sensitol condom (<LINK REF="STD-Frezieres-1998" TYPE="STUDY">Frezieres 1998</LINK>; <LINK REF="STD-Frezieres-1999" TYPE="STUDY">Frezieres 1999</LINK>); and 3) the Standard Tactylon versus the latex Trojan-Enz condom (<LINK REF="STD-Frezieres-2000" TYPE="STUDY">Frezieres 2000</LINK>; <LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK>; <LINK REF="STD-Trussell-1992" TYPE="STUDY">Trussell 1992</LINK>). The trial results included in the first two comparisons appeared to be homogenous using either a fixed-effects or a random-effects model. The Standard Tactylon versus the Trojan-Enz condom comparisons also appeared to be homogeneous with two exceptions: the results for clinical breakage and total breakage appeared to differ between the studies. The three trials differed in that the condoms were lubricated in two trials (<LINK REF="STD-Frezieres-2000" TYPE="STUDY">Frezieres 2000</LINK>; <LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK>) but unlubricated in the third (<LINK REF="STD-Trussell-1992" TYPE="STUDY">Trussell 1992</LINK>). However, the estimates for clinical breakage and total breakage from <LINK REF="STD-Trussell-1992" TYPE="STUDY">Trussell 1992</LINK> appeared to be homogenous with the estimates from the two trials that used lubricated condoms. Sensitivity analysis revealed that the statistically significant results for the two outcomes were both dependent on the inclusion of <LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK>.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-05-30 12:56:39 -0400" MODIFIED_BY="Laureen M Lopez">
<P>Although the nonlatex condoms had breakage and slippage rates similar to those found in the literature (<LINK REF="REF-Warner-2007" TYPE="REFERENCE">Warner 2007</LINK>), they did not perform as well as the latex condoms. In general, the nonlatex condoms were more likely to break during intercourse or withdrawal than were the latex condoms. While the eZ·on condom did not protect against pregnancy as well as its latex comparison condom, no differences were found in the typical-use efficacy in the comparisons between the Avanti and the Standard Tactylon and their latex counterparts. Substantial proportions of study participants reported preferences for the nonlatex condoms. Therefore, the nonlatex condoms appear to be an acceptable alternative for those with sensitivities, aversion, or reluctance to the use of latex condoms.</P>
<P>An interpretation of the findings of the trials should include a consideration of several limitations. Breakage and slippage outcomes appear to be useful for comparative studies of condom types, and the eligible trials collected data on these measures of functionality; however, breakage and slippage have not been established to be valid surrogate endpoints for contraceptive efficacy. The two randomized parallel trials with a breakage and slippage component nested within a longer efficacy study (<LINK REF="STD-Frezieres-1999" TYPE="STUDY">Frezieres 1999</LINK>; <LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK>) provided an opportunity to evaluate the ability of breakage and slippage rates to predict contraceptive efficacy. Neither trial found evidence to suggest that measures of condom functionality predicted typical-use pregnancy rates. Since slippage and breakage do not appear to be valid surrogate endpoints for pregnancy, these outcomes should not be used in future studies (<LINK REF="REF-Grimes-2005" TYPE="REFERENCE">Grimes 2005</LINK>).</P>
<P>Second, differences in experience with latex and nonlatex condoms may have resulted in unbalanced measures of condom functionality. The proportion of participants in the 10 trials who were experienced condom users (with the definition of "experienced" varying between trials) ranged from 73% to 100%. Because nonlatex condoms were new products that were not widely available at the time of the trials, prior condom experience probably was limited to the latex devices. The participants were unlikely to have become as proficient during the trials in donning, fitting, and using the condoms made from the new materials as they were with nonlatex condoms, since most trials assigned few condoms of each type to be used in a short period of time.</P>
<P>Third, despite the crossover design in eight of the included trials, the results were analyzed as if they were from parallel trials. This analytic method is not a preferred approach since it fails to account for the within-participant correlation present in crossover trials and also violates the assumption of independence required for most statistical methods (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>).</P>
<P>Fourth, since the trials assigned multiple condoms of each type, couples who may have been predisposed to condom failures could have contributed a disproportionate number of failures. For example, <LINK REF="STD-Frezieres-1998" TYPE="STUDY">Frezieres 1998</LINK> found that only 4% of the couples broke more than one of the polyurethane condoms, but those couples accounted for 39% of the clinical breaks with the polyurethane condoms. The low number of condoms assigned to be used by the couples in each of the trials reduced the potential impact of couples who might have been prone to condom failure. However, the review would have been strengthened with the use of cluster analyses to account for inter-couple differences.</P>
<P>Fifth, the studies relied on self-reported outcomes, which might not have provided adequate assessments of slippage and breakage. The validity of self-reported condom use has been examined, and may depend on factors related to the population or intervention (<LINK REF="REF-Chen-2007" TYPE="REFERENCE">Chen 2007</LINK>; <LINK REF="REF-Gallo-2007" TYPE="REFERENCE">Gallo 2007</LINK>).</P>
<P>Sixth, couples at a greater risk of experiencing condom failure might have discontinued the trial at a higher rate than couples at lower risk of condom failure. If a disproportionate rate of study discontinuation occurred between these two groups, then the reported rates for condom slippage and breakage would underestimate the actual rates. Also, if study discontinuation occurred in a different pattern between the study condom groups, then the comparative measures of slippage and breakage could be biased. For example, potential for bias exists in the <LINK REF="STD-Frezieres-1999" TYPE="STUDY">Frezieres 1999</LINK> efficacy study since 33% of the polyurethane users who discontinued before completing two months reported a condom breakage versus 3% of the latex condom users who discontinued during this period.</P>
<P>Seventh, the participants could not be blinded as to their assigned device, which introduces the potential for bias due to media exposure or personal experiences with the study condom type. This might bias acceptability outcomes, but probably would have less effect on efficacy comparisons. Also, six of the trials did not describe any attempt to conceal the allocation process; lack of adequate allocation concealment could have introduced bias (<LINK REF="REF-Schulz-2002a" TYPE="REFERENCE">Schulz 2002a</LINK>).</P>
<P>Furthermore, the generalizability of the findings might be limited. The high proportion of experienced condom users could limit the ability to extrapolate the results of the trials to populations with less condom experience. Also, since the couples in the trials self-selected for participation and were required to meet eligibility criteria, the results from these participants may not apply to those not in a monogamous relationship, younger than 18 years of age, or with a known risk for sexually transmitted infections (STIs). For example, since the study couples were not at a high risk for STIs and the majority of the trials required the use of another effective contraceptive method, the compliance and diligence in condom use in these trials may not be applicable to other settings. Finally, the short duration of the trials may not be adequate for predicting experience with the condoms during longer, real-life use.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Only three trials examined contraceptive efficacy. While the eZ·on condom did not perform as well as its comparison latex condom in terms of preventing pregnancy, the Avanti and the Standard Tactylon had pregnancy rates similar to their latex comparisons. Despite the higher rate of clinical breakages with the nonlatex condoms, condoms made of the new materials could provide an acceptable alternative for individuals with allergies, sensitivities, or personal preferences that might prevent the consistent use of latex condoms.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-05-07 14:07:53 -0400" MODIFIED_BY="Laureen M Lopez">
<P>Since nonlatex condoms could be appropriate for certain subgroups, efficacy studies of the condom types are warranted. Breakage and slippage have not been found to be valid surrogate endpoints, so future studies should focus on pregnancy rates.</P>
<P>We only examined trials on the use of nonlatex condoms during vaginal intercourse to prevent pregnancies. The ability of the nonlatex condoms to protect against the transmission of HIV or other sexually transmitted infections (STIs) has not been established. While the new condoms are thought to provide protection comparable to that of latex condoms (<LINK REF="REF-Trussell-2007" TYPE="REFERENCE">Trussell 2007</LINK>), the consequences of infection justify research on STI transmission.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-12-17 15:36:30 -0500" MODIFIED_BY="[Empty name]">
<P>Carol Manion of FHI 360 assisted with the literature searches.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-03-16 09:00:47 -0400" MODIFIED_BY="[Empty name]">
<P>FHI (now FHI 360) developed the eZ·on condom and subsequently licensed the product to Mayer Laboratories, Inc. (Oakland, CA, USA). Two authors are employed at FHI 360 (LM Lopez and KF Schulz), and two were previously employed at FHI 360 (MF Gallo and DA Grimes). However, the authors were not involved in the development of the eZ·on condom, and were not employed at FHI 360 when the licensing agreement was executed with Mayer Laboratories for the eZ·on condom. FHI 360 is a nonprofit human development organization.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-12-18 09:42:25 -0500" MODIFIED_BY="[Empty name]">
<P>Maria Gallo drafted the review. Maria Gallo and David Grimes extracted data for the initial review. Laureen Lopez reviewed the searches for the updates (2006 through 2012), extracted data, and revised the review as needed. David Grimes and Kenneth Schulz edited and approved the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-05-30 12:50:18 -0400" MODIFIED_BY="Laureen M Lopez">
<STUDIES MODIFIED="2008-05-27 11:09:55 -0400" MODIFIED_BY="Laureen M Lopez">
<INCLUDED_STUDIES MODIFIED="2008-05-27 11:09:55 -0400" MODIFIED_BY="Laureen M Lopez">
<STUDY DATA_SOURCE="PUB" ID="STD-Bounds-2002" MODIFIED="2008-05-08 09:49:30 -0400" MODIFIED_BY="Laureen M Lopez" NAME="Bounds 2002" YEAR="">
<REFERENCE MODIFIED="2008-05-08 09:49:30 -0400" MODIFIED_BY="Laureen M Lopez" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bounds W, Molloy S, Guillebaud J</AU>
<TI>Pilot study of short-term acceptability and breakage and slippage rates for the loose-fitting polyurethane male condom eZ·on bi-directional: a randomized cross-over trial</TI>
<SO>European Journal of Contraception &amp; Reproductive Health Care</SO>
<YR>2002</YR>
<VL>7</VL>
<PG>71-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Callahan-2000" NAME="Callahan 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Callahan M, Mauck C, Taylor D, Frezieres R, Walsh T, Martens M</AU>
<TI>Comparative evaluation of three Tactylon(TM) condoms and a latex condom during vaginal intercourse: breakage and slippage</TI>
<SO>Contraception</SO>
<YR>2000</YR>
<VL>61</VL>
<PG>205-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Cook-2001" MODIFIED="2008-05-08 09:52:19 -0400" MODIFIED_BY="Laureen M Lopez" NAME="Cook 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-05-08 09:52:19 -0400" MODIFIED_BY="Laureen M Lopez" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Cook L, Nanda K, Farr G, Taylor D</AU>
<TI>A comparative assessment of the eZ·on&#8482; plastic condom and a latex condom: breakage and slippage. Final clinical study report</TI>
<SO>Family Health International, Research Triangle Park, NC</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cook L, Nanda K, Taylor D</AU>
<TI>Randomized crossover trial comparing the eZ.on plastic condom and a latex condom</TI>
<SO>Contraception</SO>
<YR>2001</YR>
<VL>63</VL>
<PG>25-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Frezieres-1998" NAME="Frezieres 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Frezieres RG, Walsh TL, Nelson AL, Clark VA, Coulson AH</AU>
<TI>Breakage and acceptability of a polyurethane condom: a randomized, controlled study</TI>
<SO>Family Planning Perspectives</SO>
<YR>1998</YR>
<VL>30</VL>
<PG>73-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Nelson A, Frezieres R, Walsh T, Clark V, Coulson A</AU>
<TI>Controlled, randomized evaluation of a commercially available polyurethane and latex condom (Avanti versus Ramses Sensitol). Final Report</TI>
<SO>N01-HD-1-3109</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Frezieres-1999" NAME="Frezieres 1999" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Frezieres RG, Walsh TL, Nelson AL, Clark VA, Coulson AH</AU>
<TI>Evaluation of the efficacy of a polyurethane condom: results from a randomized, controlled clinical trial</TI>
<SO>Family Planning Perspectives</SO>
<YR>1999</YR>
<VL>31</VL>
<PG>81-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Nelson A, Bernstein GS, Frezieres R, Walsh T, Clark V, Coulson A</AU>
<TI>Study of the efficacy, acceptability and safety of a non-latex (polyurethane) male condom</TI>
<SO>N01-HD-1-3109</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frezieres-2000" NAME="Frezieres 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frezieres RG, Walsh TL</AU>
<TI>Acceptability evaluation of a natural rubber latex, a polyurethane, and a new non-latex condom</TI>
<SO>Contraception</SO>
<YR>2000</YR>
<VL>61</VL>
<PG>369-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Nelson-2001" MODIFIED="2008-05-08 09:59:29 -0400" MODIFIED_BY="Laureen M Lopez" NAME="Nelson 2001" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Nelson A, Frezieres R, Walsh T, Bernstein L, Clark V</AU>
<TI>Phase II/III contraceptive efficacy trial comparing male latex condoms and a male non-latex condom. Final report</TI>
<SO>N01-HD-7-3275</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walsh TL, Frezieres RG, Peacock K, Nelson AL, Clark VA, Bernstein L</AU>
<TI>Evaluation of the efficacy of a nonlatex condom: results from a randomized, controlled clinical trial</TI>
<SO>Perspectives on Sexual and Reproductive Health</SO>
<YR>2003</YR>
<VL>35</VL>
<PG>79-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Potter-2003" MODIFIED="2008-05-27 09:13:04 -0400" MODIFIED_BY="Laureen M Lopez" NAME="Potter 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-05-27 09:13:04 -0400" MODIFIED_BY="Laureen M Lopez" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Potter WD, de Villemeur M</AU>
<TI>Clinical breakage, slippage and acceptability of a new commercial polyurethane condom: a randomized, controlled study</TI>
<SO>Contraception</SO>
<YR>2003</YR>
<VL>68</VL>
<PG>39-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Steiner-1993" NAME="Steiner 1993" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Steiner M, Joanis C, Taylor B, Glover L</AU>
<TI>Functionality and acceptability study of three lubricated Tactylon&#8482; condoms and a standard lubricated latex condom. Final Report</TI>
<SO>Family Health International</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steiner-2003" MODIFIED="2008-05-27 11:09:55 -0400" MODIFIED_BY="Laureen M Lopez" NAME="Steiner 2003" YEAR="">
<REFERENCE MODIFIED="2008-05-27 11:09:55 -0400" MODIFIED_BY="Laureen M Lopez" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steiner MJ, Dominik R, Rountree RW, Nanda K, Dorflinger LJ</AU>
<TI>Contraceptive effectiveness of a polyurethane condom and a latex condom: a randomized controlled trial</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>2003</YR>
<VL>101</VL>
<PG>539-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trussell-1992" NAME="Trussell 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trussell J, Warner DL, Hatcher R</AU>
<TI>Condom performance during vaginal intercourse: comparison of Trojan-Enz and Tactylon condoms</TI>
<SO>Contraception</SO>
<YR>1992</YR>
<VL>45</VL>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-05-30 12:50:18 -0400" MODIFIED_BY="Laureen M Lopez">
<ADDITIONAL_REFERENCES MODIFIED="2008-05-30 12:50:18 -0400" MODIFIED_BY="Laureen M Lopez">
<REFERENCE ID="REF-Abma-1997" NAME="Abma 1997" TYPE="JOURNAL_ARTICLE">
<AU>Abma J, Chandra A, Mosher W, Peterson L, Piccinino L</AU>
<TI>Fertility, family planning, and women's health: New data from the 1995 National Survey of Family Growth. National Center for Health Statistics</TI>
<SO>Vital Health Statistics</SO>
<YR>1997</YR>
<VL>23</VL>
<PG>1-114</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chen-2007" MODIFIED="2008-05-30 12:36:30 -0400" MODIFIED_BY="Laureen M Lopez" NAME="Chen 2007" TYPE="JOURNAL_ARTICLE">
<AU>Chen MP, Macaluso M, Blackwell R, Galvao L, Kulczycki A, Diaz J, et al</AU>
<TI>Self-reported mechanical problems during condom use and semen exposure</TI>
<SO>Sexually Transmitted Diseases</SO>
<YR>2007</YR>
<VL>34</VL>
<PG>557-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Free-1996" NAME="Free 1996" TYPE="JOURNAL_ARTICLE">
<AU>Free MJ, Srisamang V, Vail J, Mercer D, Kotz R, Marlowe DE</AU>
<TI>Latex rubber condoms: predicting and extending shelf life</TI>
<SO>Contraception</SO>
<YR>1996</YR>
<VL>53</VL>
<PG>221-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gallo-2007" MODIFIED="2008-05-30 12:42:30 -0400" MODIFIED_BY="Laureen M Lopez" NAME="Gallo 2007" TYPE="JOURNAL_ARTICLE">
<AU>Gallo MF, Behets FM, Steiner MJ, Thomsen SC, Ombidi W, Luchters S, et al</AU>
<TI>Validity of self-reported 'safe sex' among female sex workers in Mombasa, Kenya - PSA analysis</TI>
<SO>International Journal of STD &amp; AIDS 2007</SO>
<YR>2007</YR>
<VL>18</VL>
<PG>33-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grady-1993" NAME="Grady 1993" TYPE="JOURNAL_ARTICLE">
<AU>Grady WR, Klepinger DH, Billy JOG, Tanfer K</AU>
<TI>Condom characteristics: the perceptions and preferences of men in the United States</TI>
<SO>Family Planning Perspectives</SO>
<YR>1993</YR>
<VL>25</VL>
<PG>67-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grimes-2005" NAME="Grimes 2005" TYPE="JOURNAL_ARTICLE">
<AU>Grimes DA, Schulz KF</AU>
<TI>Surrogate end points in clinical research: hazardous to your health</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>2005</YR>
<VL>105</VL>
<PG>1114-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lytle-1990" NAME="Lytle 1990" TYPE="JOURNAL_ARTICLE">
<AU>Lytle CD, Carney PG, Vohra S, Cyr WH, Bockstahler LE</AU>
<TI>Virus leakage through natural membrane condoms</TI>
<SO>Sexually Transmitted Diseases</SO>
<YR>1990</YR>
<VL>17</VL>
<PG>58-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Minuk-1989" MODIFIED="2008-05-28 08:58:23 -0400" MODIFIED_BY="Laureen M Lopez" NAME="Minuk 1989" TYPE="CONFERENCE_PROC">
<AU>Minuk GY</AU>
<TI>Condoms and hepatitis B virus infection</TI>
<SO>Condoms in the prevention of sexually transmitted diseases. Sponsored by the American Social Health Association, the U.S. Centers for Disease Control, and Family Health International; 1987 Feb; Atlanta (GA)</SO>
<YR>1989</YR>
<PG>4-5</PG>
<PB>American Social Health Association</PB>
<CY>Research Triangle Park (NC)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mosher-1993" NAME="Mosher 1993" TYPE="JOURNAL_ARTICLE">
<AU>Mosher WD, Pratt WF</AU>
<TI>AIDS-related behavior among women 15-44 years of age: United States, 1988 and 1990</TI>
<SO>Advance Data from Vital and Health Statistics</SO>
<YR>1993</YR>
<VL>239</VL>
<PG>1-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murphy-1990" NAME="Murphy 1990" TYPE="BOOK">
<AU>Murphy JS</AU>
<SO>The condom industry in the United States</SO>
<YR>1990</YR>
<PB>McFarland &amp; Company, Inc.</PB>
<CY>Jefferson NC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robinson-2002" NAME="Robinson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Robinson KA, Dickersin K</AU>
<TI>Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<PG>150-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-2002a" MODIFIED="2008-05-08 10:17:43 -0400" MODIFIED_BY="Laureen M Lopez" NAME="Schulz 2002a" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Grimes DA</AU>
<TI>Allocation concealment in randomised trials: defending against deciphering</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>359</VL>
<PG>614-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-2002b" MODIFIED="2008-05-08 10:17:32 -0400" MODIFIED_BY="Laureen M Lopez" NAME="Schulz 2002b" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Grimes DA</AU>
<TI>Sample size slippages in randomised trials: exclusions and the lost and wayward</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>359</VL>
<PG>781-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steiner-1994" NAME="Steiner 1994" TYPE="JOURNAL_ARTICLE">
<AU>Steiner M, Trussell J, Glover L, Joanis C, Spruyt A, Dorflinger L</AU>
<TI>Standardized protocols for condom breakage and slippage trials: a proposal</TI>
<SO>American Journal of Public Health</SO>
<YR>1994</YR>
<VL>84</VL>
<PG>1897-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trussell-2007" MODIFIED="2008-05-27 11:24:24 -0400" MODIFIED_BY="Laureen M Lopez" NAME="Trussell 2007" TYPE="BOOK_SECTION">
<AU>Trussell J</AU>
<TI>Contraceptive efficacy</TI>
<SO>Contraceptive Technology</SO>
<YR>2007</YR>
<PG>747-826</PG>
<EN>19th revised</EN>
<ED>Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D, et al</ED>
<PB>Ardent Media, Inc.</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Warner-2007" MODIFIED="2008-05-07 14:05:47 -0400" MODIFIED_BY="Laureen M Lopez" NAME="Warner 2007" TYPE="BOOK_SECTION">
<AU>Warner L, Steiner MJ</AU>
<TI>Male condoms</TI>
<SO>Contraceptive Technology</SO>
<YR>2007</YR>
<PG>297-316</PG>
<EN>19th revised</EN>
<ED>Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D, et al</ED>
<PB>Ardent Media, Inc.</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-05-08 10:08:04 -0400" MODIFIED_BY="Laureen M Lopez">
<REFERENCE ID="REF-Gallo-2003" MODIFIED="2008-05-08 10:08:04 -0400" MODIFIED_BY="Laureen M Lopez" NAME="Gallo 2003" TYPE="JOURNAL_ARTICLE">
<AU>Gallo M, Grimes D, Schulz K</AU>
<TI>Nonlatex versus latex male condoms for contraception</TI>
<SO>Contraception</SO>
<YR>2003</YR>
<VL>68</VL>
<PG>319-26</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-11-03 12:01:03 -0400" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-11-03 12:01:03 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-11-03 12:01:03 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bounds-2002">
<CHAR_METHODS>
<P>Randomized, crossover trial.<BR/>Postal and telephone contact (no clinic visits) with UK population.<BR/>Participants were not blinded. Investigator and outcome assessor blinding was not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-27 10:57:37 -0400" MODIFIED_BY="Laureen M Lopez">
<P>43 healthy, sexually active couples aged 18 to 50 years in a stable monogamous relationship. Exclusions included allergy to latex, current STI; planned genital surgery; require condom use for specific STI protection.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-08 09:47:02 -0400" MODIFIED_BY="Laureen M Lopez">
<P>Couples were assigned to use 6 condoms of each of the 3 condom types in a randomized sequence.<BR/>The eZ·on condom (Family Health International, Research Triangle Park, NC and Mayer Laboratories, Inc., Oakland, CA) versus Avanti (SSL International plc, Knutsford, UK) versus the latex Durex Gossamer (SSL International plc, Knutsford, UK).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-27 10:59:09 -0400" MODIFIED_BY="Laureen M Lopez">
<P>Ease of use and acceptability; breakage and slippage.<BR/>Breakage and slippage outcomes were abstracted in method consistent with <LINK REF="REF-Steiner-1994" TYPE="REFERENCE">Steiner 1994</LINK> definitions.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-03 12:01:03 -0400" MODIFIED_BY="[Empty name]">
<P>Randomized with random sampling numbers.<BR/>Allocation concealment methods not reported.<BR/>47% loss to follow up and early discontinuation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-03 12:01:02 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Callahan-2000">
<CHAR_METHODS MODIFIED="2008-05-27 10:59:21 -0400" MODIFIED_BY="Laureen M Lopez">
<P>Randomized crossover trial.<BR/>Two centers in United States.<BR/>Blinding not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-27 11:03:09 -0400" MODIFIED_BY="Laureen M Lopez">
<P>443 healthy, sexually active couples aged 18 to 45 years in a mutually monogamous, heterosexual relationship using an effective nonbarrier method of contraception. Exclusions included history of sensitivity to latex, Tactylon, silicone oil or water-based lubricants; at risk for STDs; recent abnormal Papanicolaou smear.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Couples were assigned to use 3 condoms of each of the 4 condom types with each type used during a 3-week period in a randomized sequence. Standard Tactylon condom versus Baggy Tactylon condom versus Low-Modulus Tactylon condom versus the standard latex condom Aladan (Dothan, AL). All Tactylon condoms were manufactured by Sensicon Corp., Vista, CA (formerly Tactyl Technologies).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-27 11:01:34 -0400" MODIFIED_BY="Laureen M Lopez">
<P>Breakage and slippage; medical events; adverse events; acceptability.<BR/>Breakage and slippage definitions consistent with <LINK REF="REF-Steiner-1994" TYPE="REFERENCE">Steiner 1994</LINK>, except that breakage while removing condom after withdrawal was classified as nonclinical breakage.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-03 12:01:02 -0400" MODIFIED_BY="[Empty name]">
<P>Randomization and allocation concealment methods not reported.<BR/>11% loss to follow up and early discontinuation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-03 09:51:24 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cook-2001">
<CHAR_METHODS MODIFIED="2008-05-27 11:01:39 -0400" MODIFIED_BY="Laureen M Lopez">
<P>Randomized crossover trial.<BR/>Two centers in United States.<BR/>Participants were not blinded. Outcome assessors were blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-27 11:01:56 -0400" MODIFIED_BY="Laureen M Lopez">
<P>360 sexually active couples in a mutually monogamous, heterosexual relationship using an effective nonbarrier method of contraception. Women aged 18 to 45 years and males aged 18 years or older. Exclusions included risk for STI.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Couples were assigned to use 4 condoms of each of the 2 condom types with each type used during a 3-week period in a randomized sequence. The eZ·on condom (Family Health International, Research Triangle Park, NC and Mayer Laboratories, Inc., Oakland, CA) versus a latex condom (Kimono Select, Mayer Laboratories, Inc., Oakland, CA).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Breakage and slippage; medical events; adverse events; acceptability.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-03 09:51:24 -0400" MODIFIED_BY="[Empty name]">
<P>Randomized with computer-generated permuted block scheme stratified by site.<BR/>4% loss to follow up and early discontinuation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-03 09:51:42 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frezieres-1998">
<CHAR_METHODS MODIFIED="2008-05-27 11:02:19 -0400" MODIFIED_BY="Laureen M Lopez">
<P>Randomized crossover trial.<BR/>One center in United States.<BR/>Participants were not blinded. Investigators and outcome assessors were blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-27 11:02:28 -0400" MODIFIED_BY="Laureen M Lopez">
<P>360 couples aged 18 to 45 years in monogamous, heterosexual relationship without known risk of STD.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Couples were assigned to use 3 condoms of each of the 2 condom types with each type used during a 2-week period in a randomized sequence. The polyurethane condom Avanti or Avanti Super Thin (London International Group) versus the latex condom Ramses Sensitol (London International Group).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Breakage and slippage; acceptability.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-03 09:51:42 -0400" MODIFIED_BY="[Empty name]">
<P>Randomized with computer-generated sequence of binary numbers.<BR/>49% of eligible couples declined participation. 6% loss to follow up and early discontinuation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-03 09:52:09 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frezieres-1999">
<CHAR_METHODS>
<P>Randomized parallel trial.<BR/>One center in United States.<BR/>Participants were not blinded. Investigators and research staff were blinded.<BR/>Six-month trial. Nested breakage, slippage and acceptability study within the efficacy study based on data from the condoms used for the first five acts of intercourse.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-27 11:04:04 -0400" MODIFIED_BY="Laureen M Lopez">
<P>805 couples aged 18 to 45 years in monogamous heterosexual relationship without known risk of STD or infertility.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Polyurethane condom (similar to the Avanti, London International Group condom commercially produced after April 1996) versus the latex condom Ramses Sensitol (London International Group).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Contraceptive efficacy; breakage and slippage; continuation; acceptability.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-03 09:52:09 -0400" MODIFIED_BY="[Empty name]">
<P>Randomized with computer-generated sequence of binary numbers.<BR/>64% of eligible couples declined participation. 31% loss to follow up and early discontinuation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-03 12:01:00 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frezieres-2000">
<CHAR_METHODS MODIFIED="2008-05-27 11:04:34 -0400" MODIFIED_BY="Laureen M Lopez">
<P>Randomized crossover trial.<BR/>One center in United States.<BR/>Unblinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-27 11:04:38 -0400" MODIFIED_BY="Laureen M Lopez">
<P>54 couples aged 18 to 45 years in monogamous heterosexual relationship and currently using condoms.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Couples were assigned to use 3 condoms of each of the 3 condom types with each type used during a 2-week period in a randomized sequence. <BR/>The polyurethane condom Avanti (London International Group) versus the synthetic elastomers condom Tactylon, (Sensicon Corp., Vista, CA) versus the latex condom Trojan-Enz (Carter Wallace, Inc.).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Condom breakage and slippage; acceptability.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-03 12:01:00 -0400" MODIFIED_BY="[Empty name]">
<P>Randomization and allocation concealment methods not described.<BR/>6% loss to follow up and early discontinuation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-03 09:52:33 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nelson-2001">
<CHAR_METHODS>
<P>Randomized parallel trial. Seven centers in United States.<BR/>Six-month trial.<BR/>Nested breakage, slippage and acceptability study within the efficacy study based on data from the condoms used for the first five acts of intercourse.<BR/>Participants were unblinded. Investigators and outcome assessors were blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-27 11:05:38 -0400" MODIFIED_BY="Laureen M Lopez">
<P>830 sexually active, healthy couples (women aged 18 to 40 years and men aged 18 to 50 years) in monogamous heterosexual relationship. Exclusions included irregular menses, known STI, known infertility, and allergies to study products.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tactylon (Sensicon Corp., Vista, CA) versus either latex condom Trojan-Enz (Carter Wallace) or LifeStyles (Ansell). Study groups given Astroglide water-based lubricant.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Contraceptive efficacy; breakage and slippage; semen exposure from condom failure; safety; acceptability.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-03 09:52:33 -0400" MODIFIED_BY="[Empty name]">
<P>Randomized with computer-generated batch scheme. <BR/>31% loss to follow up and early discontinuation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-03 12:00:57 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Potter-2003">
<CHAR_METHODS MODIFIED="2008-05-27 11:05:58 -0400" MODIFIED_BY="Laureen M Lopez">
<P>Randomized crossover trial.<BR/>Couples in region of Paris (France) were recruited by a market research organization. Couples were asked to complete a brief questionnaire immediately after using each condom.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-27 11:06:18 -0400" MODIFIED_BY="Laureen M Lopez">
<P>250 couples (aged 18 to 55 years) in monogamous heterosexual relationship and using condoms as current contraceptive method. Exclusions included using other contraceptive methods, known STI, and women with history of serious complications in pregnancy or birth.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Couples were assigned to use 5 Protex (or Sagami) Original and 5 latex control condoms supplied by Sagami Rubber Industries Co, Ltd. (Tokyo, Japan). Assignment was random for which condom type to use first. Time period was not specified.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical and nonclinical breakage, clinical and nonclinical slippage.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-03 12:00:57 -0400" MODIFIED_BY="[Empty name]">
<P>No mention of blinding, allocation concealment, or randomization method.<BR/>250 couples were recruited, 36 did not return any questionnaires, 6 returned only some of the questionnaires.<BR/>Of 208 with all questionnaires, 2 were excluded from analysis due to response "errors." Independent audit conducted of analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-27 11:07:09 -0400" MODIFIED_BY="Laureen M Lopez" STUDY_ID="STD-Steiner-1993">
<CHAR_METHODS MODIFIED="2008-05-27 11:06:47 -0400" MODIFIED_BY="Laureen M Lopez">
<P>Randomized crossover trial.<BR/>One center in United States.<BR/>Unblinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-27 11:07:09 -0400" MODIFIED_BY="Laureen M Lopez">
<P>320 couples aged 21 years or older in monogamous, heterosexual relationship and currently using hormonal method, IUD or sterilization for contraception. Excluded pregnancy, lactation, STI, and allergies or sensitivities to latex.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-08 09:47:48 -0400" MODIFIED_BY="Laureen M Lopez">
<P>Couples were assigned to use 2 condoms of each of the 4 condom types in a randomized sequence during the 6-week study period. Standard Tactylon versus Baggy Tactylon versus Low-Modulus Tactylon versus the standard lubricated USAID latex condom (Ansell, Inc.). All Tactylon condoms were manufactured by Sensicon Corp., Vista, CA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Condom breakage and slippage; acceptability.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-07 14:19:36 -0400" MODIFIED_BY="Laureen M Lopez">
<P>Randomization and allocation concealment methods not reported.<BR/>11% did not complete questionnaires; 24% did not follow perfectly the randomized order for condoms; and 9% did not use the two condoms of the same type consecutively.<BR/>11% loss to follow up and early discontinuation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-03 09:55:07 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steiner-2003">
<CHAR_METHODS MODIFIED="2008-05-27 11:07:21 -0400" MODIFIED_BY="Laureen M Lopez">
<P>Randomized crossover trial.<BR/>Ten centers in United States.<BR/>Participant and investigator were unblinded. Outcome assessor was blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-07 14:22:13 -0400" MODIFIED_BY="Laureen M Lopez">
<P>Healthy, sexually active females aged 18 to 35 years in a stable, mutually monogamous relationship with regular menses and willing to use condoms only for contraception.<BR/>Excluded recent, current or contraindications to pregnancy; lactation; certain pap exam results; infertility or conditions associated with infertility; or HIV or STI or high risk for HIV.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Women were assigned to one condom type for 30 weeks. <BR/>The eZ·on condom (Family Health International, Research Triangle Park, NC and Mayer Laboratories, Inc., Oakland, CA) versus a latex condom (Kimono Select, Mayer Laboratories, Inc., Oakland, CA).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-27 11:07:59 -0400" MODIFIED_BY="Laureen M Lopez">
<P>Contraceptive efficacy; breakage and slippage; safety; acceptability.<BR/>Breakage and slippage outcomes were abstracted in method consistent with <LINK REF="REF-Steiner-1994" TYPE="REFERENCE">Steiner 1994</LINK> definitions.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-03 09:55:07 -0400" MODIFIED_BY="[Empty name]">
<P>Randomized with computer-generated, permuted blocked randomization scheme, stratified by site and prior condom experience.<BR/>27% loss to follow up and early discontinuation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-27 11:08:26 -0400" MODIFIED_BY="Laureen M Lopez" STUDY_ID="STD-Trussell-1992">
<CHAR_METHODS>
<P>Randomized, crossover trial.<BR/>One center in United States.<BR/>Blinding not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-27 11:08:26 -0400" MODIFIED_BY="Laureen M Lopez">
<P>50 couples aged 18 to 55 years in monogamous heterosexual relationship and currently using oral contraceptive, Norplant, IUD or sterilization for contraception if still fertile. Excluded pregnancy, lactation and STI.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Couples were assigned to use 5 condoms of each of the 2 condom types in an alternating sequence over a 5-week period. Half of the couples started with the polyurethane condom and the other half started with the latex condom. The polyurethane condom Tactylon (Tactyl Technologies) versus the latex condom Trojan-Enz (Carter-Wallace, Inc.).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Condom breakage and slippage; acceptability.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-07 14:19:23 -0400" MODIFIED_BY="Laureen M Lopez">
<P>Randomization and allocation concealment methods not described.<BR/>2% loss to follow up and early discontinuation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>STD = sexually transmitted disease(s)</P>
<P>STI = sexually transmitted infection(s)</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-11-03 09:55:17 -0400" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-11-03 09:55:17 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-03 09:51:01 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bounds-2002">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-03 09:51:12 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Callahan-2000">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-03 09:51:28 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cook-2001">
<DESCRIPTION>
<P>Allocation was concealed by sealed, opaque, sequentially-numbered envelopes opened at admission.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-03 09:51:54 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frezieres-1998">
<DESCRIPTION>
<P>Allocation concealed with sealed containers. Packages of 3 condoms were numbered to specify order of use and sealed in envelope that was labeled by couple identification number.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-03 09:52:13 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frezieres-1999">
<DESCRIPTION>
<P>Manufacturer provided study condoms packaged in sealed opaque foil wrappers, which were then sealed in opaque containers labeled with the couple identification number.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-03 09:52:21 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Frezieres-2000">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-03 09:52:36 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nelson-2001">
<DESCRIPTION>
<P>Condoms were supplied in sealed, opaque containers, which were labeled with subject identification numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-03 09:52:52 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Potter-2003">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-03 09:54:56 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Steiner-1993">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-03 09:55:10 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Steiner-2003">
<DESCRIPTION>
<P>Allocation concealed with centralized telephone system.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-03 09:55:17 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Trussell-1992">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2012-12-17 15:35:34 -0500" MODIFIED_BY="Laureen M Lopez">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-12-17 15:35:34 -0500" MODIFIED_BY="Laureen M Lopez" NO="1">
<TITLE>Nonlatex versus latex: hazard ratio of pregnancy</TITLE>
<TABLE COLS="4" ROWS="2">
<TR>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>Comparison</P>
</TH>
<TH>
<P>Nonlatex probability</P>
</TH>
<TH>
<P>Latex probability</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Steiner-2003" TYPE="STUDY">Steiner 2003</LINK>
</P>
</TD>
<TD>
<P>eZ·on versus Kimono Select</P>
</TD>
<TD>
<P>9.0 (95% CI 5.9 to 12.2)*</P>
</TD>
<TD>
<P>5.4 (95% CI 2.9 to 7.8)*</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*stratified by site and prior condom experience</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2012-12-17 15:35:34 -0500" MODIFIED_BY="Laureen M Lopez" NO="2">
<TITLE>Nonlatex versus latex: 6-month cumulative lifetable pregnancy rate per 100 women</TITLE>
<TABLE COLS="4" ROWS="3">
<TR>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>Comparison</P>
</TH>
<TH>
<P>Nonlatex rate</P>
</TH>
<TH>
<P>Latex rate</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Frezieres-1999" TYPE="STUDY">Frezieres 1999</LINK>
</P>
</TD>
<TD>
<P>Avanti versus Ramses Sensitol</P>
</TD>
<TD>
<P>4.1 (95% CI 1.9 to 6.3)</P>
</TD>
<TD>
<P>6.2 (95% CI 3.6 to 8.8)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK>
</P>
</TD>
<TD>
<P>Standard Tactylon versus LifeStyles/Trojan-Enz</P>
</TD>
<TD>
<P>10.8</P>
</TD>
<TD>
<P>7.9</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2008-05-08 09:48:45 -0400" MODIFIED_BY="Laureen M Lopez" NO="3">
<TITLE MODIFIED="2008-05-08 09:48:45 -0400" MODIFIED_BY="Laureen M Lopez">Nonlatex versus latex: 6-month cumulative lifetable discontinuation rate per 100 women</TITLE>
<TABLE COLS="5" ROWS="7">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>Comparison</P>
</TH>
<TH>
<P>Nonlatex rate</P>
</TH>
<TH>
<P>Latex rate</P>
</TH>
</TR>
<TR>
<TD>
<P>Discontinuation - overall</P>
</TD>
<TD>
<P>
<LINK REF="STD-Frezieres-1999" TYPE="STUDY">Frezieres 1999</LINK>
</P>
</TD>
<TD>
<P>Avanti versus Ramses Sensitol</P>
</TD>
<TD>
<P>37.6</P>
</TD>
<TD>
<P>27.6</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>
<LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK>
</P>
</TD>
<TD>
<P>Standard Tactylon versus LifeStyles/Trojan-Enz</P>
</TD>
<TD>
<P>30.9</P>
</TD>
<TD>
<P>26.0</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation - condom-related</P>
</TD>
<TD>
<P>
<LINK REF="STD-Frezieres-1999" TYPE="STUDY">Frezieres 1999</LINK>
</P>
</TD>
<TD>
<P>Avanti versus Ramses Sensitol</P>
</TD>
<TD>
<P>17.5 (13.5 to 21.5)</P>
</TD>
<TD>
<P>11.0 (7.8 to 14.3)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>
<LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK>
</P>
</TD>
<TD>
<P>Standard Tactylon versus LifeStyles/Trojan-Enz</P>
</TD>
<TD>
<P>17.7</P>
</TD>
<TD>
<P>12.7</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation - not condom-related</P>
</TD>
<TD>
<P>
<LINK REF="STD-Frezieres-1999" TYPE="STUDY">Frezieres 1999</LINK>
</P>
</TD>
<TD>
<P>Avanti versus Ramses Sensitol</P>
</TD>
<TD>
<P>20.6 (16.2 to 25.0)</P>
</TD>
<TD>
<P>15.9 (12.1 to 19.7)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>
<LINK REF="STD-Nelson-2001" TYPE="STUDY">Nelson 2001</LINK>
</P>
</TD>
<TD>
<P>Standard Tactylon versus LifeStyles/Trojan-Enz</P>
</TD>
<TD>
<P>24.9</P>
</TD>
<TD>
<P>21.6</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2008-05-07 15:32:29 -0400" MODIFIED_BY="Laureen M Lopez" NO="4">
<TITLE>Nonlatex versus latex: hazard ratio of genital irritation - males</TITLE>
<TABLE COLS="4" ROWS="2">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Comparison</P>
</TH>
<TH>
<P>Hazard Ratio*</P>
</TH>
<TH>
<P>95% CI</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Steiner-2003" TYPE="STUDY">Steiner 2003</LINK>
</P>
</TD>
<TD>
<P>eZ·on versus Kimono Select (latex) condom</P>
</TD>
<TD>
<P>1.0</P>
</TD>
<TD>
<P>0.7 to 1.5</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*stratified by site and prior condom experience</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2008-05-07 15:32:36 -0400" MODIFIED_BY="Laureen M Lopez" NO="5">
<TITLE>Nonlatex versus latex: hazard ratio of genital irritation - females</TITLE>
<TABLE COLS="4" ROWS="2">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Comparison</P>
</TH>
<TH>
<P>Hazard Ratio*</P>
</TH>
<TH>
<P>95% CI</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Steiner-2003" TYPE="STUDY">Steiner 2003</LINK>
</P>
</TD>
<TD>
<P>eZ·on versus Kimono Select (latex) condom</P>
</TD>
<TD>
<P>0.6</P>
</TD>
<TD>
<P>0.5 to 0.8</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*stratified by site and prior condom experience</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>eZ·on versus Kimono Select (latex) condom</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.472458531367004" CI_START="0.8183622065076741" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0977269299423016" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="119" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.16804307265976356" LOG_CI_START="-0.08705443536159309" LOG_EFFECT_SIZE="0.040494318649085245" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.5337764969241681" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="442" TOTAL_2="436" WEIGHT="100.0" Z="0.6222515205758197">
<NAME>Six-month overall discontinuation - per couple</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Kimono Select</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.472458531367004" CI_START="0.8183622065076741" EFFECT_SIZE="1.0977269299423016" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="119" LOG_CI_END="0.16804307265976356" LOG_CI_START="-0.08705443536159309" LOG_EFFECT_SIZE="0.040494318649085245" ORDER="290" O_E="4.1526195899772205" SE="0.149845538964775" STUDY_ID="STD-Steiner-2003" TOTAL_1="442" TOTAL_2="436" VAR="44.53611848612226" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9065019061713535" CI_START="0.9593575162726087" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.6698426422109816" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.46337061211588154" LOG_CI_START="-0.018019517532510763" LOG_EFFECT_SIZE="0.22267554729168537" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.06979600836858699" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1314" TOTAL_2="1305" WEIGHT="100.0" Z="1.8132322457389072">
<NAME>Nonclinical breakage - per condom</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Kimono Select</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9065019061713535" CI_START="0.9593575162726087" EFFECT_SIZE="1.6698426422109816" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="19" LOG_CI_END="0.46337061211588154" LOG_CI_START="-0.018019517532510763" LOG_EFFECT_SIZE="0.22267554729168537" ORDER="291" O_E="6.412371134020617" SE="0.2827709450750386" STUDY_ID="STD-Cook-2001" TOTAL_1="1314" TOTAL_2="1305" VAR="12.506345817005823" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7451489746752769" CI_END="6.191355513459378" CI_START="2.8468813540951188" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="4.198339501260172" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.7917857423267055" LOG_CI_START="0.45436936797748056" LOG_EFFECT_SIZE="0.623077555152093" METHOD="PETO" NO="3" P_CHI2="0.3880164849685228" P_Q="1.0" P_Z="4.5336992260085187E-13" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1725" TOTAL_2="1725" WEIGHT="100.0" Z="7.238591014017735">
<NAME>Clinical breakage - per condom</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Kimono Select</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.102391759398282" CI_START="2.9619058644420475" EFFECT_SIZE="4.586569066712791" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="11" LOG_CI_END="0.8514046237882511" LOG_CI_START="0.4715712516183331" LOG_EFFECT_SIZE="0.6614879377032921" ORDER="292" O_E="30.596811819595644" SE="0.2231160030181256" STUDY_ID="STD-Cook-2001" TOTAL_1="1283" TOTAL_2="1289" VAR="20.088085934293904" WEIGHT="78.91254873436867"/>
<DICH_DATA CI_END="7.026307610901085" CI_START="1.2940546094748568" EFFECT_SIZE="3.0153649449900453" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="5" LOG_CI_END="0.8467271592323394" LOG_CI_START="0.11195260407082641" LOG_EFFECT_SIZE="0.4793398816515829" ORDER="293" O_E="5.924829157175399" SE="0.4316102108945808" STUDY_ID="STD-Steiner-2003" TOTAL_1="442" TOTAL_2="436" VAR="5.368050328537215" WEIGHT="21.087451265631323"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.360686319582521" CI_START="2.202167620508279" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.0988646656764547" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.6395548473764696" LOG_CI_START="0.34285037271531" LOG_EFFECT_SIZE="0.4912026100458898" METHOD="PETO" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="8.609250387159313E-11" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1317" TOTAL_2="1307" WEIGHT="100.0" Z="6.489551098961196">
<NAME>Total breakage - per condom</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Kimono Select</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.360686319582521" CI_START="2.2021676205082787" EFFECT_SIZE="3.0988646656764547" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="32" LOG_CI_END="0.6395548473764696" LOG_CI_START="0.3428503727153099" LOG_EFFECT_SIZE="0.4912026100458898" ORDER="294" O_E="37.23513719512195" SE="0.17428567712680187" STUDY_ID="STD-Cook-2001" TOTAL_1="1317" TOTAL_2="1307" VAR="32.92127176449905" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.024481178275440996" CI_END="3.766997987060968" CI_START="1.352994037855249" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.2575929254642464" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.57599538813304" LOG_CI_START="0.1312958828265433" LOG_EFFECT_SIZE="0.35364563547979166" METHOD="PETO" NO="5" P_CHI2="0.8756668197383287" P_Q="1.0" P_Z="0.0018251065749810824" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1719" TOTAL_2="1720" WEIGHT="100.0" Z="3.1173082072688603">
<NAME>Complete slippage - per condom</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Kimono Select</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.501773851988443" CI_START="1.0414499122664502" EFFECT_SIZE="2.1652648759901787" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="9" LOG_CI_END="0.6533836742939109" LOG_CI_START="0.017638387726514496" LOG_EFFECT_SIZE="0.3355110310102127" ORDER="295" O_E="5.539632955876611" SE="0.3734399283196112" STUDY_ID="STD-Cook-2001" TOTAL_1="1277" TOTAL_2="1284" VAR="7.170649552900633" WEIGHT="48.929073777168256"/>
<DICH_DATA CI_END="4.810113813329927" CI_START="1.1478470991309615" EFFECT_SIZE="2.3497393870641323" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="9" LOG_CI_END="0.6821553524479231" LOG_CI_START="0.05988404100077634" LOG_EFFECT_SIZE="0.37101969672434976" ORDER="296" O_E="6.394077448747153" SE="0.36552524863672403" STUDY_ID="STD-Steiner-2003" TOTAL_1="442" TOTAL_2="436" VAR="7.484542134473325" WEIGHT="51.070926222831744"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4247429796426785" CI_START="0.9400724756168939" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1573079365451888" ESTIMABLE="YES" EVENTS_1="228" EVENTS_2="201" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.15373652568450136" LOG_CI_START="-0.026838662839520192" LOG_EFFECT_SIZE="0.06344893142249061" METHOD="PETO" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.16840405502026526" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1253" TOTAL_2="1247" WEIGHT="100.0" Z="1.3773500275658332">
<NAME>Partial slippage - per condom</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Kimono Select</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4247429796426785" CI_START="0.9400724756168939" EFFECT_SIZE="1.1573079365451888" ESTIMABLE="YES" EVENTS_1="228" EVENTS_2="201" LOG_CI_END="0.15373652568450136" LOG_CI_START="-0.026838662839520192" LOG_EFFECT_SIZE="0.06344893142249061" ORDER="297" O_E="12.985199999999992" SE="0.10607075960060947" STUDY_ID="STD-Cook-2001" TOTAL_1="1253" TOTAL_2="1247" VAR="88.88094062386554" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3790913102220683" CI_END="4.6554550415745055" CI_START="2.4813435644700657" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.3987914627247466" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="34" I2="27.488485164990646" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.6679621369578278" LOG_CI_START="0.39468690043643373" LOG_EFFECT_SIZE="0.5313245186971308" METHOD="PETO" NO="7" P_CHI2="0.24025618328669418" P_Q="1.0" P_Z="2.5083973995245046E-14" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1719" TOTAL_2="1720" WEIGHT="100.0" Z="7.621451061614415">
<NAME>Total clinical failure - per condom</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Kimono Select</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.63171563956333" CI_START="2.640616503009634" EFFECT_SIZE="3.8563196519594154" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="20" LOG_CI_END="0.7506407179937342" LOG_CI_START="0.42170533315685255" LOG_EFFECT_SIZE="0.5861730255752934" ORDER="298" O_E="36.153065208902774" SE="0.1932182733095994" STUDY_ID="STD-Cook-2001" TOTAL_1="1277" TOTAL_2="1284" VAR="26.78573738309649" WEIGHT="69.02070139046236"/>
<DICH_DATA CI_END="4.514550501568132" CI_START="1.4575844922531571" EFFECT_SIZE="2.565217105934588" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="14" LOG_CI_END="0.6546145155782748" LOG_CI_START="0.1636337390439147" LOG_EFFECT_SIZE="0.40912412731109477" ORDER="299" O_E="11.325740318906607" SE="0.2884045385303238" STUDY_ID="STD-Steiner-2003" TOTAL_1="442" TOTAL_2="436" VAR="12.022528605921522" WEIGHT="30.97929860953763"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.051069045393346" CI_START="2.1679966729402116" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.96356275659279" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.6075696452516683" LOG_CI_START="0.33605861138811327" LOG_EFFECT_SIZE="0.47181412831989084" METHOD="PETO" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="9.63886565909566E-12" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1311" TOTAL_2="1302" WEIGHT="100.0" Z="6.811794612876495">
<NAME>Total failure - per condom</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Kimono Select</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.051069045393345" CI_START="2.167996672940212" EFFECT_SIZE="2.96356275659279" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="41" LOG_CI_END="0.6075696452516682" LOG_CI_START="0.3360586113881133" LOG_EFFECT_SIZE="0.47181412831989084" ORDER="300" O_E="42.710677382319176" SE="0.15948692529274555" STUDY_ID="STD-Cook-2001" TOTAL_1="1311" TOTAL_2="1302" VAR="39.31423497542019" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.561753399766041" CI_START="0.9734665697987451" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.107300271517567" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.6591318043918504" LOG_CI_START="-0.01167895816677924" LOG_EFFECT_SIZE="0.3237264231125356" METHOD="PETO" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.058528669845115865" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1425" TOTAL_2="1382" WEIGHT="100.0" Z="1.8917172041916648">
<NAME>Medical event - per male</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Kimono Select</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.561753399766041" CI_START="0.9734665697987451" EFFECT_SIZE="2.107300271517567" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" LOG_CI_END="0.6591318043918504" LOG_CI_START="-0.01167895816677924" LOG_EFFECT_SIZE="0.3237264231125356" ORDER="301" O_E="4.800855005343783" SE="0.39403756249376704" STUDY_ID="STD-Cook-2001" TOTAL_1="1425" TOTAL_2="1382" VAR="6.440576636259369" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9988499896398753" CI_START="0.9797726854934997" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.714115313431863" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.4769547417511719" LOG_CI_START="-0.008874672151378167" LOG_EFFECT_SIZE="0.23404003479989685" METHOD="PETO" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.05897784558037009" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1425" TOTAL_2="1382" WEIGHT="100.0" Z="1.8883584485492229">
<NAME>Medical event - per female</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Kimono Select</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9988499896398753" CI_START="0.9797726854934997" EFFECT_SIZE="1.714115313431863" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="18" LOG_CI_END="0.4769547417511719" LOG_CI_START="-0.008874672151378167" LOG_EFFECT_SIZE="0.23404003479989685" ORDER="302" O_E="6.617028856430352" SE="0.2853786026207423" STUDY_ID="STD-Cook-2001" TOTAL_1="1425" TOTAL_2="1382" VAR="12.278835633396314" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4203538850558495" CI_START="0.5861680683302906" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9124505976482292" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.15239656352334552" LOG_CI_START="-0.2319778435667587" LOG_EFFECT_SIZE="-0.03979064002170663" METHOD="PETO" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.6848947054452743" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="442" TOTAL_2="436" WEIGHT="100.0" Z="0.40579299727445794">
<NAME>Adverse genital experience - per male</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Kimono Select</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4203538850558495" CI_START="0.5861680683302906" EFFECT_SIZE="0.9124505976482292" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="45" LOG_CI_END="0.15239656352334552" LOG_CI_START="-0.2319778435667587" LOG_EFFECT_SIZE="-0.03979064002170663" ORDER="303" O_E="-1.797266514806381" SE="0.22578342940872845" STUDY_ID="STD-Steiner-2003" TOTAL_1="442" TOTAL_2="436" VAR="19.61624466115896" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9032845700370391" CI_START="0.4553331665350826" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6413231818336568" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="94" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="-0.04417540834944947" LOG_CI_START="-0.34167071446545133" LOG_EFFECT_SIZE="-0.1929230614074504" METHOD="PETO" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.0110208051791156" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="442" TOTAL_2="436" WEIGHT="100.0" Z="2.5420384414292005">
<NAME>Adverse genital experience - per female</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Kimono Select</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9032845700370391" CI_START="0.4553331665350826" EFFECT_SIZE="0.6413231818336568" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="94" LOG_CI_END="-0.04417540834944947" LOG_CI_START="-0.34167071446545133" LOG_EFFECT_SIZE="-0.1929230614074504" ORDER="304" O_E="-14.546697038724375" SE="0.17475021543805497" STUDY_ID="STD-Steiner-2003" TOTAL_1="442" TOTAL_2="436" VAR="32.74647524120408" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6553787578967374" CI_START="0.8399026094468846" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1791339781298866" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="86" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.21889737795753658" LOG_CI_START="-0.07577106945232145" LOG_EFFECT_SIZE="0.07156315425260752" METHOD="PETO" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.3411003532232557" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="337" TOTAL_2="337" WEIGHT="100.0" Z="0.951993375524894">
<NAME>Preferred choice - per male</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Kimono Select</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6553787578967374" CI_START="0.8399026094468846" EFFECT_SIZE="1.1791339781298866" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="86" LOG_CI_END="0.21889737795753658" LOG_CI_START="-0.07577106945232145" LOG_EFFECT_SIZE="0.07156315425260752" ORDER="305" O_E="5.5" SE="0.17308970464088982" STUDY_ID="STD-Cook-2001" TOTAL_1="337" TOTAL_2="337" VAR="33.37778603268945" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2956559936038046" CI_START="0.6699229677908127" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9316596527010359" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="103" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.11248970839315975" LOG_CI_START="-0.1739751325032411" LOG_EFFECT_SIZE="-0.030742712055040727" METHOD="PETO" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.673990839796534" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="337" TOTAL_2="337" WEIGHT="100.0" Z="0.4206771639159448">
<NAME>Preferred choice - per female</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Kimono Select</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2956559936038046" CI_START="0.6699229677908127" EFFECT_SIZE="0.9316596527010359" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="103" LOG_CI_END="0.11248970839315975" LOG_CI_START="-0.1739751325032411" LOG_EFFECT_SIZE="-0.030742712055040727" ORDER="306" O_E="-2.5" SE="0.1682708655663779" STUDY_ID="STD-Cook-2001" TOTAL_1="337" TOTAL_2="337" VAR="35.3168647845468" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.112485124092347" CI_START="0.5584621884031595" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7882137254365548" ESTIMABLE="YES" EVENTS_1="178" EVENTS_2="206" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.0462942124010131" LOG_CI_START="-0.25300622617194424" LOG_EFFECT_SIZE="-0.10335600688546559" METHOD="PETO" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.17584799929730008" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="280" TOTAL_2="299" WEIGHT="100.0" Z="1.3536502121229401">
<NAME>Would recommend to friend - per male</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Kimono Select</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1124851240923472" CI_START="0.5584621884031594" EFFECT_SIZE="0.7882137254365548" ESTIMABLE="YES" EVENTS_1="178" EVENTS_2="206" LOG_CI_END="0.04629421240101318" LOG_CI_START="-0.25300622617194435" LOG_EFFECT_SIZE="-0.10335600688546559" ORDER="307" O_E="-7.69948186528498" SE="0.17581055917882046" STUDY_ID="STD-Steiner-2003" TOTAL_1="280" TOTAL_2="299" VAR="32.35266713924927" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5225127173722928" CI_START="0.751633546517636" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0697530712163157" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="205" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.18256092893154294" LOG_CI_START="-0.12399384493344383" LOG_EFFECT_SIZE="0.029283541999049586" METHOD="PETO" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.7080696952257093" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="280" TOTAL_2="299" WEIGHT="100.0" Z="0.374449805066034">
<NAME>Would recommend to friend - per female</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Kimono Select</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5225127173722928" CI_START="0.751633546517636" EFFECT_SIZE="1.0697530712163157" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="205" LOG_CI_END="0.18256092893154294" LOG_CI_START="-0.12399384493344383" LOG_EFFECT_SIZE="0.029283541999049586" ORDER="308" O_E="2.079447322970651" SE="0.18007179163889733" STUDY_ID="STD-Steiner-2003" TOTAL_1="280" TOTAL_2="299" VAR="30.839592348628933" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>eZ·on versus Durex Gossamer (latex) condom</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.109781805892305" CI_START="0.0027945723032823536" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.14095672852733007" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.8518562727479088" LOG_CI_START="-2.553684649508326" LOG_EFFECT_SIZE="-0.8509141883802086" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.32736273162658647" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="172" WEIGHT="100.0" Z="0.9794398019181146">
<NAME>Nonclinical breakage - per condom</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.109781805892311" CI_START="0.002794572303282351" EFFECT_SIZE="0.14095672852733007" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8518562727479092" LOG_CI_START="-2.5536846495083263" LOG_EFFECT_SIZE="-0.8509141883802086" ORDER="309" O_E="-0.4896142433234421" SE="2.0004315954327554" STUDY_ID="STD-Bounds-2002" TOTAL_1="165" TOTAL_2="172" VAR="0.2498921360582553" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.2808579937016344" CI_START="0.32831887012535094" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0378668457629074" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.5159874331027646" LOG_CI_START="-0.48370415548022755" LOG_EFFECT_SIZE="0.016141638811268615" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.9495327264136837" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="164" TOTAL_2="170" WEIGHT="100.0" Z="0.06329358190636393">
<NAME>Clinical breakage - per condom</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.2808579937016344" CI_START="0.32831887012535094" EFFECT_SIZE="1.0378668457629074" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.5159874331027646" LOG_CI_START="-0.48370415548022755" LOG_EFFECT_SIZE="0.016141638811268615" ORDER="310" O_E="0.10778443113772429" SE="0.5872237876868224" STUDY_ID="STD-Bounds-2002" TOTAL_1="164" TOTAL_2="170" VAR="2.8999647573278753" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.69357336858316" CI_START="0.29408270356894556" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8900187292940793" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.43032880952253494" LOG_CI_START="-0.5315305177080286" LOG_EFFECT_SIZE="-0.050600854092746846" METHOD="PETO" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.8366214431141168" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="172" WEIGHT="100.0" Z="0.20621695668181014">
<NAME>Total breakage - per condom</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6935733685831607" CI_START="0.2940827035689455" EFFECT_SIZE="0.8900187292940793" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.430328809522535" LOG_CI_START="-0.5315305177080287" LOG_EFFECT_SIZE="-0.050600854092746846" ORDER="311" O_E="-0.3649851632047474" SE="0.5650009300956919" STUDY_ID="STD-Bounds-2002" TOTAL_1="165" TOTAL_2="172" VAR="3.132576419873129" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.3368758803398055" CI_START="0.23058072852240524" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.6371769929915396" LOG_CI_START="-0.6371769929915396" LOG_EFFECT_SIZE="0.0" METHOD="PETO" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="0.0">
<NAME>Total breakage - per couple</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.336875880339805" CI_START="0.2305807285224053" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6371769929915395" LOG_CI_START="-0.6371769929915395" LOG_EFFECT_SIZE="0.0" ORDER="312" O_E="0.0" SE="0.7485618395204279" STUDY_ID="STD-Bounds-2002" TOTAL_1="33" TOTAL_2="33" VAR="1.7846153846153847" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.239479586924054" CI_START="0.4069031528579047" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.0411948774047897" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="1.0102778845430789" LOG_CI_START="-0.3905089450361584" LOG_EFFECT_SIZE="0.30988446975346035" METHOD="PETO" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.3858471260243206" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="164" TOTAL_2="170" WEIGHT="100.00000000000001" Z="0.8671732018889855">
<NAME>Complete slippage - per condom</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.239479586924054" CI_START="0.4069031528579047" EFFECT_SIZE="2.0411948774047897" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0102778845430789" LOG_CI_START="-0.3905089450361584" LOG_EFFECT_SIZE="0.30988446975346035" ORDER="313" O_E="1.0538922155688621" SE="0.8228291177014807" STUDY_ID="STD-Bounds-2002" TOTAL_1="164" TOTAL_2="170" VAR="1.4770006838564336" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="21.22563025675212" CI_START="0.3834924934027352" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.853045718387003" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="1.3268605946976544" LOG_CI_START="-0.41624313264244894" LOG_EFFECT_SIZE="0.4553087310276028" METHOD="PETO" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.30587885985834407" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="1.0239077579421856">
<NAME>Complete slippage - per couple</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.22563025675211" CI_START="0.3834924934027354" EFFECT_SIZE="2.853045718387003" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3268605946976542" LOG_CI_START="-0.4162431326424488" LOG_EFFECT_SIZE="0.4553087310276028" ORDER="314" O_E="1.0" SE="1.0239077579421856" STUDY_ID="STD-Bounds-2002" TOTAL_1="33" TOTAL_2="33" VAR="0.9538461538461539" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.2386392409698583" CI_START="0.6530308218370936" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.2090907423875654" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.3499841122125134" LOG_CI_START="-0.18506632035145656" LOG_EFFECT_SIZE="0.08245889593052844" METHOD="PETO" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.545766022293747" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="164" TOTAL_2="170" WEIGHT="100.0" Z="0.6041167575710708">
<NAME>Partial slippage - per condom</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2386392409698583" CI_START="0.6530308218370936" EFFECT_SIZE="1.2090907423875654" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" LOG_CI_END="0.3499841122125134" LOG_CI_START="-0.18506632035145656" LOG_EFFECT_SIZE="0.08245889593052844" ORDER="315" O_E="1.9221556886227553" SE="0.31429127263043233" STUDY_ID="STD-Bounds-2002" TOTAL_1="164" TOTAL_2="170" VAR="10.123608853932637" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.522824242059038" CI_START="0.7300201091711109" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.182153263474385" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.8144356765859141" LOG_CI_START="-0.13666517661685365" LOG_EFFECT_SIZE="0.3388852499845303" METHOD="PETO" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.16250278948116761" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="1.396703372991148">
<NAME>Partial slippage - per couple</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.522824242059038" CI_START="0.7300201091711109" EFFECT_SIZE="2.182153263474385" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.8144356765859141" LOG_CI_START="-0.13666517661685365" LOG_EFFECT_SIZE="0.3388852499845303" ORDER="316" O_E="2.5" SE="0.5586813491964592" STUDY_ID="STD-Bounds-2002" TOTAL_1="33" TOTAL_2="33" VAR="3.203846153846154" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.3897023990734" CI_START="0.5083982961439832" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.3127524230120806" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.5301615707359142" LOG_CI_START="-0.29379591361863133" LOG_EFFECT_SIZE="0.11818282855864137" METHOD="PETO" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.573947289809473" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="164" TOTAL_2="170" WEIGHT="100.0" Z="0.562247669240996">
<NAME>Total clinical failure - per condom</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3897023990734" CI_START="0.5083982961439832" EFFECT_SIZE="1.3127524230120806" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.5301615707359142" LOG_CI_START="-0.29379591361863133" LOG_EFFECT_SIZE="0.11818282855864137" ORDER="317" O_E="1.1616766467065869" SE="0.4839967049651873" STUDY_ID="STD-Bounds-2002" TOTAL_1="164" TOTAL_2="170" VAR="4.268892220414325" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9440227580102194" CI_START="0.46328582408225116" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1678715723750048" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="0.4689411628801541" LOG_CI_START="-0.3341509884155452" LOG_EFFECT_SIZE="0.0673950872323044" METHOD="PETO" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.7421871526122548" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="172" WEIGHT="100.0" Z="0.3289583729516876">
<NAME>Total failure - per condom</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9440227580102194" CI_START="0.46328582408225116" EFFECT_SIZE="1.1678715723750048" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.4689411628801541" LOG_CI_START="-0.3341509884155452" LOG_EFFECT_SIZE="0.0673950872323044" ORDER="318" O_E="0.697329376854599" SE="0.47174030504135656" STUDY_ID="STD-Bounds-2002" TOTAL_1="165" TOTAL_2="172" VAR="4.493596089476127" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.169293918526405" CI_START="0.43159528480701403" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.493667593883448" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.7134312262216977" LOG_CI_START="-0.36492330864501415" LOG_EFFECT_SIZE="0.17425395878834177" METHOD="PETO" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.5264523661544017" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="0.6334307917217433">
<NAME>Total failure - per couple</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.169293918526405" CI_START="0.43159528480701403" EFFECT_SIZE="1.493667593883448" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.7134312262216977" LOG_CI_START="-0.36492330864501415" LOG_EFFECT_SIZE="0.17425395878834177" ORDER="319" O_E="1.0" SE="0.6334307917217433" STUDY_ID="STD-Bounds-2002" TOTAL_1="33" TOTAL_2="33" VAR="2.4923076923076923" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7001885316608483" CI_START="0.7201541137252043" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1065250856550766" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="89" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="0.23049708239010722" LOG_CI_START="-0.14257455415441622" LOG_EFFECT_SIZE="0.043961264117845476" METHOD="PETO" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.6441468844608715" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="164" TOTAL_2="170" WEIGHT="100.0" Z="0.4619085770437406">
<NAME>Felt "identical" or "almost identical" to coitus without condom - per male</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7001885316608483" CI_START="0.7201541137252043" EFFECT_SIZE="1.1065250856550766" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="89" LOG_CI_END="0.23049708239010722" LOG_CI_START="-0.14257455415441622" LOG_EFFECT_SIZE="0.043961264117845476" ORDER="320" O_E="2.1077844311377305" SE="0.21914412604063768" STUDY_ID="STD-Bounds-2002" TOTAL_1="164" TOTAL_2="170" VAR="20.82285771016095" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.818869109655403" CI_START="0.28738190541719544" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.4851063440319577" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="144" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="-0.08678551154517325" LOG_CI_START="-0.5415405800600215" LOG_EFFECT_SIZE="-0.31416304580259735" METHOD="PETO" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.0067681149515241" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="164" TOTAL_2="170" WEIGHT="100.0" Z="2.7080435059577286">
<NAME>"Easy" or "fairly easy" to don condom - per male</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.818869109655403" CI_START="0.28738190541719544" EFFECT_SIZE="0.4851063440319577" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="144" LOG_CI_END="-0.08678551154517325" LOG_CI_START="-0.5415405800600215" LOG_EFFECT_SIZE="-0.31416304580259735" ORDER="321" O_E="-10.137724550898213" SE="0.2671253783195158" STUDY_ID="STD-Bounds-2002" TOTAL_1="164" TOTAL_2="170" VAR="14.014244801652021" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7860776372583516" CI_START="0.5152347771609794" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9592962594657688" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="147" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="0.25190033288403185" LOG_CI_START="-0.28799483078145194" LOG_EFFECT_SIZE="-0.018047248948709994" METHOD="PETO" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.8957494470391225" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="164" TOTAL_2="170" WEIGHT="100.0" Z="0.13103269056663108">
<NAME>Coitus with condom was "comfortable" - per male</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7860776372583516" CI_START="0.5152347771609794" EFFECT_SIZE="0.9592962594657688" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="147" LOG_CI_END="0.25190033288403185" LOG_CI_START="-0.28799483078145194" LOG_EFFECT_SIZE="-0.018047248948709994" ORDER="322" O_E="-0.4131736526946099" SE="0.3171370916612672" STUDY_ID="STD-Bounds-2002" TOTAL_1="164" TOTAL_2="170" VAR="9.942736310838429" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8213066379976093" CI_START="0.26825758554161505" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6989844928466976" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-002.15" LOG_CI_END="0.26038307044029113" LOG_CI_START="-0.5714479886079096" LOG_EFFECT_SIZE="-0.15553245908380917" METHOD="PETO" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.46359959152633357" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="0.7329325225725953">
<NAME>"Excellent" or "good" acceptability - per male</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8213066379976093" CI_START="0.26825758554161505" EFFECT_SIZE="0.6989844928466976" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" LOG_CI_END="0.26038307044029113" LOG_CI_START="-0.5714479886079096" LOG_EFFECT_SIZE="-0.15553245908380917" ORDER="323" O_E="-1.5" SE="0.4886216817150636" STUDY_ID="STD-Bounds-2002" TOTAL_1="33" TOTAL_2="33" VAR="4.188461538461539" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.3643252647895188" CI_START="0.48456406716867606" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.276805049169505" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-002.16" LOG_CI_END="0.5268979769815358" LOG_CI_START="-0.31464879409648805" LOG_EFFECT_SIZE="0.10612459144252392" METHOD="PETO" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.621074033608899" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="0.49432873905493196">
<NAME>"Excellent" or "good" acceptability - per female</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3643252647895188" CI_START="0.48456406716867606" EFFECT_SIZE="1.276805049169505" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" LOG_CI_END="0.5268979769815358" LOG_CI_START="-0.31464879409648805" LOG_EFFECT_SIZE="0.10612459144252392" ORDER="324" O_E="1.0" SE="0.494328739054932" STUDY_ID="STD-Bounds-2002" TOTAL_1="33" TOTAL_2="33" VAR="4.092307692307693" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.230631973536342" CI_START="0.4527788852814618" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.3840306459807514" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.17" LOG_CI_END="0.6264052473085772" LOG_CI_START="-0.3441138340714635" LOG_EFFECT_SIZE="0.14114570661855685" METHOD="PETO" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.5686182113923786" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="0.5700877125495689">
<NAME>Preferred choice - per male</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.230631973536341" CI_START="0.45277888528146193" EFFECT_SIZE="1.3840306459807514" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.626405247308577" LOG_CI_START="-0.3441138340714634" LOG_EFFECT_SIZE="0.14114570661855685" ORDER="325" O_E="1.0" SE="0.5700877125495689" STUDY_ID="STD-Bounds-2002" TOTAL_1="33" TOTAL_2="33" VAR="3.076923076923077" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.7739907873949505" CI_START="0.5342945243448423" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.5970964707799726" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.18" LOG_CI_END="0.678881576592102" LOG_CI_START="-0.2722192766106657" LOG_EFFECT_SIZE="0.20333114999071816" METHOD="PETO" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.4020183426271057" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="0.8380220237946888">
<NAME>Preferred choice - per female</NAME>
<GROUP_LABEL_1>eZ·on</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.7739907873949505" CI_START="0.5342945243448423" EFFECT_SIZE="1.5970964707799726" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.678881576592102" LOG_CI_START="-0.2722192766106657" LOG_EFFECT_SIZE="0.20333114999071816" ORDER="326" O_E="1.5" SE="0.5586813491964592" STUDY_ID="STD-Bounds-2002" TOTAL_1="33" TOTAL_2="33" VAR="3.203846153846154" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Avanti versus Durex Gossamer (latex) condom</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="18.597471202532937" CI_START="0.19856755930539588" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.9216801154040575" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="1.2694538948926808" LOG_CI_START="-0.7020917022931206" LOG_EFFECT_SIZE="0.28368109629978017" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.572734201247376" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="175" TOTAL_2="172" WEIGHT="100.0" Z="0.5640292901529167">
<NAME>Nonclinical breakage - per condom</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="18.597471202532937" CI_START="0.19856755930539588" EFFECT_SIZE="1.9216801154040575" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2694538948926808" LOG_CI_START="-0.7020917022931206" LOG_EFFECT_SIZE="0.28368109629978017" ORDER="327" O_E="0.48703170028818454" SE="1.158095643095042" STUDY_ID="STD-Bounds-2002" TOTAL_1="175" TOTAL_2="172" VAR="0.7456090049919933" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.719034033014898" CI_START="0.24684092229889915" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.819248966109505" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.43441464350440806" LOG_CI_START="-0.6075828395523593" LOG_EFFECT_SIZE="-0.08658409802397557" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.7446333014716034" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="172" TOTAL_2="170" WEIGHT="100.0" Z="0.3257238458255136">
<NAME>Clinical breakage - per condom</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.719034033014897" CI_START="0.2468409222988992" EFFECT_SIZE="0.819248966109505" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4344146435044079" LOG_CI_START="-0.6075828395523591" LOG_EFFECT_SIZE="-0.08658409802397557" ORDER="328" O_E="-0.5321637426900585" SE="0.6120744795182728" STUDY_ID="STD-Bounds-2002" TOTAL_1="172" TOTAL_2="170" VAR="2.6692635506265505" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.8575683559748084" CI_START="0.33759581598364097" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9821930160942638" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.45599662796236545" LOG_CI_START="-0.4716029444707813" LOG_EFFECT_SIZE="-0.007803158254207948" METHOD="PETO" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.9736943327199266" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="175" TOTAL_2="172" WEIGHT="100.0" Z="0.03297523974444528">
<NAME>Total breakage - per condom</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.8575683559748084" CI_START="0.33759581598364097" EFFECT_SIZE="0.9821930160942638" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.45599662796236545" LOG_CI_START="-0.4716029444707813" LOG_EFFECT_SIZE="-0.007803158254207948" ORDER="329" O_E="-0.060518731988472574" SE="0.5448765805391678" STUDY_ID="STD-Bounds-2002" TOTAL_1="175" TOTAL_2="172" VAR="3.3682453306905744" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.551377455777488" CI_START="0.4495744746024751" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.7161969810029571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.8163326219077346" LOG_CI_START="-0.34719835458754555" LOG_EFFECT_SIZE="0.23456713366009455" METHOD="PETO" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.42937882017834217" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="33" WEIGHT="100.0" Z="0.7902550825340117">
<NAME>Total breakage - per couple</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.551377455777488" CI_START="0.4495744746024751" EFFECT_SIZE="1.7161969810029571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.8163326219077346" LOG_CI_START="-0.34719835458754555" LOG_EFFECT_SIZE="0.23456713366009455" ORDER="330" O_E="1.15625" SE="0.6834638551645504" STUDY_ID="STD-Bounds-2002" TOTAL_1="31" TOTAL_2="33" VAR="2.1407645089285716" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.542839452403257" CI_START="0.5303545825539113" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.3646232716253635" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="1.022957593080998" LOG_CI_START="-0.2754336742540374" LOG_EFFECT_SIZE="0.3737619594134804" METHOD="PETO" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.2591460875137508" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="172" TOTAL_2="170" WEIGHT="100.0" Z="1.1284117471694517">
<NAME>Complete slippage - per condom</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.542839452403257" CI_START="0.5303545825539113" EFFECT_SIZE="2.3646232716253635" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.022957593080998" LOG_CI_START="-0.2754336742540374" LOG_EFFECT_SIZE="0.3737619594134804" ORDER="331" O_E="1.47953216374269" SE="0.7626814575730287" STUDY_ID="STD-Bounds-2002" TOTAL_1="172" TOTAL_2="170" VAR="1.7191494167039993" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="23.61287381706275" CI_START="0.6294114799672406" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.855154193476206" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="1.373148846330738" LOG_CI_START="-0.20106534016293634" LOG_EFFECT_SIZE="0.5860417530839009" METHOD="PETO" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.1444841813037067" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="33" WEIGHT="100.0" Z="1.4592940901384468">
<NAME>Complete slippage - per couple</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="23.61287381706275" CI_START="0.6294114799672406" EFFECT_SIZE="3.855154193476206" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.373148846330738" LOG_CI_START="-0.20106534016293634" LOG_EFFECT_SIZE="0.5860417530839009" ORDER="332" O_E="1.578125" SE="0.9247012056322832" STUDY_ID="STD-Bounds-2002" TOTAL_1="31" TOTAL_2="33" VAR="1.1694917224702381" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.46496933448212" CI_START="0.7511000205692441" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.360675757788047" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.39181152079457127" LOG_CI_START="-0.1243022261264236" LOG_EFFECT_SIZE="0.1337546473340738" METHOD="PETO" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.30968751694999963" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="172" TOTAL_2="170" WEIGHT="99.99999999999999" Z="1.0158779652880312">
<NAME>Partial slippage - per condom</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.46496933448212" CI_START="0.7511000205692441" EFFECT_SIZE="1.360675757788047" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="22" LOG_CI_END="0.39181152079457127" LOG_CI_START="-0.1243022261264236" LOG_EFFECT_SIZE="0.1337546473340738" ORDER="333" O_E="3.3508771929824555" SE="0.30316776974564297" STUDY_ID="STD-Bounds-2002" TOTAL_1="172" TOTAL_2="170" VAR="10.880126436376994" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.015790842189547" CI_START="0.9211075587059641" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.7172422662962603" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.9039463765286572" LOG_CI_START="-0.03568965381502849" LOG_EFFECT_SIZE="0.43412836135681426" METHOD="PETO" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.07012914691497193" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="33" WEIGHT="100.0" Z="1.8110756196003381">
<NAME>Partial slippage - per couple</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.015790842189547" CI_START="0.9211075587059641" EFFECT_SIZE="2.7172422662962603" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.9039463765286572" LOG_CI_START="-0.03568965381502849" LOG_EFFECT_SIZE="0.43412836135681426" ORDER="334" O_E="3.28125" SE="0.5519468554972459" STUDY_ID="STD-Bounds-2002" TOTAL_1="31" TOTAL_2="33" VAR="3.282505580357143" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.220257431241504" CI_START="0.4836947518455273" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.248047122140456" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="0.5078905911053911" LOG_CI_START="-0.31542862474074196" LOG_EFFECT_SIZE="0.09623098318232459" METHOD="PETO" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.64683174599461" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="172" TOTAL_2="170" WEIGHT="99.99999999999999" Z="0.45816800483734665">
<NAME>Total clinical failure - per condom</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.220257431241504" CI_START="0.4836947518455273" EFFECT_SIZE="1.248047122140456" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.5078905911053911" LOG_CI_START="-0.31542862474074196" LOG_EFFECT_SIZE="0.09623098318232459" ORDER="335" O_E="0.9473684210526319" SE="0.48362178288386576" STUDY_ID="STD-Bounds-2002" TOTAL_1="172" TOTAL_2="170" VAR="4.275513602651481" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.2097472930716626" CI_START="0.5508086464484389" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.3296452767329874" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="0.5064708412694389" LOG_CI_START="-0.25899925092170145" LOG_EFFECT_SIZE="0.12373579517386861" METHOD="PETO" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.5263132907830745" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="175" TOTAL_2="172" WEIGHT="100.00000000000001" Z="0.6336438343267111">
<NAME>Total failure - per condom</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.209747293071662" CI_START="0.5508086464484389" EFFECT_SIZE="1.3296452767329874" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.5064708412694388" LOG_CI_START="-0.25899925092170145" LOG_EFFECT_SIZE="0.12373579517386861" ORDER="336" O_E="1.4092219020172916" SE="0.4496409212911425" STUDY_ID="STD-Bounds-2002" TOTAL_1="175" TOTAL_2="172" VAR="4.946162062185258" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.057590771936889" CI_START="0.8107611707561023" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.5559306969730455" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.11" LOG_CI_END="0.906205206710497" LOG_CI_START="-0.09110705885688634" LOG_EFFECT_SIZE="0.4075490739268053" METHOD="PETO" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.1091847112569884" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="33" WEIGHT="100.0" Z="1.6018684105419154">
<NAME>Total failure - per couple</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.057590771936889" CI_START="0.8107611707561023" EFFECT_SIZE="2.5559306969730455" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.906205206710497" LOG_CI_START="-0.09110705885688634" LOG_EFFECT_SIZE="0.4075490739268053" ORDER="337" O_E="2.734375" SE="0.5858261615696148" STUDY_ID="STD-Bounds-2002" TOTAL_1="31" TOTAL_2="33" VAR="2.913818359375" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1548099932795097" CI_START="0.49513163497081614" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7561633157282366" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="89" I2="0.0" I2_Q="0.0" ID="CMP-003.12" LOG_CI_END="0.06251053344159653" LOG_CI_START="-0.3052793248211148" LOG_EFFECT_SIZE="-0.12138439568975914" METHOD="PETO" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.1957612222500357" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="172" TOTAL_2="170" WEIGHT="100.0" Z="1.293722697851821">
<NAME>Felt "identical" or "almost identical" to coitus without condom - per male</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1548099932795097" CI_START="0.49513163497081614" EFFECT_SIZE="0.7561633157282366" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="89" LOG_CI_END="0.06251053344159653" LOG_CI_START="-0.3052793248211148" LOG_EFFECT_SIZE="-0.12138439568975914" ORDER="338" O_E="-5.988304093567251" SE="0.21604158333267715" STUDY_ID="STD-Bounds-2002" TOTAL_1="172" TOTAL_2="170" VAR="21.425220342505067" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9925727617147162" CI_START="0.34163104477720735" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5823174989659821" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="144" I2="0.0" I2_Q="0.0" ID="CMP-003.13" LOG_CI_END="-0.0032376469296546274" LOG_CI_START="-0.4664426708787626" LOG_EFFECT_SIZE="-0.23484015890420865" METHOD="PETO" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.046882189320653675" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="172" TOTAL_2="170" WEIGHT="100.0" Z="1.9873629592863942">
<NAME>"Easy" or "fairly easy" to don condom - per male</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9925727617147162" CI_START="0.34163104477720735" EFFECT_SIZE="0.5823174989659821" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="144" LOG_CI_END="-0.0032376469296546274" LOG_CI_START="-0.4664426708787626" LOG_EFFECT_SIZE="-0.23484015890420865" ORDER="339" O_E="-7.304093567251471" SE="0.2720889239695541" STUDY_ID="STD-Bounds-2002" TOTAL_1="172" TOTAL_2="170" VAR="13.507602559817137" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0845847905354948" CI_START="0.35104886019231013" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6170431544871079" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="147" I2="0.0" I2_Q="0.0" ID="CMP-003.14" LOG_CI_END="0.035263509897682836" LOG_CI_START="-0.4546324327218679" LOG_EFFECT_SIZE="-0.20968446141209252" METHOD="PETO" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.0933859211714931" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="172" TOTAL_2="170" WEIGHT="100.0" Z="1.6778011685005492">
<NAME>Coitus with condom was "comfortable" - per male</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0845847905354948" CI_START="0.35104886019231013" EFFECT_SIZE="0.6170431544871079" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="147" LOG_CI_END="0.035263509897682836" LOG_CI_START="-0.4546324327218679" LOG_EFFECT_SIZE="-0.20968446141209252" ORDER="340" O_E="-5.830409356725141" SE="0.28776730171875037" STUDY_ID="STD-Bounds-2002" TOTAL_1="172" TOTAL_2="170" VAR="12.075833344114404" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.61001456621395" CI_START="0.22986821195176718" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6083511893239798" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-003.15" LOG_CI_END="0.20682980522298264" LOG_CI_START="-0.6385210823560091" LOG_EFFECT_SIZE="-0.21584563856651326" METHOD="PETO" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.31688223244596125" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="33" WEIGHT="100.0" Z="1.000885393335285">
<NAME>"Excellent" or "good" acceptability - per male</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.61001456621395" CI_START="0.22986821195176713" EFFECT_SIZE="0.6083511893239798" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" LOG_CI_END="0.20682980522298264" LOG_CI_START="-0.6385210823560092" LOG_EFFECT_SIZE="-0.21584563856651326" ORDER="341" O_E="-2.015625" SE="0.49656329591828097" STUDY_ID="STD-Bounds-2002" TOTAL_1="31" TOTAL_2="33" VAR="4.055559430803571" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.6878010569238273" CI_START="0.3808213948308925" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0117174247415526" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-003.16" LOG_CI_END="0.42939712037968664" LOG_CI_START="-0.41927866061322805" LOG_EFFECT_SIZE="0.005059229883229331" METHOD="PETO" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.9813567669206081" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="33" WEIGHT="100.0" Z="0.023367954129755026">
<NAME>"Excellent" or "good" acceptability - per female</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6878010569238273" CI_START="0.38082139483089245" EFFECT_SIZE="1.0117174247415526" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.42939712037968664" LOG_CI_START="-0.4192786606132281" LOG_EFFECT_SIZE="0.005059229883229331" ORDER="342" O_E="0.046875" SE="0.49851635476810713" STUDY_ID="STD-Bounds-2002" TOTAL_1="31" TOTAL_2="33" VAR="4.023844401041666" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.252296348533803" CI_START="0.5805143460534847" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.7461481552400433" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.17" LOG_CI_END="0.720349222158876" LOG_CI_START="-0.2361870432210493" LOG_EFFECT_SIZE="0.24208108946891335" METHOD="PETO" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.3211687469350081" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="33" WEIGHT="100.0" Z="0.992059023520315">
<NAME>Preferred choice - per male</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.252296348533803" CI_START="0.5805143460534847" EFFECT_SIZE="1.7461481552400433" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.720349222158876" LOG_CI_START="-0.2361870432210493" LOG_EFFECT_SIZE="0.24208108946891335" ORDER="343" O_E="1.765625" SE="0.5618741372150456" STUDY_ID="STD-Bounds-2002" TOTAL_1="31" TOTAL_2="33" VAR="3.167538597470238" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.0561328390855325" CI_START="0.40813130158119904" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.2866370020336826" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.18" LOG_CI_END="0.6081121697811764" LOG_CI_START="-0.38920009578620673" LOG_EFFECT_SIZE="0.10945603699748484" METHOD="PETO" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.6670384618426637" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="33" WEIGHT="100.0" Z="0.4302160874026858">
<NAME>Preferred choice - per female</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Durex Gossamer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.0561328390855325" CI_START="0.40813130158119904" EFFECT_SIZE="1.2866370020336826" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.6081121697811764" LOG_CI_START="-0.38920009578620673" LOG_EFFECT_SIZE="0.10945603699748484" ORDER="344" O_E="0.734375" SE="0.5858261615696148" STUDY_ID="STD-Bounds-2002" TOTAL_1="31" TOTAL_2="33" VAR="2.913818359375" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Avanti versus Ramses Sensitol (latex) condom</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4371902283314895" CI_START="0.41321332231375885" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7706271141386892" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.15751425571036018" LOG_CI_START="-0.38382568494021657" LOG_EFFECT_SIZE="-0.11315571461492822" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.41257056644524104" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1804" TOTAL_2="1882" WEIGHT="100.0" Z="0.819378392895295">
<NAME>Pregnancies - per condom</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Ramses Sensitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4371902283314895" CI_START="0.41321332231375885" EFFECT_SIZE="0.7706271141386892" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="23" LOG_CI_END="0.15751425571036018" LOG_CI_START="-0.38382568494021657" LOG_EFFECT_SIZE="-0.11315571461492822" ORDER="345" O_E="-2.5767769940314693" SE="0.31798576081407226" STUDY_ID="STD-Frezieres-1999" TOTAL_1="1804" TOTAL_2="1882" VAR="9.889734985204887" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.5731675638941596" CI_START="1.1146314747294814" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.6935564816295363" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.4104680682566352" LOG_CI_START="0.04713130240969866" LOG_EFFECT_SIZE="0.22879968533316689" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.013569997749062153" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="383" TOTAL_2="384" WEIGHT="100.0" Z="2.4684490262459104">
<NAME>Six-month condom-related discontinuation - per couple</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Ramses Sensitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.573167563894159" CI_START="1.1146314747294814" EFFECT_SIZE="1.6935564816295363" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="39" LOG_CI_END="0.4104680682566351" LOG_CI_START="0.04713130240969866" LOG_EFFECT_SIZE="0.22879968533316689" ORDER="346" O_E="11.565840938722296" SE="0.213425814804488" STUDY_ID="STD-Frezieres-1999" TOTAL_1="383" TOTAL_2="384" VAR="21.953618034673436" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.855021194920751" CI_START="0.8602452439597825" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.263239154069873" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="56" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.26834887609906494" LOG_CI_START="-0.06537771978547689" LOG_EFFECT_SIZE="0.101485578156794" METHOD="PETO" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.23324475466791572" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="383" TOTAL_2="384" WEIGHT="100.0" Z="1.1920421122586022">
<NAME>Six-month condom-unrelated discontinuation - per couple</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Ramses Sensitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.855021194920751" CI_START="0.8602452439597825" EFFECT_SIZE="1.263239154069873" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="56" LOG_CI_END="0.26834887609906494" LOG_CI_START="-0.06537771978547689" LOG_EFFECT_SIZE="0.101485578156794" ORDER="347" O_E="6.080834419817471" SE="0.19603265439587217" STUDY_ID="STD-Frezieres-1999" TOTAL_1="383" TOTAL_2="384" VAR="26.022148977798327" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.45060277918820213" CI_END="0.9026951964573893" CI_START="0.05635808273551251" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.22555303271491445" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="-0.04445886856008638" LOG_CI_START="-1.249043789720778" LOG_EFFECT_SIZE="-0.6467513291404321" METHOD="PETO" NO="4" P_CHI2="0.5020488703685237" P_Q="1.0" P_Z="0.03532258350897845" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2859" TOTAL_2="2917" WEIGHT="100.0" Z="2.104640843166521">
<NAME>Nonclinical breakage - per condom</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Ramses Sensitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5787040946106847" CI_START="0.05101786603663905" EFFECT_SIZE="0.36271197946439615" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4114015098577102" LOG_CI_START="-1.2922777109142787" LOG_EFFECT_SIZE="-0.44043810052828414" ORDER="348" O_E="-1.0126274890723654" SE="1.0007496076296203" STUDY_ID="STD-Frezieres-1998" TOTAL_1="1036" TOTAL_2="1023" VAR="0.998502468792279" WEIGHT="49.9918480795293"/>
<DICH_DATA CI_END="0.9970190223043204" CI_START="0.019737946437945027" EFFECT_SIZE="0.14028224427865058" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="-0.0012965556271710733" LOG_CI_START="-1.7046980338883564" LOG_EFFECT_SIZE="-0.8529972947577638" ORDER="349" O_E="-1.9617971482378262" SE="1.0005864603039267" STUDY_ID="STD-Frezieres-1999" TOTAL_1="1823" TOTAL_2="1894" VAR="0.9988281103929832" WEIGHT="50.008151920470695"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.24611541151066785" CI_END="6.747175212547845" CI_START="3.628325861339579" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="4.9478227852942265" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.8291219881832578" LOG_CI_START="0.5597062842939236" LOG_EFFECT_SIZE="0.6944141362385907" METHOD="PETO" NO="5" P_CHI2="0.6198237469334426" P_Q="1.0" P_Z="5.3281166224407386E-24" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2829" TOTAL_2="2883" WEIGHT="100.0" Z="10.10354391176979">
<NAME>Clinical breakage - per condom</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Ramses Sensitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.073175330680033" CI_START="2.9674158120810152" EFFECT_SIZE="4.58138104919044" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="11" LOG_CI_END="0.8496144235572233" LOG_CI_START="0.47237840652559954" LOG_EFFECT_SIZE="0.6609964150414114" ORDER="350" O_E="30.99654491609082" SE="0.2215903037527763" STUDY_ID="STD-Frezieres-1998" TOTAL_1="1025" TOTAL_2="1001" VAR="20.365660249883756" WEIGHT="51.00579388438936"/>
<DICH_DATA CI_END="8.349396352908698" CI_START="3.441539387459495" EFFECT_SIZE="5.360482852322722" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="8" LOG_CI_END="0.9216550778695395" LOG_CI_START="0.5367527442975478" LOG_EFFECT_SIZE="0.7292039110835437" ORDER="351" O_E="32.84644601193706" SE="0.22609353603746732" STUDY_ID="STD-Frezieres-1999" TOTAL_1="1804" TOTAL_2="1882" VAR="19.56247084840857" WEIGHT="48.99420611561063"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.07018716760691568" CI_END="5.82509050464986" CI_START="3.1772781306856874" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="4.302084688809468" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="0.7653026774001462" LOG_CI_START="0.5020552335035839" LOG_EFFECT_SIZE="0.6336789554518651" METHOD="PETO" NO="6" P_CHI2="0.7910644644001618" P_Q="1.0" P_Z="3.876615934785663E-21" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2859" TOTAL_2="2917" WEIGHT="100.00000000000001" Z="9.435897360011069">
<NAME>Total breakage - per condom</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Ramses Sensitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.319143607804444" CI_START="2.702522375767665" EFFECT_SIZE="4.132508559674223" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="14" LOG_CI_END="0.800658225180152" LOG_CI_START="0.431769298418945" LOG_EFFECT_SIZE="0.6162137617995485" ORDER="352" O_E="30.219038368139877" SE="0.21668718160917022" STUDY_ID="STD-Frezieres-1998" TOTAL_1="1036" TOTAL_2="1023" VAR="21.29774183130782" WEIGHT="50.92570947876989"/>
<DICH_DATA CI_END="6.913445828795142" CI_START="2.9101243568583266" EFFECT_SIZE="4.485419389109267" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="12" LOG_CI_END="0.8396945642225797" LOG_CI_START="0.4639115478668022" LOG_EFFECT_SIZE="0.651803056044691" ORDER="353" O_E="30.802259887005647" SE="0.22073680396331485" STUDY_ID="STD-Frezieres-1999" TOTAL_1="1823" TOTAL_2="1894" VAR="20.52345624191001" WEIGHT="49.074290521230125"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4577399837377518" CI_END="4.950638717973395" CI_START="2.5764347269833285" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.571413937607188" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="0.6946612340439539" LOG_CI_START="0.4110191442471056" LOG_EFFECT_SIZE="0.5528401891455298" METHOD="PETO" NO="7" P_CHI2="0.4986821232671106" P_Q="1.0" P_Z="2.1681673275168698E-14" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2829" TOTAL_2="2883" WEIGHT="100.0" Z="7.640240281035963">
<NAME>Complete slippage - per condom</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Ramses Sensitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.7875922481037945" CI_START="2.3263148319915508" EFFECT_SIZE="4.256335437000505" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="6" LOG_CI_END="0.8914032041430091" LOG_CI_START="0.3666684896461145" LOG_EFFECT_SIZE="0.6290358468945618" ORDER="354" O_E="15.245310957551826" SE="0.3082317687742043" STUDY_ID="STD-Frezieres-1998" TOTAL_1="1025" TOTAL_2="1001" VAR="10.525559801480972" WEIGHT="29.218758577212064"/>
<DICH_DATA CI_END="4.897301551000588" CI_START="2.253283478707176" EFFECT_SIZE="3.321898354121729" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="23" LOG_CI_END="0.6899568464939173" LOG_CI_START="0.3528158324223167" LOG_EFFECT_SIZE="0.521386339458117" ORDER="355" O_E="30.610960390667387" SE="0.19803830054059304" STUDY_ID="STD-Frezieres-1999" TOTAL_1="1804" TOTAL_2="1882" VAR="25.49773589626964" WEIGHT="70.78124142278793"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.16822269050698857" CI_END="5.541199269920318" CI_START="3.5122284692438237" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="4.411570902702033" ESTIMABLE="YES" EVENTS_1="265" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-004.08" LOG_CI_END="0.7436037683282304" LOG_CI_START="0.5455827588583811" LOG_EFFECT_SIZE="0.6445932635933058" METHOD="PETO" NO="8" P_CHI2="0.681696472203333" P_Q="1.0" P_Z="2.74004163353189E-37" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2829" TOTAL_2="2883" WEIGHT="100.0" Z="12.760055962772748">
<NAME>Total clinical failure - per condom</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Ramses Sensitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.685039092316171" CI_START="3.2676193617760845" EFFECT_SIZE="4.673773975309712" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="17" LOG_CI_END="0.8251039512431128" LOG_CI_START="0.5142314607403868" LOG_EFFECT_SIZE="0.6696677059917499" ORDER="356" O_E="46.24185587364265" SE="0.1826080397649473" STUDY_ID="STD-Frezieres-1998" TOTAL_1="1025" TOTAL_2="1001" VAR="29.988877557037057" WEIGHT="40.57494644666183"/>
<DICH_DATA CI_END="5.700481087442435" CI_START="3.155249922008599" EFFECT_SIZE="4.241042620224918" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="31" LOG_CI_END="0.7559115091470394" LOG_CI_START="0.4990337646738147" LOG_EFFECT_SIZE="0.627472636910427" ORDER="357" O_E="63.45740640260445" SE="0.1508912586689148" STUDY_ID="STD-Frezieres-1999" TOTAL_1="1804" TOTAL_2="1882" VAR="43.92096135417189" WEIGHT="59.425053553338174"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2439661520164496" CI_END="4.27023748374475" CI_START="2.820333876221044" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.4703739618251843" ESTIMABLE="YES" EVENTS_1="301" EVENTS_2="82" I2="19.611960632609197" I2_Q="0.0" ID="CMP-004.09" LOG_CI_END="0.6304520284235937" LOG_CI_START="0.4503005239283621" LOG_EFFECT_SIZE="0.5403762761759779" METHOD="PETO" NO="9" P_CHI2="0.26470813152954464" P_Q="1.0" P_Z="6.417594307821121E-32" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2859" TOTAL_2="2917" WEIGHT="100.00000000000003" Z="11.758081536674814">
<NAME>Total failure - per condom</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Ramses Sensitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.162114408076001" CI_START="2.1872109180977053" EFFECT_SIZE="3.0171877760118937" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="39" LOG_CI_END="0.6193140139133765" LOG_CI_START="0.3398906651360329" LOG_EFFECT_SIZE="0.47960233952470466" ORDER="358" O_E="40.99174356483729" SE="0.16413465823969547" STUDY_ID="STD-Frezieres-1998" TOTAL_1="1036" TOTAL_2="1023" VAR="37.11926854119307" WEIGHT="41.56716452164301"/>
<DICH_DATA CI_END="5.028578202668143" CI_START="2.922620559161115" EFFECT_SIZE="3.8336178785146755" ESTIMABLE="YES" EVENTS_1="179" EVENTS_2="43" LOG_CI_END="0.7014452085109165" LOG_CI_START="0.46577243500872917" LOG_EFFECT_SIZE="0.5836088217598228" ORDER="359" O_E="70.12025827280064" SE="0.13843535375422836" STUDY_ID="STD-Frezieres-1999" TOTAL_1="1823" TOTAL_2="1894" VAR="52.180227752007255" WEIGHT="58.43283547835701"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6790798925580751" CI_START="0.5772415380114241" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6260935406254052" ESTIMABLE="YES" EVENTS_1="909" EVENTS_2="1592" I2="0.0" I2_Q="0.0" ID="CMP-004.10" LOG_CI_END="-0.16807912872977435" LOG_CI_START="-0.238642424841069" LOG_EFFECT_SIZE="-0.20336077678542167" METHOD="PETO" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="1.3564518239731595E-29" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17831" TOTAL_2="19912" WEIGHT="100.0" Z="11.297085604925908">
<NAME>Transitory discomfort - per condom by male</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Ramses Sensitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6790798925580751" CI_START="0.5772415380114241" EFFECT_SIZE="0.6260935406254052" ESTIMABLE="YES" EVENTS_1="909" EVENTS_2="1592" LOG_CI_END="-0.16807912872977435" LOG_CI_START="-0.238642424841069" LOG_EFFECT_SIZE="-0.20336077678542167" ORDER="360" O_E="-272.55236732639173" SE="0.04144922942972358" STUDY_ID="STD-Frezieres-1999" TOTAL_1="17831" TOTAL_2="19912" VAR="582.0590923706853" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.530747061599431" CI_START="0.8399497041830113" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1339094062443682" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="150" I2="0.0" I2_Q="0.0" ID="CMP-004.11" LOG_CI_END="0.18490343444298038" LOG_CI_START="-0.07574671852115217" LOG_EFFECT_SIZE="0.05457835796091407" METHOD="PETO" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.4117567391625351" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="346" TOTAL_2="341" WEIGHT="100.0" Z="0.8208060860293965">
<NAME>Acceptability - per male</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Ramses Sensitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.530747061599431" CI_START="0.8399497041830113" EFFECT_SIZE="1.1339094062443682" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="150" LOG_CI_END="0.18490343444298038" LOG_CI_START="-0.07574671852115217" LOG_EFFECT_SIZE="0.05457835796091407" ORDER="361" O_E="5.360989810771457" SE="0.15310719009019735" STUDY_ID="STD-Frezieres-1998" TOTAL_1="346" TOTAL_2="341" VAR="42.658818977752325" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.476952043656326" CI_START="0.8107925314377588" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0943042018964761" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="153" I2="0.0" I2_Q="0.0" ID="CMP-004.12" LOG_CI_END="0.16936639408408666" LOG_CI_START="-0.09109026043574817" LOG_EFFECT_SIZE="0.039138066824169246" METHOD="PETO" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.5558369808697448" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="346" TOTAL_2="341" WEIGHT="100.0" Z="0.5890362182629656">
<NAME>Acceptability - per female</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Ramses Sensitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.476952043656326" CI_START="0.8107925314377588" EFFECT_SIZE="1.0943042018964761" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="153" LOG_CI_END="0.16936639408408666" LOG_CI_START="-0.09109026043574817" LOG_EFFECT_SIZE="0.039138066824169246" ORDER="362" O_E="3.8500727802037886" SE="0.1529935281461841" STUDY_ID="STD-Frezieres-1998" TOTAL_1="346" TOTAL_2="341" VAR="42.722226697611276" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.4716311596952116" CI_START="0.24563234013478677" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.3403643128126363" ESTIMABLE="YES" EVENTS_1="222" EVENTS_2="302" I2="0.0" I2_Q="0.0" ID="CMP-004.13" LOG_CI_END="-0.3263975096909291" LOG_CI_START="-0.6097144542350863" LOG_EFFECT_SIZE="-0.4680559819630078" METHOD="PETO" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="9.421863822708049E-11" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="360" TOTAL_2="363" WEIGHT="100.0" Z="6.475947768475558">
<NAME>Recommend - per male</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Ramses Sensitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.4716311596952116" CI_START="0.24563234013478677" EFFECT_SIZE="0.3403643128126363" ESTIMABLE="YES" EVENTS_1="222" EVENTS_2="302" LOG_CI_END="-0.3263975096909291" LOG_CI_START="-0.6097144542350863" LOG_EFFECT_SIZE="-0.4680559819630078" ORDER="363" O_E="-38.9128630705394" SE="0.16642177566673177" STUDY_ID="STD-Frezieres-1999" TOTAL_1="360" TOTAL_2="363" VAR="36.10602653920943" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Avanti versus Trojan-Enz (latex) condom</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.820467167072353" CI_START="0.0026853936013588454" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.31731052126128756" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="153" TOTAL_2="153" WEIGHT="100.0" Z="1.0">
<NAME>Nonclinical breakage - per condom</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Trojan-Enz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" ORDER="364" O_E="-0.5" SE="2.0" STUDY_ID="STD-Frezieres-2000" TOTAL_1="153" TOTAL_2="153" VAR="0.25" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="19.81962601924446" CI_START="0.38557292875088334" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.7644007037669662" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="1.2970954554312542" LOG_CI_START="-0.41389346571015173" LOG_EFFECT_SIZE="0.4416009948605512" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.3116712986889332" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="151" WEIGHT="100.0" Z="1.0117213907923444">
<NAME>Clinical breakage - per condom</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Trojan-Enz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="19.81962601924446" CI_START="0.38557292875088334" EFFECT_SIZE="2.7644007037669662" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2970954554312542" LOG_CI_START="-0.41389346571015173" LOG_EFFECT_SIZE="0.4416009948605512" ORDER="365" O_E="1.0066445182724253" SE="1.0050433618102164" STUDY_ID="STD-Frezieres-2000" TOTAL_1="150" TOTAL_2="151" VAR="0.9899890729682895" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.817032880384305" CI_START="0.25853601707653384" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.5098081213609222" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.9453224603616116" LOG_CI_START="-0.5874789460788017" LOG_EFFECT_SIZE="0.17892175714140499" METHOD="PETO" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.6472630615415012" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="152" TOTAL_2="153" WEIGHT="100.0" Z="0.45756769086238247">
<NAME>Total breakage - per condom</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Trojan-Enz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.817032880384305" CI_START="0.25853601707653384" EFFECT_SIZE="1.5098081213609222" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9453224603616116" LOG_CI_START="-0.5874789460788017" LOG_EFFECT_SIZE="0.17892175714140499" ORDER="366" O_E="0.5081967213114753" SE="0.9003751336324302" STUDY_ID="STD-Frezieres-2000" TOTAL_1="152" TOTAL_2="153" VAR="1.2335393711367912" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.784060136180019" CI_START="0.5405228890493807" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.4143386963080142" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="1.0327823009956145" LOG_CI_START="-0.2671859106332122" LOG_EFFECT_SIZE="0.3827981951812012" METHOD="PETO" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.2483809852211588" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="151" WEIGHT="100.0" Z="1.1542908037143749">
<NAME>Complete slippage - per condom</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Trojan-Enz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.784060136180019" CI_START="0.5405228890493807" EFFECT_SIZE="2.4143386963080142" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0327823009956145" LOG_CI_START="-0.2671859106332122" LOG_EFFECT_SIZE="0.3827981951812012" ORDER="367" O_E="1.5116279069767442" SE="0.7636077624572019" STUDY_ID="STD-Frezieres-2000" TOTAL_1="150" TOTAL_2="151" VAR="1.7149810708491076" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.5800289124149" CI_START="0.7750782018298437" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.5787968863566224" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="0.9334887513080403" LOG_CI_START="-0.1106544769649389" LOG_EFFECT_SIZE="0.41141713717155076" METHOD="PETO" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.1224565114152974" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="151" WEIGHT="100.0" Z="1.544544368328749">
<NAME>Total clinical failure - per condom</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Trojan-Enz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.5800289124149" CI_START="0.7750782018298437" EFFECT_SIZE="2.5787968863566224" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9334887513080403" LOG_CI_START="-0.1106544769649389" LOG_EFFECT_SIZE="0.41141713717155076" ORDER="368" O_E="2.5182724252491697" SE="0.6133349008798858" STUDY_ID="STD-Frezieres-2000" TOTAL_1="150" TOTAL_2="151" VAR="2.6583039922296665" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.708756859654844" CI_START="0.7185377142517201" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.0253288881451375" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="0.7565415464645787" LOG_CI_START="-0.1435504318978073" LOG_EFFECT_SIZE="0.3064955572833856" METHOD="PETO" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.18194263744905162" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="152" TOTAL_2="153" WEIGHT="100.0" Z="1.3347974832303486">
<NAME>Total failure - per condom</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Trojan-Enz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.708756859654844" CI_START="0.7185377142517201" EFFECT_SIZE="2.0253288881451375" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.7565415464645787" LOG_CI_START="-0.1435504318978073" LOG_EFFECT_SIZE="0.3064955572833856" ORDER="369" O_E="2.524590163934426" SE="0.5287184836172162" STUDY_ID="STD-Frezieres-2000" TOTAL_1="152" TOTAL_2="153" VAR="3.5772641762966946" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2180773044722606" CI_START="0.22715012214586175" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5260098939126298" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-005.07" LOG_CI_END="0.08567485138418457" LOG_CI_START="-0.643687025315305" LOG_EFFECT_SIZE="-0.27900608696556023" METHOD="PETO" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.13374196780102937" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="51" WEIGHT="99.99999999999999" Z="1.4995077187047912">
<NAME>Preference - per male (Avanti versus Tactylon versus Trojan-Enz)</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Trojan-Enz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2180773044722604" CI_START="0.2271501221458618" EFFECT_SIZE="0.5260098939126298" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.08567485138418449" LOG_CI_START="-0.643687025315305" LOG_EFFECT_SIZE="-0.27900608696556023" ORDER="370" O_E="-3.5" SE="0.4284307767727975" STUDY_ID="STD-Frezieres-2000" TOTAL_1="51" TOTAL_2="51" VAR="5.448019801980198" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7583563780602887" CI_START="0.32790272389599845" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.759321964614399" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-005.08" LOG_CI_END="0.24510690107879038" LOG_CI_START="-0.48425497562069914" LOG_EFFECT_SIZE="-0.11957403727095438" METHOD="PETO" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.520453724285563" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="51" WEIGHT="99.99999999999999" Z="0.6426461651591963">
<NAME>Preference - per female (Avanti versus Tactylon versus Trojan-Enz)</NAME>
<GROUP_LABEL_1>Avanti</GROUP_LABEL_1>
<GROUP_LABEL_2>Trojan-Enz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7583563780602884" CI_START="0.32790272389599845" EFFECT_SIZE="0.759321964614399" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" LOG_CI_END="0.24510690107879032" LOG_CI_START="-0.48425497562069914" LOG_EFFECT_SIZE="-0.11957403727095438" ORDER="371" O_E="-1.5" SE="0.4284307767727975" STUDY_ID="STD-Frezieres-2000" TOTAL_1="51" TOTAL_2="51" VAR="5.448019801980198" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Standard Tactylon versus Aladan (latex) condom</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.091391098385081" CI_START="1.9860299829949593" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.4781727040992902" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.7847164843179911" LOG_CI_START="0.29798580073084735" LOG_EFFECT_SIZE="0.5413511425244193" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="1.3017030907440596E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1143" TOTAL_2="1166" WEIGHT="100.0" Z="4.359818594208294">
<NAME>Clinical breakage - per condom</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Aladan</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.091391098385081" CI_START="1.9860299829949593" EFFECT_SIZE="3.4781727040992902" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="10" LOG_CI_END="0.7847164843179911" LOG_CI_START="0.29798580073084735" LOG_EFFECT_SIZE="0.5413511425244193" ORDER="372" O_E="15.249025552187096" SE="0.2859080128948296" STUDY_ID="STD-Callahan-2000" TOTAL_1="1143" TOTAL_2="1166" VAR="12.23340477464276" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.490138497520166" CI_START="0.26727585314109115" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6310927334576798" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.17322663479716432" LOG_CI_START="-0.5730402755168589" LOG_EFFECT_SIZE="-0.19990682035984728" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.293693435720757" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1143" TOTAL_2="1166" WEIGHT="100.0" Z="1.0500537080073629">
<NAME>Complete slippage - per condom</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Aladan</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4901384975201661" CI_START="0.26727585314109115" EFFECT_SIZE="0.6310927334576798" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.1732266347971644" LOG_CI_START="-0.5730402755168589" LOG_EFFECT_SIZE="-0.19990682035984728" ORDER="373" O_E="-2.395409268081421" SE="0.4383608771992407" STUDY_ID="STD-Callahan-2000" TOTAL_1="1143" TOTAL_2="1166" VAR="5.203989664559853" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.3848988201195946" CI_START="1.3157655292741472" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.110386975792377" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.5295456914789243" LOG_CI_START="0.11917850446417388" LOG_EFFECT_SIZE="0.32436209797154913" METHOD="PETO" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.0019457763333616685" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1143" TOTAL_2="1166" WEIGHT="100.0" Z="3.0983862749788402">
<NAME>Total clinical failure - per condom</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Aladan</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3848988201195946" CI_START="1.3157655292741472" EFFECT_SIZE="2.110386975792377" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="23" LOG_CI_END="0.5295456914789243" LOG_CI_START="0.11917850446417388" LOG_EFFECT_SIZE="0.32436209797154913" ORDER="374" O_E="12.853616284105676" SE="0.2410517170028013" STUDY_ID="STD-Callahan-2000" TOTAL_1="1143" TOTAL_2="1166" VAR="17.209947338478845" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6261740422123883" CI_START="0.19491916701870543" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.3493613068397449" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="-0.20330493984523654" LOG_CI_START="-0.7101454532313994" LOG_EFFECT_SIZE="-0.456725196538318" METHOD="PETO" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="4.11909070028242E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1182" TOTAL_2="1196" WEIGHT="99.99999999999999" Z="3.5323337910245263">
<NAME>Medical event - per condom by male</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Aladan</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6261740422123883" CI_START="0.19491916701870543" EFFECT_SIZE="0.3493613068397449" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="35" LOG_CI_END="-0.20330493984523654" LOG_CI_START="-0.7101454532313994" LOG_EFFECT_SIZE="-0.456725196538318" ORDER="375" O_E="-11.864592094196805" SE="0.2977206264640364" STUDY_ID="STD-Callahan-2000" TOTAL_1="1182" TOTAL_2="1196" VAR="11.28189755151886" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.5667056894236715" CI_START="0.2719268794876163" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.39255892514736845" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="87" I2="0.0" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="-0.24664242725103527" LOG_CI_START="-0.5655478610547536" LOG_EFFECT_SIZE="-0.40609514415289444" METHOD="PETO" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="5.986624235161246E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1182" TOTAL_2="1196" WEIGHT="100.0" Z="4.991648134325358">
<NAME>Medical event - per condom by female</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Aladan</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5667056894236715" CI_START="0.2719268794876163" EFFECT_SIZE="0.39255892514736845" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="87" LOG_CI_END="-0.24664242725103527" LOG_CI_START="-0.5655478610547536" LOG_EFFECT_SIZE="-0.40609514415289444" ORDER="376" O_E="-26.64676198486123" SE="0.18732663042366096" STUDY_ID="STD-Callahan-2000" TOTAL_1="1182" TOTAL_2="1196" VAR="28.497119104328718" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Standard Tactylon versus LifeStyles (latex) condom</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.6805368465869446" CI_START="0.7501143162650096" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.4179947333825789" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.4282217814025503" LOG_CI_START="-0.12487254575518529" LOG_EFFECT_SIZE="0.15167461782368252" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.2823932212288438" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="415" TOTAL_2="207" WEIGHT="100.00000000000001" Z="1.07495873201576">
<NAME>Pregnancy - per female</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>LifeStyles</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6805368465869446" CI_START="0.7501143162650096" EFFECT_SIZE="1.4179947333825789" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="12" LOG_CI_END="0.4282217814025503" LOG_CI_START="-0.12487254575518529" LOG_EFFECT_SIZE="0.15167461782368252" ORDER="377" O_E="3.308681672025724" SE="0.324890345633529" STUDY_ID="STD-Nelson-2001" TOTAL_1="415" TOTAL_2="207" VAR="9.473847458152832" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5805398270503002" CI_START="0.8083005654347957" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.130288120744871" ESTIMABLE="YES" EVENTS_1="189" EVENTS_2="88" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.19880544383282722" LOG_CI_START="-0.09242711739701288" LOG_EFFECT_SIZE="0.053189163217907204" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.4740439905399626" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="415" TOTAL_2="207" WEIGHT="100.0" Z="0.7159147578463777">
<NAME>Six-month discontinuation - per couple</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>LifeStyles</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5805398270503002" CI_START="0.8083005654347957" EFFECT_SIZE="1.130288120744871" ESTIMABLE="YES" EVENTS_1="189" EVENTS_2="88" LOG_CI_END="0.19880544383282722" LOG_CI_START="-0.09242711739701288" LOG_EFFECT_SIZE="0.053189163217907204" ORDER="378" O_E="4.184887459807072" SE="0.1710714480908364" STUDY_ID="STD-Nelson-2001" TOTAL_1="415" TOTAL_2="207" VAR="34.16999669151477" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2998666678700181" CI_START="0.1303349095964571" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.41160418443486063" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="0.11389880740068607" LOG_CI_START="-0.8849392449588048" LOG_EFFECT_SIZE="-0.38552021877905934" METHOD="PETO" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.1302874115738793" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1820" TOTAL_2="938" WEIGHT="100.00000000000001" Z="1.5129694795548483">
<NAME>Nonclinical breakage - per condom</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>LifeStyles</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2998666678700181" CI_START="0.1303349095964571" EFFECT_SIZE="0.41160418443486063" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.11389880740068607" LOG_CI_START="-0.8849392449588048" LOG_EFFECT_SIZE="-0.38552021877905934" ORDER="379" O_E="-2.5786802030456855" SE="0.5867224162840652" STUDY_ID="STD-Nelson-2001" TOTAL_1="1820" TOTAL_2="938" VAR="2.904923083729919" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.898392026317901" CI_START="2.421734902238138" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="4.0873067831342595" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-007.04" LOG_CI_END="0.8387478711025311" LOG_CI_START="0.38412660090597966" LOG_EFFECT_SIZE="0.6114372360042554" METHOD="PETO" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="1.3490207548342095E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1792" TOTAL_2="922" WEIGHT="100.0" Z="5.272058480048426">
<NAME>Clinical breakage - per condom</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>LifeStyles</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.898392026317901" CI_START="2.421734902238138" EFFECT_SIZE="4.0873067831342595" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="2" LOG_CI_END="0.8387478711025311" LOG_CI_START="0.38412660090597966" LOG_EFFECT_SIZE="0.6114372360042554" ORDER="380" O_E="19.742078113485633" SE="0.26704678452503594" STUDY_ID="STD-Nelson-2001" TOTAL_1="1792" TOTAL_2="922" VAR="14.022495002136408" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.485710943778206" CI_START="1.7240437319532487" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.780928232798342" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-007.05" LOG_CI_END="0.651831284501806" LOG_CI_START="0.23654827790696256" LOG_EFFECT_SIZE="0.44418978120438435" METHOD="PETO" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="2.7555178300711008E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1820" TOTAL_2="938" WEIGHT="100.0" Z="4.192784003370919">
<NAME>Total breakage - per condom</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>LifeStyles</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.485710943778206" CI_START="1.7240437319532487" EFFECT_SIZE="2.780928232798342" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="9" LOG_CI_END="0.651831284501806" LOG_CI_START="0.23654827790696256" LOG_EFFECT_SIZE="0.44418978120438435" ORDER="381" O_E="17.18781725888325" SE="0.24393929375784737" STUDY_ID="STD-Nelson-2001" TOTAL_1="1820" TOTAL_2="938" VAR="16.80492102104395" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4209752917167608" CI_START="0.2114480691298426" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.548144581031979" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-007.06" LOG_CI_END="0.15258652636915773" LOG_CI_START="-0.6747962763249946" LOG_EFFECT_SIZE="-0.26110487497791846" METHOD="PETO" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.21606925935379595" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1792" TOTAL_2="922" WEIGHT="100.0" Z="1.237048073704592">
<NAME>Complete slippage - per condom</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>LifeStyles</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4209752917167608" CI_START="0.2114480691298426" EFFECT_SIZE="0.548144581031979" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.15258652636915773" LOG_CI_START="-0.6747962763249946" LOG_EFFECT_SIZE="-0.26110487497791846" ORDER="382" O_E="-2.545320560058954" SE="0.4860087539134716" STUDY_ID="STD-Nelson-2001" TOTAL_1="1792" TOTAL_2="922" VAR="4.233619437407988" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.111247232926333" CI_START="1.6342759362539243" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.5920864994752852" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-007.07" LOG_CI_END="0.613973594189044" LOG_CI_START="0.21332538602442008" LOG_EFFECT_SIZE="0.413649490106732" METHOD="PETO" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="5.184899351204279E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1792" TOTAL_2="922" WEIGHT="100.0" Z="4.047132054060878">
<NAME>Total clinical failure - per condom</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>LifeStyles</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.111247232926333" CI_START="1.6342759362539243" EFFECT_SIZE="2.5920864994752852" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="11" LOG_CI_END="0.613973594189044" LOG_CI_START="0.21332538602442008" LOG_EFFECT_SIZE="0.413649490106732" ORDER="383" O_E="17.19675755342668" SE="0.23534274071651576" STUDY_ID="STD-Nelson-2001" TOTAL_1="1792" TOTAL_2="922" VAR="18.055037152721308" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.107839936767824" CI_START="1.3158608236332172" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.0222474672787984" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-007.08" LOG_CI_END="0.4924586432149239" LOG_CI_START="0.1192099571164647" LOG_EFFECT_SIZE="0.3058343001656943" METHOD="PETO" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.0013184677337403298" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1820" TOTAL_2="938" WEIGHT="100.0" Z="3.211929396604232">
<NAME>Total failure - per condom</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>LifeStyles</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.107839936767824" CI_START="1.3158608236332172" EFFECT_SIZE="2.0222474672787984" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="18" LOG_CI_END="0.4924586432149239" LOG_CI_START="0.1192099571164647" LOG_EFFECT_SIZE="0.3058343001656943" ORDER="384" O_E="14.649746192893403" SE="0.21924812582502898" STUDY_ID="STD-Nelson-2001" TOTAL_1="1820" TOTAL_2="938" VAR="20.803107857456865" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9016343871025717" CI_START="0.3726249586947001" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.579630465255077" ESTIMABLE="YES" EVENTS_1="285" EVENTS_2="157" I2="0.0" I2_Q="0.0" ID="CMP-007.09" LOG_CI_END="-0.044969533248431365" LOG_CI_START="-0.4287280591006475" LOG_EFFECT_SIZE="-0.2368487961745394" METHOD="PETO" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.015550050803314654" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="370" TOTAL_2="183" WEIGHT="100.00000000000001" Z="2.419308388017588">
<NAME>Recommend - per male</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>LifeStyles</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9016343871025717" CI_START="0.37262495869470014" EFFECT_SIZE="0.579630465255077" ESTIMABLE="YES" EVENTS_1="285" EVENTS_2="157" LOG_CI_END="-0.044969533248431365" LOG_CI_START="-0.4287280591006474" LOG_EFFECT_SIZE="-0.2368487961745394" ORDER="385" O_E="-10.732368896925834" SE="0.22542165772093162" STUDY_ID="STD-Nelson-2001" TOTAL_1="370" TOTAL_2="183" VAR="19.67925809616602" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0513122769583234" CI_START="0.415920474336843" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6612581197298467" ESTIMABLE="YES" EVENTS_1="301" EVENTS_2="162" I2="0.0" I2_Q="0.0" ID="CMP-007.10" LOG_CI_END="0.021731736024281106" LOG_CI_START="-0.3809897002826997" LOG_EFFECT_SIZE="-0.1796289821292093" METHOD="PETO" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.08038855276263462" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="373" TOTAL_2="187" WEIGHT="100.0" Z="1.748436034502376">
<NAME>Recommend - per female</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>LifeStyles</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0513122769583232" CI_START="0.415920474336843" EFFECT_SIZE="0.6612581197298467" ESTIMABLE="YES" EVENTS_1="301" EVENTS_2="162" LOG_CI_END="0.021731736024281016" LOG_CI_START="-0.3809897002826997" LOG_EFFECT_SIZE="-0.1796289821292093" ORDER="386" O_E="-7.391071428571422" SE="0.236560565189981" STUDY_ID="STD-Nelson-2001" TOTAL_1="373" TOTAL_2="187" VAR="17.86961936060202" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>Standard Tactylon versus Trojan-Enz (latex) condom</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.691375689718943" CI_START="0.7539781815852098" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.4245134427224366" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.42997432525671136" LOG_CI_START="-0.12264122144355134" LOG_EFFECT_SIZE="0.15366655190658002" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.2757044972990801" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="415" TOTAL_2="208" WEIGHT="100.0" Z="1.0900196679725747">
<NAME>Pregnancy - per female</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Trojan-Enz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6913756897189427" CI_START="0.7539781815852098" EFFECT_SIZE="1.4245134427224366" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="12" LOG_CI_END="0.4299743252567113" LOG_CI_START="-0.12264122144355134" LOG_EFFECT_SIZE="0.15366655190658002" ORDER="387" O_E="3.357945425361155" SE="0.32460910762280787" STUDY_ID="STD-Nelson-2001" TOTAL_1="415" TOTAL_2="208" VAR="9.490270658595884" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9426622703090188" CI_START="0.9916982067571655" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.387996646177597" ESTIMABLE="YES" EVENTS_1="189" EVENTS_2="78" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.2883973055457434" LOG_CI_START="-0.0036204720808702775" LOG_EFFECT_SIZE="0.14238841673243652" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.05595778902322776" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="415" TOTAL_2="208" WEIGHT="100.0" Z="1.9113642387080605">
<NAME>Six-month discontinuation - per couple</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Trojan-Enz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9426622703090188" CI_START="0.9916982067571655" EFFECT_SIZE="1.387996646177597" ESTIMABLE="YES" EVENTS_1="189" EVENTS_2="78" LOG_CI_END="0.2883973055457434" LOG_CI_START="-0.0036204720808702775" LOG_EFFECT_SIZE="0.14238841673243652" ORDER="388" O_E="11.142857142857139" SE="0.171532688089185" STUDY_ID="STD-Nelson-2001" TOTAL_1="415" TOTAL_2="208" VAR="33.98648205262813" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.45190332407222655" CI_END="1.1394828502759384" CI_START="0.21720379414734417" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.4974937169912439" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="0.05670779324033127" LOG_CI_START="-0.663132592698001" LOG_EFFECT_SIZE="-0.30321239972883485" METHOD="PETO" NO="3" P_CHI2="0.7977568150090597" P_Q="1.0" P_Z="0.09870615948371854" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2217" TOTAL_2="1281" WEIGHT="100.0" Z="1.6511587700370858">
<NAME>Nonclinical breakage - per condom</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Trojan-Enz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.86533602910583" CI_START="0.0027029457268253772" EFFECT_SIZE="0.13622272454730858" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8366617989675151" LOG_CI_START="-2.5681626745294994" LOG_EFFECT_SIZE="-0.8657504377809923" ORDER="389" O_E="-0.49836065573770494" SE="2.0000107498851105" STUDY_ID="STD-Frezieres-2000" TOTAL_1="152" TOTAL_2="153" VAR="0.24999731255038968" WEIGHT="4.469747204488327"/>
<DICH_DATA CI_END="1.9716423716000437" CI_START="0.15788719792532274" EFFECT_SIZE="0.5579400410104735" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.2948281427928689" LOG_CI_START="-0.8016530827579536" LOG_EFFECT_SIZE="-0.25341246998254235" ORDER="390" O_E="-1.4065852756196815" SE="0.6440784995581559" STUDY_ID="STD-Nelson-2001" TOTAL_1="1820" TOTAL_2="883" VAR="2.410584702363208" WEIGHT="43.099280246856715"/>
<DICH_DATA CI_END="1.5880766750998074" CI_START="0.16096949852049816" EFFECT_SIZE="0.5056005399551271" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.20087146708909523" LOG_CI_START="-0.7932564089320244" LOG_EFFECT_SIZE="-0.2961924709214646" ORDER="391" O_E="-2.0" SE="0.5839556353871571" STUDY_ID="STD-Trussell-1992" TOTAL_1="245" TOTAL_2="245" VAR="2.9325153374233133" WEIGHT="52.430972548654964"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.008398296606833" CI_END="4.284498636786246" CI_START="1.6272308083788185" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.6404295446452704" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="10" I2="50.104758758803264" I2_Q="0.0" ID="CMP-008.04" LOG_CI_END="0.6319000089858525" LOG_CI_START="0.21144915815871823" LOG_EFFECT_SIZE="0.4216745835722854" METHOD="PETO" NO="4" P_CHI2="0.13476839407423058" P_Q="1.0" P_Z="8.447475498561647E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2186" TOTAL_2="1271" WEIGHT="100.0" Z="3.93133701773576">
<NAME>Clinical breakage - per condom</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Trojan-Enz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.7312965066028605" CI_START="0.002649835179899061" EFFECT_SIZE="0.1335545816867692" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8280987211978558" LOG_CI_START="-2.5767811383977035" LOG_EFFECT_SIZE="-0.874341208599924" ORDER="392" O_E="-0.5032894736842105" SE="2.0000432839535613" STUDY_ID="STD-Frezieres-2000" TOTAL_1="153" TOTAL_2="151" VAR="0.2499891793628809" WEIGHT="1.5248491648797902"/>
<DICH_DATA CI_END="5.122945063022865" CI_START="1.8403314534771757" EFFECT_SIZE="3.0704913180005233" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="6" LOG_CI_END="0.7095196986532395" LOG_CI_START="0.2648960487989002" LOG_EFFECT_SIZE="0.4872078737260699" ORDER="393" O_E="16.446355140186917" SE="0.2611741328470017" STUDY_ID="STD-Nelson-2001" TOTAL_1="1792" TOTAL_2="883" VAR="14.660192640524173" WEIGHT="89.42220044024594"/>
<DICH_DATA CI_END="4.913070982828614" CI_START="0.19676818713650557" EFFECT_SIZE="0.9832273748040969" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6913530387588972" LOG_CI_START="-0.7060451155992148" LOG_EFFECT_SIZE="-0.007346038420158804" ORDER="394" O_E="-0.025104602510460428" SE="0.8208385931023787" STUDY_ID="STD-Trussell-1992" TOTAL_1="241" TOTAL_2="237" VAR="1.4841727904319624" WEIGHT="9.052950394874262"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.500846925025577" CI_END="2.622864373331644" CI_START="1.1310061437098442" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.7223459932184821" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="24" I2="78.949245095909" I2_Q="0.0" ID="CMP-008.05" LOG_CI_END="0.4187758340762361" LOG_CI_START="0.05346496405192467" LOG_EFFECT_SIZE="0.23612039906408036" METHOD="PETO" NO="5" P_CHI2="0.008648067323609898" P_Q="1.0" P_Z="0.011287694561561085" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2218" TOTAL_2="1281" WEIGHT="100.00000000000001" Z="2.5336638800264786">
<NAME>Total breakage - per condom</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Trojan-Enz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1592994762712605" CI_START="0.008371336353657584" EFFECT_SIZE="0.134447841946769" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.33431287942199767" LOG_CI_START="-2.077205208112679" LOG_EFFECT_SIZE="-0.8714461643453407" ORDER="395" O_E="-1.0" SE="1.4165376618249232" STUDY_ID="STD-Frezieres-2000" TOTAL_1="153" TOTAL_2="153" VAR="0.49836065573770494" WEIGHT="2.2947963094933805"/>
<DICH_DATA CI_END="3.87513523312091" CI_START="1.4923404471355912" EFFECT_SIZE="2.4047912688020436" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="11" LOG_CI_END="0.5882868629644924" LOG_CI_START="0.17386790989677506" LOG_EFFECT_SIZE="0.38107738643063377" ORDER="396" O_E="14.807251202367738" SE="0.2434317444388795" STUDY_ID="STD-Nelson-2001" TOTAL_1="1820" TOTAL_2="883" VAR="16.8750697845834" WEIGHT="77.70446446415853"/>
<DICH_DATA CI_END="1.6160346497271587" CI_START="0.24638021265416074" EFFECT_SIZE="0.6309983840361792" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.20845066833459316" LOG_CI_START="-0.6083941742680963" LOG_EFFECT_SIZE="-0.19997175296675151" ORDER="397" O_E="-2.0" SE="0.4798187039920025" STUDY_ID="STD-Trussell-1992" TOTAL_1="245" TOTAL_2="245" VAR="4.34355828220859" WEIGHT="20.000739226348102"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7058034484722273" CI_END="1.7714317507532913" CI_START="0.343816609540036" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7804150553234905" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-008.06" LOG_CI_END="0.24832442461036539" LOG_CI_START="-0.4636731466793798" LOG_EFFECT_SIZE="-0.1076743610345072" METHOD="PETO" NO="6" P_CHI2="0.7026463424779272" P_Q="1.0" P_Z="0.5533116462459099" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2186" TOTAL_2="1271" WEIGHT="100.0" Z="0.5928050268590479">
<NAME>Complete slippage - per condom</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Trojan-Enz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.643474029984189" CI_START="0.25341263477282727" EFFECT_SIZE="1.4799883538490433" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9366883314613862" LOG_CI_START="-0.596171735643088" LOG_EFFECT_SIZE="0.17025829790914912" ORDER="398" O_E="0.48355263157894735" SE="0.9004095911968745" STUDY_ID="STD-Frezieres-2000" TOTAL_1="153" TOTAL_2="151" VAR="1.233444960882861" WEIGHT="21.575059569850627"/>
<DICH_DATA CI_END="1.9009584182449375" CI_START="0.250206040899054" EFFECT_SIZE="0.689660264001627" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.27897261716829463" LOG_CI_START="-0.6017022090412647" LOG_EFFECT_SIZE="-0.161364795936485" ORDER="399" O_E="-1.3884112149532708" SE="0.5173127523261926" STUDY_ID="STD-Nelson-2001" TOTAL_1="1792" TOTAL_2="883" VAR="3.7367464555536296" WEIGHT="65.36207932479785"/>
<DICH_DATA CI_END="4.863127894862133" CI_START="0.05211309265056238" EFFECT_SIZE="0.5034209317822261" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6869156911808668" LOG_CI_START="-1.2830531528701001" LOG_EFFECT_SIZE="-0.29806873084461666" ORDER="400" O_E="-0.5125523012552302" SE="1.1571694504985863" STUDY_ID="STD-Trussell-1992" TOTAL_1="241" TOTAL_2="237" VAR="0.7468030460330319" WEIGHT="13.06286110535153"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5174932396883998" CI_START="0.6596046311659797" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.000472672621064" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="58" I2="0.0" I2_Q="0.0" ID="CMP-008.07" LOG_CI_END="0.1811267650042549" LOG_CI_START="-0.18071630378135603" LOG_EFFECT_SIZE="2.052306114494564E-4" METHOD="PETO" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.9982260569574251" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="241" TOTAL_2="237" WEIGHT="100.0" Z="0.0022233097254893254">
<NAME>Partial slippage - per condom</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Trojan-Enz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5174932396883998" CI_START="0.6596046311659796" EFFECT_SIZE="1.000472672621064" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="58" LOG_CI_END="0.1811267650042549" LOG_CI_START="-0.1807163037813561" LOG_EFFECT_SIZE="2.052306114494564E-4" ORDER="401" O_E="0.01046025104602677" SE="0.2125484097567457" STUDY_ID="STD-Trussell-1992" TOTAL_1="241" TOTAL_2="237" VAR="22.135242284419068" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.9811068698859255" CI_END="2.9482785287933018" CI_START="1.2756436925233976" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.9393176400624363" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="21" I2="32.91082516352285" I2_Q="0.0" ID="CMP-008.08" LOG_CI_END="0.4695685096496969" LOG_CI_START="0.10572938599961502" LOG_EFFECT_SIZE="0.28764894782465594" METHOD="PETO" NO="8" P_CHI2="0.22524802475395955" P_Q="1.0" P_Z="0.0019412871015118322" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2186" TOTAL_2="1271" WEIGHT="100.0" Z="3.09907066766892">
<NAME>Total clinical failure - per condom</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Trojan-Enz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.954662699097647" CI_START="0.19650103502773736" EFFECT_SIZE="0.986709860387546" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6950140941579676" LOG_CI_START="-0.706635157727989" LOG_EFFECT_SIZE="-0.005810531785010727" ORDER="402" O_E="-0.019736842105263275" SE="0.8233357088335068" STUDY_ID="STD-Frezieres-2000" TOTAL_1="153" TOTAL_2="151" VAR="1.4751836722799703" WEIGHT="6.738141002536069"/>
<DICH_DATA CI_END="3.619908338368135" CI_START="1.4444785172962784" EFFECT_SIZE="2.286674403878794" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="13" LOG_CI_END="0.5586975736699286" LOG_CI_START="0.15971108727467045" LOG_EFFECT_SIZE="0.3592043304722995" ORDER="403" O_E="15.057943925233644" SE="0.23436663712353487" STUDY_ID="STD-Nelson-2001" TOTAL_1="1792" TOTAL_2="883" VAR="18.205743641617573" WEIGHT="83.15769081394905"/>
<DICH_DATA CI_END="2.9292137788958033" CI_START="0.2099601670869191" EFFECT_SIZE="0.7842309700912535" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4667510683722078" LOG_CI_START="-0.6778630902909323" LOG_EFFECT_SIZE="-0.10555601095936219" ORDER="404" O_E="-0.53765690376569" SE="0.6723520227301928" STUDY_ID="STD-Trussell-1992" TOTAL_1="241" TOTAL_2="237" VAR="2.2121092331967915" WEIGHT="10.104168183514885"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.961285503295426" CI_END="2.0855921481033297" CI_START="0.9857840565826986" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.4338561601968045" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="36" I2="71.26967427132224" I2_Q="0.0" ID="CMP-008.09" LOG_CI_END="0.31922938311912585" LOG_CI_START="-0.006218210115307192" LOG_EFFECT_SIZE="0.15650558650190927" METHOD="PETO" NO="9" P_CHI2="0.030787648898251252" P_Q="1.0" P_Z="0.059420748060450314" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2218" TOTAL_2="1281" WEIGHT="99.99999999999999" Z="1.8850673306537518">
<NAME>Total failure - per condom</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Trojan-Enz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.435962046725967" CI_START="0.14751407228213767" EFFECT_SIZE="0.5994486478734257" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3866705175298496" LOG_CI_START="-0.8311665476657282" LOG_EFFECT_SIZE="-0.22224801506793934" ORDER="405" O_E="-1.0" SE="0.7153635204865797" STUDY_ID="STD-Frezieres-2000" TOTAL_1="153" TOTAL_2="153" VAR="1.9540983606557376" WEIGHT="7.141406471639446"/>
<DICH_DATA CI_END="2.974308405808443" CI_START="1.2480245342384815" EFFECT_SIZE="1.926657692181121" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="18" LOG_CI_END="0.47338599848199947" LOG_CI_START="0.09622312299036212" LOG_EFFECT_SIZE="0.2848045607361808" ORDER="406" O_E="13.360710321864602" SE="0.22154734005013182" STUDY_ID="STD-Nelson-2001" TOTAL_1="1820" TOTAL_2="883" VAR="20.37355986187508" WEIGHT="74.45678026110427"/>
<DICH_DATA CI_END="1.4578309385224624" CI_START="0.25412121913963914" EFFECT_SIZE="0.6086589976307033" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.163707162717241" LOG_CI_START="-0.5949590698158097" LOG_EFFECT_SIZE="-0.21562595354928432" ORDER="407" O_E="-2.5" SE="0.4456443004483323" STUDY_ID="STD-Trussell-1992" TOTAL_1="245" TOTAL_2="245" VAR="5.035276073619632" WEIGHT="18.401813267256276"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.222949288700468" CI_START="0.4498528171934134" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-008.10" LOG_CI_END="0.34692955541659587" LOG_CI_START="-0.3469295554165959" LOG_EFFECT_SIZE="0.0" METHOD="PETO" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="51" WEIGHT="100.0" Z="0.0">
<NAME>Preference - per male (Avanti versus Tactylon versus Trojan-Enz)</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Trojan-Enz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.222949288700468" CI_START="0.4498528171934134" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" LOG_CI_END="0.34692955541659587" LOG_CI_START="-0.3469295554165959" LOG_EFFECT_SIZE="0.0" ORDER="408" O_E="0.0" SE="0.4075762763614089" STUDY_ID="STD-Frezieres-2000" TOTAL_1="51" TOTAL_2="51" VAR="6.01980198019802" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.198490014643552" CI_START="0.8681492717977262" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.9091663229961984" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-008.11" LOG_CI_END="0.6230931246314394" LOG_CI_START="-0.0614055947032338" LOG_EFFECT_SIZE="0.2808437649641028" METHOD="PETO" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.10776691978815045" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="49" WEIGHT="99.99999999999999" Z="1.6083117442419756">
<NAME>Preference - per male (Tactylon versus Trojan-Enz)</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Trojan-Enz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.198490014643552" CI_START="0.8681492717977262" EFFECT_SIZE="1.9091663229961984" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="20" LOG_CI_END="0.6230931246314394" LOG_CI_START="-0.0614055947032338" LOG_EFFECT_SIZE="0.2808437649641028" ORDER="409" O_E="4.0" SE="0.4020779360604939" STUDY_ID="STD-Trussell-1992" TOTAL_1="49" TOTAL_2="49" VAR="6.185567010309279" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.6597377993378077" CI_START="0.5282634263288406" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1853447612464993" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-008.12" LOG_CI_END="0.42483882538542705" LOG_CI_START="-0.27714945611866454" LOG_EFFECT_SIZE="0.07384468463338124" METHOD="PETO" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.6800818868548455" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="51" WEIGHT="100.0" Z="0.41235139145353933">
<NAME>Preference - per female (Avanti versus Tactylon versus Trojan-Enz)</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Trojan-Enz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6597377993378077" CI_START="0.5282634263288406" EFFECT_SIZE="1.1853447612464993" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.42483882538542705" LOG_CI_START="-0.27714945611866454" LOG_EFFECT_SIZE="0.07384468463338124" ORDER="410" O_E="1.0" SE="0.41235139145353933" STUDY_ID="STD-Frezieres-2000" TOTAL_1="51" TOTAL_2="51" VAR="5.881188118811881" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.571759293325686" CI_START="0.7385560567543024" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.6241750088442293" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-008.13" LOG_CI_END="0.5528821833904137" LOG_CI_START="-0.1316165359442595" LOG_EFFECT_SIZE="0.21063282372307712" METHOD="PETO" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.22772737375397423" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="49" WEIGHT="99.99999999999999" Z="1.2062338081814818">
<NAME>Preference - per female (Tactylon versus Trojan-Enz)</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Trojan-Enz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.571759293325686" CI_START="0.7385560567543025" EFFECT_SIZE="1.6241750088442293" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" LOG_CI_END="0.5528821833904137" LOG_CI_START="-0.13161653594425946" LOG_EFFECT_SIZE="0.21063282372307712" ORDER="411" O_E="3.0" SE="0.4020779360604939" STUDY_ID="STD-Trussell-1992" TOTAL_1="49" TOTAL_2="49" VAR="6.185567010309279" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0447729641540375" CI_START="0.43635201473583696" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6751953701338204" ESTIMABLE="YES" EVENTS_1="285" EVENTS_2="152" I2="0.0" I2_Q="0.0" ID="CMP-008.14" LOG_CI_END="0.01902192573169467" LOG_CI_START="-0.36016301445688725" LOG_EFFECT_SIZE="-0.17057054436259628" METHOD="PETO" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.07784659674276433" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="370" TOTAL_2="182" WEIGHT="100.0" Z="1.7633196276614527">
<NAME>Recommend - per male</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Trojan-Enz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0447729641540375" CI_START="0.43635201473583696" EFFECT_SIZE="0.6751953701338204" ESTIMABLE="YES" EVENTS_1="285" EVENTS_2="152" LOG_CI_END="0.01902192573169467" LOG_CI_START="-0.36016301445688725" LOG_EFFECT_SIZE="-0.17057054436259628" ORDER="412" O_E="-7.916666666666686" SE="0.22273511086249875" STUDY_ID="STD-Nelson-2001" TOTAL_1="370" TOTAL_2="182" VAR="20.15684865900383" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8783248847181659" CI_START="0.3392808537028287" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5458926787525346" ESTIMABLE="YES" EVENTS_1="301" EVENTS_2="163" I2="0.0" I2_Q="0.0" ID="CMP-008.15" LOG_CI_END="-0.0563448126336327" LOG_CI_START="-0.46944064776963534" LOG_EFFECT_SIZE="-0.26289273020163406" METHOD="PETO" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.012608912980175658" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="373" TOTAL_2="183" WEIGHT="100.0" Z="2.4946283122073605">
<NAME>Recommend - per female</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Trojan-Enz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8783248847181659" CI_START="0.3392808537028287" EFFECT_SIZE="0.5458926787525346" ESTIMABLE="YES" EVENTS_1="301" EVENTS_2="163" LOG_CI_END="-0.0563448126336327" LOG_CI_START="-0.46944064776963534" LOG_EFFECT_SIZE="-0.26289273020163406" ORDER="413" O_E="-10.28057553956836" SE="0.24265453841625093" STUDY_ID="STD-Nelson-2001" TOTAL_1="373" TOTAL_2="183" VAR="16.983342309236413" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>Standard Tactylon versus standard USAID (latex) condom</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.652026935900468" CI_START="0.8899977944531259" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.774938718332434" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="0.9371178628353304" LOG_CI_START="-0.05061106960005785" LOG_EFFECT_SIZE="0.44325339661763624" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.07855924890497416" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="561" TOTAL_2="567" WEIGHT="100.0" Z="1.7591075139483068">
<NAME>Nonclinical breakage - per condom</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.652026935900468" CI_START="0.8899977944531259" EFFECT_SIZE="2.774938718332434" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9371178628353304" LOG_CI_START="-0.05061106960005785" LOG_EFFECT_SIZE="0.44325339661763624" ORDER="414" O_E="3.0319148936170217" SE="0.5801968642496168" STUDY_ID="STD-Steiner-1993" TOTAL_1="561" TOTAL_2="567" VAR="2.9706346707006066" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.552806546584044" CI_START="1.498937674321949" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.364697056131544" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="0.8781083610605976" LOG_CI_START="0.1757835753027246" LOG_EFFECT_SIZE="0.5269459681816611" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.0032707477499652644" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="552" TOTAL_2="564" WEIGHT="100.0" Z="2.941075526247203">
<NAME>Clinical breakage - per condom</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.552806546584044" CI_START="1.498937674321949" EFFECT_SIZE="3.364697056131544" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="5" LOG_CI_END="0.8781083610605976" LOG_CI_START="0.1757835753027246" LOG_EFFECT_SIZE="0.5269459681816611" ORDER="415" O_E="7.129032258064516" SE="0.41254905571793343" STUDY_ID="STD-Steiner-1993" TOTAL_1="552" TOTAL_2="564" VAR="5.875553771995725" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.180837050448201" CI_START="1.6388874646788139" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.1827183920670596" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="0.7910472941461014" LOG_CI_START="0.21454913346864615" LOG_EFFECT_SIZE="0.5027982138073738" METHOD="PETO" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="6.28975907185499E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="561" TOTAL_2="567" WEIGHT="100.0" Z="3.4188015080411702">
<NAME>Total breakage - per condom</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.180837050448202" CI_START="1.6388874646788136" EFFECT_SIZE="3.1827183920670596" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="8" LOG_CI_END="0.7910472941461015" LOG_CI_START="0.2145491334686461" LOG_EFFECT_SIZE="0.5027982138073738" ORDER="416" O_E="10.095744680851062" SE="0.3386378732938567" STUDY_ID="STD-Steiner-1993" TOTAL_1="561" TOTAL_2="567" VAR="8.7202501623792" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4010276495757528" CI_START="0.1573785497062546" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.46956543696123404" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="0.1464467062634226" LOG_CI_START="-0.8030544611703218" LOG_EFFECT_SIZE="-0.3283038774534496" METHOD="PETO" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.17529898030710658" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="552" TOTAL_2="564" WEIGHT="100.0" Z="1.3553722688571908">
<NAME>Complete slippage - per condom</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4010276495757528" CI_START="0.1573785497062546" EFFECT_SIZE="0.46956543696123404" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.1464467062634226" LOG_CI_START="-0.8030544611703218" LOG_EFFECT_SIZE="-0.3283038774534496" ORDER="417" O_E="-2.43010752688172" SE="0.5577416858571626" STUDY_ID="STD-Steiner-1993" TOTAL_1="552" TOTAL_2="564" VAR="3.2146506996583755" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.254809235838795" CI_START="0.8779803821538406" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.6904610781439469" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-009.05" LOG_CI_END="0.5125255396782932" LOG_CI_START="-0.05651518798628805" LOG_EFFECT_SIZE="0.2280051758460026" METHOD="PETO" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.11626394993966742" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="552" TOTAL_2="564" WEIGHT="100.0" Z="1.570650082572999">
<NAME>Total clinical failure - per condom</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.254809235838795" CI_START="0.8779803821538406" EFFECT_SIZE="1.6904610781439469" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="14" LOG_CI_END="0.5125255396782932" LOG_CI_START="-0.05651518798628805" LOG_EFFECT_SIZE="0.2280051758460026" ORDER="418" O_E="4.698924731182796" SE="0.3342573402272057" STUDY_ID="STD-Steiner-1993" TOTAL_1="552" TOTAL_2="564" VAR="8.95031033422563" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.3971233026354066" CI_START="1.081439398709399" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.9167115019594685" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-009.06" LOG_CI_END="0.5311113103914661" LOG_CI_START="0.034002187627618786" LOG_EFFECT_SIZE="0.28255674900954236" METHOD="PETO" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.02587475032388042" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="561" TOTAL_2="567" WEIGHT="100.0" Z="2.228086455418003">
<NAME>Total failure - per condom</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3971233026354066" CI_START="1.081439398709399" EFFECT_SIZE="1.9167115019594685" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="17" LOG_CI_END="0.5311113103914661" LOG_CI_START="0.034002187627618786" LOG_EFFECT_SIZE="0.28255674900954236" ORDER="419" O_E="7.63031914893617" SE="0.29200435944132774" STUDY_ID="STD-Steiner-1993" TOTAL_1="561" TOTAL_2="567" VAR="11.727929037829433" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.1679226478827367" CI_START="0.9748485289919249" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.4537524563201139" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="53" I2="0.0" I2_Q="0.0" ID="CMP-009.07" LOG_CI_END="0.33604378238802896" LOG_CI_START="-0.011062859310039046" LOG_EFFECT_SIZE="0.16249046153899493" METHOD="PETO" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.06650132810471845" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="275" TOTAL_2="275" WEIGHT="100.0" Z="1.835029435851291">
<NAME>Preference - per male (Standard versus Baggy versus Low-Modulus Tactylon versus Standard latex)</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1679226478827367" CI_START="0.9748485289919249" EFFECT_SIZE="1.4537524563201139" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="53" LOG_CI_END="0.33604378238802896" LOG_CI_START="-0.011062859310039046" LOG_EFFECT_SIZE="0.16249046153899493" ORDER="420" O_E="9.0" SE="0.2038921595390324" STUDY_ID="STD-Steiner-1993" TOTAL_1="275" TOTAL_2="275" VAR="24.05464480874317" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8858655746542412" CI_START="0.8592034467416287" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.272926628613883" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="59" I2="0.0" I2_Q="0.0" ID="CMP-009.08" LOG_CI_END="0.2755107327986985" LOG_CI_START="-0.06590398944495321" LOG_EFFECT_SIZE="0.10480337167687262" METHOD="PETO" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.2288632933167688" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="275" TOTAL_2="275" WEIGHT="100.0" Z="1.2032921872563156">
<NAME>Preference - per female (Standard versus Baggy versus Low-Modulus Tactylon versus Standard latex)</NAME>
<GROUP_LABEL_1>Standard Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8858655746542412" CI_START="0.8592034467416287" EFFECT_SIZE="1.272926628613883" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="59" LOG_CI_END="0.2755107327986985" LOG_CI_START="-0.06590398944495321" LOG_EFFECT_SIZE="0.10480337167687262" ORDER="421" O_E="6.0" SE="0.2005486978760526" STUDY_ID="STD-Steiner-1993" TOTAL_1="275" TOTAL_2="275" VAR="24.863387978142075" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" NO="10">
<NAME>Baggy Tactylon versus Aladan (latex) condom</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.131693120391966" CI_START="2.020967748839365" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.5202207376942107" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="0.787580411111328" LOG_CI_START="0.3055593829795009" LOG_EFFECT_SIZE="0.5465698970454145" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="8.795027565739992E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1148" TOTAL_2="1166" WEIGHT="100.0" Z="4.444857177267385">
<NAME>Clinical breakage - per condom</NAME>
<GROUP_LABEL_1>Baggy Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Aladan</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.131693120391966" CI_START="2.020967748839365" EFFECT_SIZE="3.5202207376942107" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="10" LOG_CI_END="0.787580411111328" LOG_CI_START="0.3055593829795009" LOG_EFFECT_SIZE="0.5465698970454145" ORDER="422" O_E="15.698357821953326" SE="0.2831415379672061" STUDY_ID="STD-Callahan-2000" TOTAL_1="1148" TOTAL_2="1166" VAR="12.473629107405081" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.4731103243432893" CI_START="0.5571694397179567" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.173857527034284" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="0.39324349047565227" LOG_CI_START="-0.25401271228725875" LOG_EFFECT_SIZE="0.06961538909419672" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6733123879218363" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1148" TOTAL_2="1166" WEIGHT="100.0" Z="0.4216063277939637">
<NAME>Complete slippage - per condom</NAME>
<GROUP_LABEL_1>Baggy Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Aladan</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4731103243432893" CI_START="0.5571694397179567" EFFECT_SIZE="1.173857527034284" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.39324349047565227" LOG_CI_START="-0.25401271228725875" LOG_EFFECT_SIZE="0.06961538909419672" ORDER="423" O_E="1.108902333621435" SE="0.38020149747281057" STUDY_ID="STD-Callahan-2000" TOTAL_1="1148" TOTAL_2="1166" VAR="6.91786932067258" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.778861773295397" CI_START="1.5404636807233025" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.412716169845764" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="0.5773610061819037" LOG_CI_START="0.1876514634790569" LOG_EFFECT_SIZE="0.38250623483048035" METHOD="PETO" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="1.1934249354402132E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1148" TOTAL_2="1166" WEIGHT="100.0" Z="3.847472858530469">
<NAME>Total clinical failure - per condom</NAME>
<GROUP_LABEL_1>Baggy Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Aladan</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.778861773295397" CI_START="1.5404636807233025" EFFECT_SIZE="2.412716169845764" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="23" LOG_CI_END="0.5773610061819037" LOG_CI_START="0.1876514634790569" LOG_EFFECT_SIZE="0.38250623483048035" ORDER="424" O_E="16.80726015557476" SE="0.2289173144770006" STUDY_ID="STD-Callahan-2000" TOTAL_1="1148" TOTAL_2="1166" VAR="19.082827093559462" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4925251834675068" CI_START="0.5650322456825178" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9183272053861615" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-010.04" LOG_CI_END="0.17392166774023565" LOG_CI_START="-0.24792676683122306" LOG_EFFECT_SIZE="-0.037002549545493674" METHOD="PETO" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.7309684657321625" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1188" TOTAL_2="1196" WEIGHT="100.0" Z="0.3438375421210269">
<NAME>Medical event - per condom by male</NAME>
<GROUP_LABEL_1>Baggy Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Aladan</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.492525183467507" CI_START="0.5650322456825178" EFFECT_SIZE="0.9183272053861615" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="35" LOG_CI_END="0.1739216677402357" LOG_CI_START="-0.24792676683122306" LOG_EFFECT_SIZE="-0.037002549545493674" ORDER="425" O_E="-1.3875838926174495" SE="0.2477958586507038" STUDY_ID="STD-Callahan-2000" TOTAL_1="1188" TOTAL_2="1196" VAR="16.28590556984963" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7011220774152881" CI_START="0.3457357271480333" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.49234434215771616" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="87" I2="0.0" I2_Q="0.0" ID="CMP-010.05" LOG_CI_END="-0.15420635730877194" LOG_CI_START="-0.46125573963165495" LOG_EFFECT_SIZE="-0.3077310484702135" METHOD="PETO" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="8.543101511399606E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1188" TOTAL_2="1196" WEIGHT="100.0" Z="3.92863042005487">
<NAME>Medical event - per condom by female</NAME>
<GROUP_LABEL_1>Baggy Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Aladan</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7011220774152881" CI_START="0.3457357271480333" EFFECT_SIZE="0.49234434215771616" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="87" LOG_CI_END="-0.15420635730877194" LOG_CI_START="-0.46125573963165495" LOG_EFFECT_SIZE="-0.3077310484702135" ORDER="426" O_E="-21.781879194630875" SE="0.1803623270954169" STUDY_ID="STD-Callahan-2000" TOTAL_1="1188" TOTAL_2="1196" VAR="30.740316866749584" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" NO="11">
<NAME>Baggy Tactylon versus standard USAID (latex) condom</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.716223665971704" CI_START="1.4315469263365508" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.729508027155894" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="0.9874975036402207" LOG_CI_START="0.15580558883333448" LOG_EFFECT_SIZE="0.5716515462367776" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.007053528111779023" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="565" TOTAL_2="567" WEIGHT="100.0" Z="2.6943064430074966">
<NAME>Nonclinical breakage - per condom</NAME>
<GROUP_LABEL_1>Baggy Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.716223665971704" CI_START="1.4315469263365508" EFFECT_SIZE="3.729508027155894" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" LOG_CI_END="0.9874975036402207" LOG_CI_START="0.15580558883333448" LOG_EFFECT_SIZE="0.5716515462367776" ORDER="427" O_E="5.515017667844523" SE="0.4885399476989405" STUDY_ID="STD-Steiner-1993" TOTAL_1="565" TOTAL_2="567" VAR="4.18986313692529" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.153333646828735" CI_START="0.9063005197476" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.3615184696083316" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="0.7891104640963391" LOG_CI_START="-0.04272777094664675" LOG_EFFECT_SIZE="0.37319134657484615" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.0786429235595804" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="551" TOTAL_2="564" WEIGHT="100.0" Z="1.7586149994437466">
<NAME>Clinical breakage - per condom</NAME>
<GROUP_LABEL_1>Baggy Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.153333646828735" CI_START="0.9063005197476" EFFECT_SIZE="2.3615184696083316" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.7891104640963391" LOG_CI_START="-0.04272777094664675" LOG_EFFECT_SIZE="0.37319134657484615" ORDER="428" O_E="3.5991031390134527" SE="0.4886258969299222" STUDY_ID="STD-Steiner-1993" TOTAL_1="551" TOTAL_2="564" VAR="4.188389273813802" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.909610704535565" CI_START="1.5098323229075357" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.9870589645181376" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-011.03" LOG_CI_END="0.7715588726848737" LOG_CI_START="0.17892871863125248" LOG_EFFECT_SIZE="0.475243795658063" METHOD="PETO" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.0016695142938257044" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="565" TOTAL_2="567" WEIGHT="100.0" Z="3.143480691944805">
<NAME>Total breakage - per condom</NAME>
<GROUP_LABEL_1>Baggy Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.909610704535565" CI_START="1.5098323229075357" EFFECT_SIZE="2.9870589645181376" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="8" LOG_CI_END="0.7715588726848737" LOG_CI_START="0.17892871863125248" LOG_EFFECT_SIZE="0.475243795658063" ORDER="429" O_E="9.030035335689046" SE="0.3481138860576716" STUDY_ID="STD-Steiner-1993" TOTAL_1="565" TOTAL_2="567" VAR="8.251963631110257" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.83059659506241" CI_START="0.7601999867047176" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.7064640285214279" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-011.04" LOG_CI_END="0.5832664182939292" LOG_CI_START="-0.11907214232837392" LOG_EFFECT_SIZE="0.23209713798277767" METHOD="PETO" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.1951848841925511" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="551" TOTAL_2="564" WEIGHT="100.0" Z="1.2953924413832676">
<NAME>Complete slippage - per condom</NAME>
<GROUP_LABEL_1>Baggy Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.83059659506241" CI_START="0.7601999867047176" EFFECT_SIZE="1.7064640285214279" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.5832664182939292" LOG_CI_START="-0.11907214232837392" LOG_EFFECT_SIZE="0.23209713798277767" ORDER="430" O_E="3.1399103139013445" SE="0.4125571471414864" STUDY_ID="STD-Steiner-1993" TOTAL_1="551" TOTAL_2="564" VAR="5.875323301486156" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.689800059143089" CI_START="1.0602617121676663" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.9779165119547912" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-011.05" LOG_CI_END="0.5670028334860371" LOG_CI_START="0.025413078586776085" LOG_EFFECT_SIZE="0.29620795603640654" METHOD="PETO" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.03204096295047067" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="551" TOTAL_2="564" WEIGHT="100.0" Z="2.143899217124474">
<NAME>Total clinical failure - per condom</NAME>
<GROUP_LABEL_1>Baggy Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.689800059143089" CI_START="1.0602617121676663" EFFECT_SIZE="1.9779165119547912" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="14" LOG_CI_END="0.5670028334860371" LOG_CI_START="0.025413078586776085" LOG_EFFECT_SIZE="0.29620795603640654" ORDER="431" O_E="6.739013452914797" SE="0.31813250294034984" STUDY_ID="STD-Steiner-1993" TOTAL_1="551" TOTAL_2="564" VAR="9.880613590652361" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.350462293922988" CI_START="1.5630360847911917" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.6076674540525855" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-011.06" LOG_CI_END="0.6385354089160338" LOG_CI_START="0.19396900440741202" LOG_EFFECT_SIZE="0.41625220666172286" METHOD="PETO" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="2.4229455132920844E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="565" TOTAL_2="567" WEIGHT="100.0" Z="3.6702698416631185">
<NAME>Total failure - per condom</NAME>
<GROUP_LABEL_1>Baggy Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.350462293922988" CI_START="1.5630360847911917" EFFECT_SIZE="2.6076674540525855" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="17" LOG_CI_END="0.6385354089160338" LOG_CI_START="0.19396900440741202" LOG_EFFECT_SIZE="0.41625220666172286" ORDER="432" O_E="14.054770318021202" SE="0.26114050664755817" STUDY_ID="STD-Steiner-1993" TOTAL_1="565" TOTAL_2="567" VAR="14.663968372652269" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0182689358292203" CI_START="0.89904136973931" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.3470364763324718" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="53" I2="0.0" I2_Q="0.0" ID="CMP-011.07" LOG_CI_END="0.30497903581794045" LOG_CI_START="-0.046220323576979694" LOG_EFFECT_SIZE="0.12937935612048038" METHOD="PETO" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.1487182465140488" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="275" TOTAL_2="275" WEIGHT="99.99999999999999" Z="1.444073695214099">
<NAME>Preference - per male (Standard versus Baggy versus Low-Modulus Tactylon versus Standard latex)</NAME>
<GROUP_LABEL_1>Baggy Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0182689358292203" CI_START="0.8990413697393099" EFFECT_SIZE="1.3470364763324718" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="53" LOG_CI_END="0.30497903581794045" LOG_CI_START="-0.04622032357697975" LOG_EFFECT_SIZE="0.12937935612048038" ORDER="433" O_E="7.0" SE="0.20629624217344272" STUDY_ID="STD-Steiner-1993" TOTAL_1="275" TOTAL_2="275" VAR="23.497267759562842" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6574859727376583" CI_START="0.7436068979969641" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1101882735198254" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="59" I2="0.0" I2_Q="0.0" ID="CMP-011.08" LOG_CI_END="0.2194498616690224" LOG_CI_START="-0.12865659019099068" LOG_EFFECT_SIZE="0.045396635739015846" METHOD="PETO" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.6092119781802741" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="275" TOTAL_2="275" WEIGHT="99.99999999999999" Z="0.5111986324432478">
<NAME>Preference - per female (Standard versus Baggy versus Low-Modulus Tactylon versus Standard latex)</NAME>
<GROUP_LABEL_1>Baggy Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6574859727376583" CI_START="0.7436068979969641" EFFECT_SIZE="1.1101882735198254" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="59" LOG_CI_END="0.2194498616690224" LOG_CI_START="-0.12865659019099068" LOG_EFFECT_SIZE="0.045396635739015846" ORDER="434" O_E="2.5" SE="0.20447945297729908" STUDY_ID="STD-Steiner-1993" TOTAL_1="275" TOTAL_2="275" VAR="23.916666666666668" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" NO="12">
<NAME>Low-Modulus Tactylon versus Aladan (latex) condom</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.453032835232999" CI_START="2.2955924028985275" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.8488352981409344" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="0.8097638749512631" LOG_CI_START="0.3608947788102807" LOG_EFFECT_SIZE="0.5853293268807719" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="3.19405754781932E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1175" TOTAL_2="1166" WEIGHT="100.0" Z="5.111621226073721">
<NAME>Clinical breakage - per condom</NAME>
<GROUP_LABEL_1>Low-Modulus Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Aladan</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.453032835232999" CI_START="2.295592402898527" EFFECT_SIZE="3.8488352981409344" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="10" LOG_CI_END="0.8097638749512631" LOG_CI_START="0.36089477881028065" LOG_EFFECT_SIZE="0.5853293268807719" ORDER="435" O_E="19.386586928662965" SE="0.26366792901107394" STUDY_ID="STD-Callahan-2000" TOTAL_1="1175" TOTAL_2="1166" VAR="14.384189104146897" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5917271038679939" CI_START="0.2969454962796584" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6874999598544459" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-012.02" LOG_CI_END="0.20186861148998403" LOG_CI_START="-0.5273232572053634" LOG_EFFECT_SIZE="-0.16272732285768973" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.38169592840808375" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1175" TOTAL_2="1166" WEIGHT="100.0" Z="0.874775777937109">
<NAME>Complete slippage - per condom</NAME>
<GROUP_LABEL_1>Low-Modulus Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Aladan</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5917271038679939" CI_START="0.2969454962796584" EFFECT_SIZE="0.6874999598544459" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.20186861148998403" LOG_CI_START="-0.5273232572053634" LOG_EFFECT_SIZE="-0.16272732285768973" ORDER="436" O_E="-2.0422896198205898" SE="0.42833091322961137" STUDY_ID="STD-Callahan-2000" TOTAL_1="1175" TOTAL_2="1166" VAR="5.4505604637276726" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.7811685328802533" CI_START="1.5583816931734398" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.427448005713832" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-012.03" LOG_CI_END="0.5776260350109687" LOG_CI_START="0.19267383776320113" LOG_EFFECT_SIZE="0.3851499363870849" METHOD="PETO" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="8.783831162739892E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1175" TOTAL_2="1166" WEIGHT="100.0" Z="3.9219415260576596">
<NAME>Total clinical failure - per condom</NAME>
<GROUP_LABEL_1>Low-Modulus Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Aladan</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.7811685328802533" CI_START="1.5583816931734398" EFFECT_SIZE="2.427448005713832" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="23" LOG_CI_END="0.5776260350109687" LOG_CI_START="0.19267383776320113" LOG_EFFECT_SIZE="0.3851499363870849" ORDER="437" O_E="17.34429730884238" SE="0.22612282620744725" STUDY_ID="STD-Callahan-2000" TOTAL_1="1175" TOTAL_2="1166" VAR="19.55740323983668" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0591456521947977" CI_START="0.3703433184408389" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6262966673598127" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-012.04" LOG_CI_END="0.02495568777022803" LOG_CI_START="-0.4313954862775415" LOG_EFFECT_SIZE="-0.20321989925365677" METHOD="PETO" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.08088019361133375" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1197" TOTAL_2="1196" WEIGHT="100.0" Z="1.745601659994117">
<NAME>Medical event - per condom by male</NAME>
<GROUP_LABEL_1>Low-Modulus Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Aladan</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0591456521947977" CI_START="0.3703433184408389" EFFECT_SIZE="0.6262966673598127" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="35" LOG_CI_END="0.02495568777022803" LOG_CI_START="-0.4313954862775415" LOG_EFFECT_SIZE="-0.20321989925365677" ORDER="438" O_E="-6.511909736732136" SE="0.2680629386104037" STUDY_ID="STD-Callahan-2000" TOTAL_1="1197" TOTAL_2="1196" VAR="13.916385529671182" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8539792883068573" CI_START="0.4324466278459546" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6077009655073692" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="87" I2="0.0" I2_Q="0.0" ID="CMP-012.05" LOG_CI_END="-0.06855266219521053" LOG_CI_START="-0.3640674851062417" LOG_EFFECT_SIZE="-0.2163100736507261" METHOD="PETO" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.0041138481246374235" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1197" TOTAL_2="1196" WEIGHT="100.0" Z="2.8692973819202887">
<NAME>Medical event - per condom by female</NAME>
<GROUP_LABEL_1>Low-Modulus Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Aladan</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8539792883068573" CI_START="0.4324466278459546" EFFECT_SIZE="0.6077009655073692" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="87" LOG_CI_END="-0.06855266219521053" LOG_CI_START="-0.3640674851062417" LOG_EFFECT_SIZE="-0.2163100736507261" ORDER="439" O_E="-16.529460927705813" SE="0.1735868697999052" STUDY_ID="STD-Callahan-2000" TOTAL_1="1197" TOTAL_2="1196" VAR="33.18686711433212" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.225330478966554" CI_START="1.1959030065810399" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.6313428243114712" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="91" I2="0.0" I2_Q="0.0" ID="CMP-012.06" LOG_CI_END="0.3473945162309844" LOG_CI_START="0.0776959577336583" LOG_EFFECT_SIZE="0.21254523698232133" METHOD="PETO" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.0020067315881023458" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="395" TOTAL_2="395" WEIGHT="100.0" Z="3.0892342316691375">
<NAME>Preference - per male (Standard versus Baggy versus Low-Modulus Tactylon versus Aladan)</NAME>
<GROUP_LABEL_1>Low-Modulus Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Aladan</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.225330478966554" CI_START="1.1959030065810399" EFFECT_SIZE="1.6313428243114712" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="91" LOG_CI_END="0.3473945162309844" LOG_CI_START="0.0776959577336583" LOG_EFFECT_SIZE="0.21254523698232133" ORDER="440" O_E="19.5" SE="0.158422268290725" STUDY_ID="STD-Callahan-2000" TOTAL_1="395" TOTAL_2="395" VAR="39.84442332065906" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0127762220803094" CI_START="1.081675354879659" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.4755237830384362" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="95" I2="0.0" I2_Q="0.0" ID="CMP-012.07" LOG_CI_END="0.3037954932602518" LOG_CI_START="0.034096934762925676" LOG_EFFECT_SIZE="0.16894621401158877" METHOD="PETO" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.014067107730024103" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="395" TOTAL_2="395" WEIGHT="100.0" Z="2.4555451585062373">
<NAME>Preference - per female (Standard versus Baggy versus Low-Modulus Tactylon versus Aladan)</NAME>
<GROUP_LABEL_1>Low-Modulus Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Aladan</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0127762220803094" CI_START="1.081675354879659" EFFECT_SIZE="1.4755237830384362" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="95" LOG_CI_END="0.3037954932602518" LOG_CI_START="0.034096934762925676" LOG_EFFECT_SIZE="0.16894621401158877" ORDER="441" O_E="15.5" SE="0.158422268290725" STUDY_ID="STD-Callahan-2000" TOTAL_1="395" TOTAL_2="395" VAR="39.84442332065906" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" NO="13">
<NAME>Low-Modulus Tactylon versus standard USAID (latex) condom</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.665106073360304" CI_START="0.41331560666506273" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.6597567171721004" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="0.823807065484084" LOG_CI_START="-0.3837181955879976" LOG_EFFECT_SIZE="0.22004443494804313" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.47502990108306775" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="565" TOTAL_2="567" WEIGHT="100.0" Z="0.7143190811821646">
<NAME>Nonclinical breakage - per condom</NAME>
<GROUP_LABEL_1>Low-Modulus Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.665106073360304" CI_START="0.4133156066650626" EFFECT_SIZE="1.6597567171721004" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.823807065484084" LOG_CI_START="-0.38371819558799775" LOG_EFFECT_SIZE="0.22004443494804313" ORDER="442" O_E="1.0070671378091873" SE="0.7093063157001845" STUDY_ID="STD-Steiner-1993" TOTAL_1="565" TOTAL_2="567" VAR="1.987615369413464" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.118002606125517" CI_START="1.3169293902578534" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.0616836596779047" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-013.02" LOG_CI_END="0.8523581426767796" LOG_CI_START="0.11956249003888218" LOG_EFFECT_SIZE="0.4859603163578309" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.009334960578161255" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="560" TOTAL_2="564" WEIGHT="100.0" Z="2.599537032045383">
<NAME>Clinical breakage - per condom</NAME>
<GROUP_LABEL_1>Low-Modulus Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.118002606125518" CI_START="1.3169293902578532" EFFECT_SIZE="3.0616836596779047" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="5" LOG_CI_END="0.8523581426767797" LOG_CI_START="0.11956249003888211" LOG_EFFECT_SIZE="0.4859603163578309" ORDER="443" O_E="6.03914590747331" SE="0.43044779375648345" STUDY_ID="STD-Steiner-1993" TOTAL_1="560" TOTAL_2="564" VAR="5.3970821376555" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.400862945367623" CI_START="1.2667946927144778" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.6156805071089986" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-013.03" LOG_CI_END="0.7324631565765494" LOG_CI_START="0.1027062352101013" LOG_EFFECT_SIZE="0.41758469589332536" METHOD="PETO" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.009342500202405476" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="565" TOTAL_2="567" WEIGHT="100.0" Z="2.5992599261002227">
<NAME>Total breakage - per condom</NAME>
<GROUP_LABEL_1>Low-Modulus Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.4008629453676225" CI_START="1.266794692714478" EFFECT_SIZE="2.6156805071089986" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="8" LOG_CI_END="0.7324631565765493" LOG_CI_START="0.10270623521010139" LOG_EFFECT_SIZE="0.41758469589332536" ORDER="444" O_E="7.0265017667844525" SE="0.3699223329576882" STUDY_ID="STD-Steiner-1993" TOTAL_1="565" TOTAL_2="567" VAR="7.307669496531263" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0968277144709666" CI_START="0.29148311686763245" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7817863376578228" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-013.04" LOG_CI_END="0.32156274819143693" LOG_CI_START="-0.5353865951539132" LOG_EFFECT_SIZE="-0.10691192348123815" METHOD="PETO" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6248096358084425" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="560" TOTAL_2="564" WEIGHT="100.0" Z="0.48904528877544856">
<NAME>Complete slippage - per condom</NAME>
<GROUP_LABEL_1>Low-Modulus Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0968277144709666" CI_START="0.29148311686763245" EFFECT_SIZE="0.7817863376578228" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.32156274819143693" LOG_CI_START="-0.5353865951539132" LOG_EFFECT_SIZE="-0.10691192348123815" ORDER="445" O_E="-0.9715302491103204" SE="0.5033762862487218" STUDY_ID="STD-Steiner-1993" TOTAL_1="560" TOTAL_2="564" VAR="3.946521701714102" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.3143330594014655" CI_START="0.9093475924003654" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.7360532215285511" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-013.05" LOG_CI_END="0.5203961488003314" LOG_CI_START="-0.041270078707094" LOG_EFFECT_SIZE="0.23956303504661872" METHOD="PETO" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.0945369936316635" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="560" TOTAL_2="564" WEIGHT="100.0" Z="1.6719357430557709">
<NAME>Total clinical failure - per condom</NAME>
<GROUP_LABEL_1>Low-Modulus Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3143330594014655" CI_START="0.9093475924003654" EFFECT_SIZE="1.7360532215285511" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="14" LOG_CI_END="0.5203961488003314" LOG_CI_START="-0.041270078707094" LOG_EFFECT_SIZE="0.23956303504661872" ORDER="446" O_E="5.067615658362989" SE="0.32992552233052785" STUDY_ID="STD-Steiner-1993" TOTAL_1="560" TOTAL_2="564" VAR="9.186882760962183" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.203058079962927" CI_START="0.9965598471007195" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.7866278488881164" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-013.06" LOG_CI_END="0.5055648136493727" LOG_CI_START="-0.0014966151921448523" LOG_EFFECT_SIZE="0.25203409922861386" METHOD="PETO" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.05136782090057013" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="565" TOTAL_2="567" WEIGHT="100.0" Z="1.9483941363580655">
<NAME>Total failure - per condom</NAME>
<GROUP_LABEL_1>Low-Modulus Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.203058079962927" CI_START="0.9965598471007194" EFFECT_SIZE="1.7866278488881164" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="17" LOG_CI_END="0.5055648136493727" LOG_CI_START="-0.0014966151921449007" LOG_EFFECT_SIZE="0.25203409922861386" ORDER="447" O_E="6.541519434628974" SE="0.29785039329606083" STUDY_ID="STD-Steiner-1993" TOTAL_1="565" TOTAL_2="567" VAR="11.272069146267748" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.6850677216371928" CI_START="1.2404250728355661" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.8250000888165026" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="53" I2="0.0" I2_Q="0.0" ID="CMP-013.07" LOG_CI_END="0.4289552437646014" LOG_CI_START="0.09357053609163604" LOG_EFFECT_SIZE="0.26126288992811875" METHOD="PETO" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.0022611117662608184" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="275" TOTAL_2="275" WEIGHT="100.0" Z="3.053602880756758">
<NAME>Preference - per male (Standard versus Baggy versus Low-Modulus Tactylon versus Standard latex)</NAME>
<GROUP_LABEL_1>Low-Modulus Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6850677216371928" CI_START="1.2404250728355661" EFFECT_SIZE="1.8250000888165026" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="53" LOG_CI_END="0.4289552437646014" LOG_CI_START="0.09357053609163604" LOG_EFFECT_SIZE="0.26126288992811875" ORDER="448" O_E="15.5" SE="0.19700663746817793" STUDY_ID="STD-Steiner-1993" TOTAL_1="275" TOTAL_2="275" VAR="25.765482695810565" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.2349024385015874" CI_START="1.0381859366598287" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.523234808379557" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="59" I2="0.0" I2_Q="0.0" ID="CMP-013.08" LOG_CI_END="0.34925856937166727" LOG_CI_START="0.016275141598888505" LOG_EFFECT_SIZE="0.1827668554852779" METHOD="PETO" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.03143224208987299" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="275" TOTAL_2="275" WEIGHT="100.0" Z="2.1515572514510914">
<NAME>Preference - per female (Standard versus Baggy versus Low-Modulus Tactylon versus Standard latex)</NAME>
<GROUP_LABEL_1>Low-Modulus Tactylon</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard USAID latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.234902438501587" CI_START="1.0381859366598287" EFFECT_SIZE="1.523234808379557" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="59" LOG_CI_END="0.3492585693716672" LOG_CI_START="0.016275141598888505" LOG_EFFECT_SIZE="0.1827668554852779" ORDER="449" O_E="11.0" SE="0.19559611376828107" STUDY_ID="STD-Steiner-1993" TOTAL_1="275" TOTAL_2="275" VAR="26.1384335154827" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" NO="14">
<NAME>Protex (Sagami) Original versus Sagami latex condom</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.2065379619704575" CI_START="0.008617787064453986" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.13789660730379003" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="0.3437114035858264" LOG_CI_START="-2.064604241029169" LOG_EFFECT_SIZE="-0.8604464187216713" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.16135843440345862" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="941" TOTAL_2="960" WEIGHT="100.0" Z="1.4005174073355735">
<NAME>Nonclinical breakage - per condom</NAME>
<GROUP_LABEL_1>Protex Original</GROUP_LABEL_1>
<GROUP_LABEL_2>Control latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2065379619704575" CI_START="0.008617787064453986" EFFECT_SIZE="0.13789660730379003" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.3437114035858264" LOG_CI_START="-2.064604241029169" LOG_EFFECT_SIZE="-0.8604464187216713" ORDER="450" O_E="-0.9900052603892688" SE="1.4146565310015542" STUDY_ID="STD-Potter-2003" TOTAL_1="941" TOTAL_2="960" VAR="0.4996869209834304" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.317323171684648" CI_START="0.20583025320492782" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5207158169103083" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-014.02" LOG_CI_END="0.11969233112130342" LOG_CI_START="-0.686490791700245" LOG_EFFECT_SIZE="-0.2833992302894707" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.1682093292644732" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="939" TOTAL_2="958" WEIGHT="100.0" Z="1.3779804337002648">
<NAME>Clinical breakage - per condom</NAME>
<GROUP_LABEL_1>Protex Original</GROUP_LABEL_1>
<GROUP_LABEL_2>Control latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3173231716846479" CI_START="0.20583025320492787" EFFECT_SIZE="0.5207158169103083" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.11969233112130334" LOG_CI_START="-0.6864907917002449" LOG_EFFECT_SIZE="-0.2833992302894707" ORDER="451" O_E="-2.9098576700052714" SE="0.4735559570161961" STUDY_ID="STD-Potter-2003" TOTAL_1="939" TOTAL_2="958" VAR="4.459204521890668" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0974772910507777" CI_START="0.18844474746611153" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.4547678869069979" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-014.03" LOG_CI_END="0.04039554260584717" LOG_CI_START="-0.7248159631667496" LOG_EFFECT_SIZE="-0.3422102102804512" METHOD="PETO" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.07959671221803226" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="941" TOTAL_2="960" WEIGHT="100.0" Z="1.7530308476330867">
<NAME>Total breakage - per condom</NAME>
<GROUP_LABEL_1>Protex Original</GROUP_LABEL_1>
<GROUP_LABEL_2>Control latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0974772910507777" CI_START="0.18844474746611153" EFFECT_SIZE="0.4547678869069979" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="0.04039554260584717" LOG_CI_START="-0.7248159631667496" LOG_EFFECT_SIZE="-0.3422102102804512" ORDER="452" O_E="-3.9000526038926875" SE="0.4494890263488667" STUDY_ID="STD-Potter-2003" TOTAL_1="941" TOTAL_2="960" VAR="4.949505520641562" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.516841709770915" CI_START="0.7232114877259563" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.997459211216097" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-014.04" LOG_CI_END="0.7416905232799735" LOG_CI_START="-0.1407346840034227" LOG_EFFECT_SIZE="0.3004779196382754" METHOD="PETO" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.18194528809015775" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="939" TOTAL_2="958" WEIGHT="100.0" Z="1.3347893867483398">
<NAME>Complete slippage - per condom</NAME>
<GROUP_LABEL_1>Protex Original</GROUP_LABEL_1>
<GROUP_LABEL_2>Control latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.516841709770914" CI_START="0.7232114877259566" EFFECT_SIZE="1.997459211216097" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.7416905232799734" LOG_CI_START="-0.14073468400342257" LOG_EFFECT_SIZE="0.3004779196382754" ORDER="453" O_E="2.575118608328941" SE="0.5183409348334903" STUDY_ID="STD-Potter-2003" TOTAL_1="939" TOTAL_2="958" VAR="3.7219367173133926" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9097333201030664" CI_START="0.4821433186863327" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9595650893818308" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-014.05" LOG_CI_END="0.2809727255232116" LOG_CI_START="-0.316823847108007" LOG_EFFECT_SIZE="-0.017925560792397686" METHOD="PETO" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.9064296325197756" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="939" TOTAL_2="958" WEIGHT="100.0" Z="0.117543174933713">
<NAME>Total clinical failure - per condom</NAME>
<GROUP_LABEL_1>Protex Original</GROUP_LABEL_1>
<GROUP_LABEL_2>Control latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9097333201030664" CI_START="0.4821433186863327" EFFECT_SIZE="0.9595650893818308" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.2809727255232116" LOG_CI_START="-0.316823847108007" LOG_EFFECT_SIZE="-0.017925560792397686" ORDER="454" O_E="-0.3347390616763306" SE="0.35114866590433674" STUDY_ID="STD-Potter-2003" TOTAL_1="939" TOTAL_2="958" VAR="8.109945850350032" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6726639190312427" CI_START="0.43918032282856034" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8570887234958969" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-014.06" LOG_CI_END="0.22340868885684698" LOG_CI_START="-0.35735712638677747" LOG_EFFECT_SIZE="-0.06697421876496525" METHOD="PETO" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.6512342955481278" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="941" TOTAL_2="960" WEIGHT="100.0" Z="0.45204815168734935">
<NAME>Total failure - per condom</NAME>
<GROUP_LABEL_1>Protex Original</GROUP_LABEL_1>
<GROUP_LABEL_2>Control latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6726639190312427" CI_START="0.43918032282856034" EFFECT_SIZE="0.8570887234958969" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.22340868885684698" LOG_CI_START="-0.35735712638677747" LOG_EFFECT_SIZE="-0.06697421876496525" ORDER="455" O_E="-1.3250920568122027" SE="0.34114471471125524" STUDY_ID="STD-Potter-2003" TOTAL_1="941" TOTAL_2="960" VAR="8.592562614383318" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.2358181481701296" CI_START="1.21172351520127" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.6459627656333855" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="71" I2="0.0" I2_Q="0.0" ID="CMP-014.07" LOG_CI_END="0.3494364770059848" LOG_CI_START="0.08340353606746498" LOG_EFFECT_SIZE="0.21642000653672488" METHOD="PETO" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.0014281825993805377" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="939" TOTAL_2="958" WEIGHT="100.0" Z="3.1888939531283897">
<NAME>Adverse event by male - per condom</NAME>
<GROUP_LABEL_1>Protex Original</GROUP_LABEL_1>
<GROUP_LABEL_2>Control latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2358181481701296" CI_START="1.21172351520127" EFFECT_SIZE="1.6459627656333855" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="71" LOG_CI_END="0.3494364770059848" LOG_CI_START="0.08340353606746498" LOG_EFFECT_SIZE="0.21642000653672488" ORDER="456" O_E="20.40643120716922" SE="0.1562690663915826" STUDY_ID="STD-Potter-2003" TOTAL_1="939" TOTAL_2="958" VAR="40.95000554908504" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4819591419997045" CI_START="0.9346790871945309" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.17692659843504" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="168" I2="0.0" I2_Q="0.0" ID="CMP-014.08" LOG_CI_END="0.17083623019615915" LOG_CI_START="-0.029337474243650595" LOG_EFFECT_SIZE="0.07074937797625432" METHOD="PETO" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.1659121531331341" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="939" TOTAL_2="958" WEIGHT="100.0" Z="1.385459025701003">
<NAME>Adverse event by female - per condom</NAME>
<GROUP_LABEL_1>Protex Original</GROUP_LABEL_1>
<GROUP_LABEL_2>Control latex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4819591419997045" CI_START="0.9346790871945309" EFFECT_SIZE="1.17692659843504" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="168" LOG_CI_END="0.17083623019615915" LOG_CI_START="-0.029337474243650595" LOG_EFFECT_SIZE="0.07074937797625432" ORDER="457" O_E="11.782814971006843" SE="0.11758302486376186" STUDY_ID="STD-Potter-2003" TOTAL_1="939" TOTAL_2="958" VAR="72.32871396993475" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-12-17 15:41:27 -0500" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-12-17 15:38:33 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-12-17 15:17:42 -0500" MODIFIED_BY="[Empty name]">Search 2012</TITLE>
<APPENDIX_BODY MODIFIED="2012-12-17 15:38:33 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">MEDLINE via PubMed (01 Mar 2010 to 17 Dec 2012)</HEADING>
<P>condom*[tiab] AND latex[tiab] AND Clinical Trial[ptyp]</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">CENTRAL (2010 to 17 Dec 2012)</HEADING>
<P>latex AND condom* in title, abstract, or keywords</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">POPLINE (2010 to 2012)</HEADING>
<P>Global: condom* AND latex</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">LILACS (through 17 Dec 2012)</HEADING>
<P>latex and (condom or condoms or condon or condones or preservativo or preservativos) [Words]</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">ClinicalTrials.gov (01 Jun 2010 to 17 Dec 2012)</HEADING>
<P>1) Search terms: latex AND condom* AND contracept*<BR/>Study type: Interventional</P>
<P>2) Intervention: latex AND condom*<BR/>Study type: Interventional</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">ICTRP (01 Jun 2010 to 17 Dec 2012)</HEADING>
<P>Intervention: latex AND condom*</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-12-17 15:41:27 -0500" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-12-17 15:28:46 -0500" MODIFIED_BY="[Empty name]">Search 2010</TITLE>
<APPENDIX_BODY MODIFIED="2012-12-17 15:41:27 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">MEDLINE via PubMed (2008 to 02 Nov 2010)</HEADING>
<P>This was based on the recommended Cochrane search strategy revised for PubMed searches (<LINK REF="REF-Robinson-2002" TYPE="REFERENCE">Robinson 2002</LINK>):<BR/>(("condom"[title/abstract word]) AND ("latex*"[title/abstract word])) AND ((randomized controlled trials [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR ("clinical trial" [tw]) OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR ("latin square" [tw]) OR placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] OR comparative study [mh] OR evaluation studies [mh] OR follow-up studies [mh] OR prospective studies [mh] OR cross-over studies [mh] OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animal [mh] NOT human [mh]))</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">CENTRAL (through 02 Nov 2010)</HEADING>
<P>latex AND condom* in title, abstract, or keywords</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">POPLINE (2008 to 03 Nov 2010)</HEADING>
<P>(condom &amp; latex) &amp; (compar* / clinical trials / comparative studies / random / double-blind studies)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">LILACS (through 03 Nov 2010)</HEADING>
<P>latex and (condom or condoms or condon or condones or preservativo or preservativos) [Words]</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">ClinicalTrials.gov (through 02 Nov 2010)</HEADING>
<P>Search terms: latex AND condom* AND contraception</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">ICTRP (through 02 Nov 2010)</HEADING>
<P>Condition: contraceptive OR contraception<BR/>Intervention: latex AND condom</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-12-17 15:30:34 -0500" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2012-12-17 15:28:53 -0500" MODIFIED_BY="[Empty name]">Previous searches</TITLE>
<APPENDIX_BODY MODIFIED="2012-12-17 15:30:34 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Previous searches used the strategies listed for 2010 and also included the following: </HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">EMBASE (initial review and updates in 2006 and 2008)</HEADING>
<P>latex(w)condom?</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>